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Abstract 
Dehydrophos is a vinyl phosphonate tripeptide produced by Streptomyces 
luridus with demonstrated broad spectrum antibiotic activity. Dehydrophos 
antibiotic activity was determined to be dependent on uptake into the cell via non-
specific oligopeptide permeases, followed by aminopeptidase catalyzed 
digestion. Bioactivity was abolished in Salmonella quadruple mutants lacking 
peptidases PepA, PepB, PepD, and PepN. However, reintroduction of any one of 
these peptidases resulted in restored bioactivity. Following peptidase action the 
released C-terminal portion of dehydrophos, a phosphonate analogue of 
dehydroalanine, undergoes a tautomeric rearrangement followed by hydrolysis to 
yield methyl acetylphosphonate, a structural analogue of pyruvate, and known 
inhibitor of pyruvate dehydrogenase and pyruvate oxidase. To identify genes 
necessary for the biosynthesis of this unusual compound we screened a fosmid 
library of S. luridus for the presence of the phosphoenolpyruvate mutase gene, 
which is required for biosynthesis of most phosphonates. Integration of one such 
fosmid clone into the chromosome of Streptomyces lividans led to heterologous 
production of dehydrophos. Deletion analysis of this clone allowed identification 
of the minimal contiguous dehydrophos cluster, which contained 17 open reading 
frames (ORFs). Bioinformatic analyses of these ORFs are consistent with a 
proposed biosynthetic pathway that generates dehydrophos from 
phosphoenolpyruvate. The early steps of this pathway are supported by analysis 
of intermediates accumulated by blocked mutants and in vitro biochemical 
experiments.
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Chapter 1: General Introduction 
 
The need for phosphorus 
 
 Phosphorus is an essential element for all living cells, predominantly 
present in the fully oxidized state (+5) as inorganic phosphate (PO43-), or in 
biological systems as phosphate esters and phosphoanhydrides. These 
compounds play a prominent role in central metabolism, energy conservation, 
signaling and regulatory processes. Phosphate is also necessary as a 
component of nucleic acids and phospholipids. Biochemical reactions involving 
phosphate are rather simplistic, involving formation or hydrolysis of phosphate 
esters and anhydrides. However, increasing evidence reveals the biochemistry of 
alternate species of phosphorus are important to biology as well. 
In particular, a growing body of literature describes the role reduced 
phosphorus compounds play in biological systems. These molecules have been 
termed C-P compounds, and contain a carbon-phosphorus bond instead of the 
carbon-oxygen bond of phosphate esters. Most known natural C-P compounds 
exist in the +3 oxidation state and contain a single carbon-phosphorus bond, and 
are commonly referred to as phosphonates or phosphonic acids. Several C-P 
compounds contain phosphorus bonded to two carbon atoms, resulting in a 
further reduced +1 oxidation state. These are known as phosphinates or 
phosphinic acids. 
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The chemistry of C-P compounds is notable. Structurally, C-P compounds 
resemble analogous phosphate esters; however the C-P bond proves resistant to 
many treatments capable of hydrolyzing phosphate esters including acid, base, 
extreme temperature, and the action of phosphatases (16). Organisms exploit 
the robust nature of the C-P bond by incorporating C-P containing compounds as 
a structural component of macromolecules and by utilizing the chemistry of the 
C-P bond in small molecule antibiotics. C-P compounds are also hydrolyzed by 
many organisms to provide a source of cellular phosphate. Each of these roles 
will be examined below. 
 
Role of reduced phosphorus in biological systems 
 
As a source of phosphate 
 
 
 
Phosphate is the limiting nutrient in freshwater marine environments, and 
is present at astonishingly low concentrations in some saltwater marine 
environments (46), making the ability to utilize reduced forms of phosphorus a 
desirable trait in these environments. Two forms of inorganic reduced 
phosphorus, hypophosphite (+1) and phosphite (+3) (Figure 1.1) have been 
shown to support the growth of environmental isolates when supplied as the sole 
phosphorus source (56). Subsequent research investigating this phenomenon 
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Figure 1.1 Oxidation states of assorted phosphorus containing molecules.  
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identified a two enzyme pathway present within Pseudomonas stutzeri WM88 
and Alcaligenes faecalis WM2072 conferring the ability to oxidize these 
compounds to phosphate for cellular use (40). Characterization of this system in 
Pseudomonas stutzeri WM88 identified a 2-oxoglutarate dependent 
dioxygenase, HtxA, which catalyzes oxidation of hypophosphite to phosphite 
(55). Also characterized was PtxD, an NAD+ dependent phosphite 
oxidoreductase responsible for the formation of phosphate from phosphite (11). 
Xanthobacter flavus can also transform hypophosphite to phosphate utilizing a 
two enzyme pathway. In this case, a PtxD homolog is responsible for the terminal 
oxidation of phosphite to phosphate, but the initial transformation of 
hypophosphite to phosphite is catalyzed by a unique enzyme, unrelated to HtxA 
(M. Wilson, personal communication).  
The source of inorganic reduced phosphorous compounds present in the 
environment is uncertain. Highly reduced phosphorus in the form of phosphine 
gas (PH3, phosphorus in the -3 oxidation state, Figure 1.1), can be found 
environmentally, in activated sewage sludge, as well as in the human digestive 
tract, with preliminary experiments demonstrating a correlation between 
phosphine production and the presence of several anaerobic bacteria (14,36). It 
has also been shown that lightning strikes are capable of generating phosphite, 
phosphine, and methylphosphine (45).  
Organic compounds containing reduced phosphorus (phosphonates and 
phosphinates) can also be oxidized to provide organisms with phosphate 
necessary for growth. Prominent among these breakdown routes is the C-P lyase 
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pathway, which is capable of liberating phosphate from a variety of phosphonate 
substrates including alkylphosphonates, phenylphosphonate, 
2-aminoethylphosphonate (2-AEP), and N-phosphonomethyl glycine. Genetic 
studies identified a fourteen gene locus responsible for C-P lyase activity in 
Escherichia coli (53). Unfortunately, complete reconstitution of the C-P lyase 
activity in vitro has proven elusive. Recent work demonstrated accumulation of 
intermediates in phnN, phnO, and phnP mutants using a TLC based assay, but 
failed to chemically identify these compounds (17). These results are consistent 
with the observation of ethylphosphonate α-D-ribofuranose accumulation in the 
supernatant of cultures provided ethylphosphonate as a sole phosphorus source 
(1), and with C-P bond cleavage schemes derived from bioinformatic analysis of 
gene function within the Phn operon. Taken together, the data suggest a 
mechanism of bond activation following addition of a small molecule, most likely 
some form of ribose. However, the exact mechanism of bond cleavage remains 
unclear. 
Other pathways involved in phosphonate hydrolysis demonstrate a higher 
level of substrate specificity. Phosponopyruvate hydrolase converts 
phosphonopyruvate to pyruvate and phosphate (29). Phosphonoacetate 
hydrolase catalyzes formation of acetate and phosphate from phosphonoacetate 
(38). Yet another pathway, the phosphonatase pathway, is comprised of two 
steps; transamination of 2-AEP to phosphonoacetaldehyde, followed by cleavage 
to acetaldehyde and phosphate (19,32).  An additional pathway for 2-AEP 
breakdown has been reported following functional screens of marine 
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metagenomic libraries. This pathway contains two proteins, PhnY and PhnZ, 
responsible for the processing of 2-AEP via a currently unknown mechanism 
(37). 
 
As a structural component  
 
 
The first phosphonate-containing natural products identified were 
polymeric in nature. Much of this research originated with the discovery of 2-
aminoethylphosphonate (2-AEP, Figure 1.2) in 1959, from an acid hydrolyzed 
extract of rumen protozoa, in the first known example of reduced phosphorus of 
biological origin (16). Follow-up studies determined that 2-AEP serves as the 
head group of a lipid analogous to phosphatidylethanolamine (Figure 1.2). Other 
phosphonates have also been isolated and identified from lipid extracts, e.g. 2-
hydroxyethylphosphonate and 1-hydroxy-2-aminoethylphosphonate (Figure 1.2) 
(54).  
Figure 1.2 Chemical structures of common phosphonate-containing headgroups. 
Included is a structural comparison of phosphatidylethanolamine to phosphonylethanolamine. 
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Polysaccharides containing phosphonate moieties have been isolated, 
and although complete structural elucidation has yet to occur, both 2-AEP and 2-
HEP have been identified as components (15). One area of research interest 
revolves around identifying the location of phosphonate attachment to the sugar 
molecule. The capsule polysaccharide of Bacteroides fragilis shows addition of 2-
AEP to a hydroxyl group of the carbohydrate via a phosphate ester linkage (2), 
similar to previous observations of 2-AEP addition to a lipid. However, 
experiments to determine the linkage of phosphonoglycans collected from 
Tetrahymena and sea anemone failed to detect a free primary amine. This would 
seem to suggest connectivity through the nitrogen atom of 2-AEP, but covalent 
modification of this nitrogen is also a confounding possibility. Finally, although 
phosphonoproteins have been observed, further examination revealed these to 
be glycoproteins with phosphonate groups attached to the sugar, rather than 
directly to the protein. 
While examples of phosphonate-bearing macromolecules accumulate and 
expand, very little is known about the role these phosphonates play when 
attached to structural components. Due to the hydrolytically resistant nature of 
the C-P bond some have speculated the attachment of 2-AEP to lipids increases 
their stability or alters the membrane fluidity in an advantageous manner (24). 
Others have postulated that phosphonate-containing compounds are acting as a 
phosphorus sink to manage P-limited environments. 
Although little research details the function of structural phosphonates, 
their abundance and distribution signal a large biological import to these 
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compounds. For example the membrane lipids of Tetrahymena pyriformis may 
be nearly 60% phosphonolipids (24), and certain sea anemones have almost 
50% of their phosphorus in a reduced form. Underscoring the importance of 
reduced phosphorus compounds is the recent estimation that up to 30% of the 
available phosphorus in the world’s oceans is in the form of phosphonic acids 
(10). 
 
Biologically active phosphonates 
 
Phosphonates structurally mimic phosphate esters, but undergo 
substantially different chemistry. This characteristic has been exploited by nature 
and man to produce compounds with important biological activities, such as 
antibiotics, herbicides, and antiviral compounds. These phosphonate- containing 
molecules function as enzyme inhibitors by acting as structural mimics of 
analogous phosphate or carboxy esters and competing for binding to active sites. 
The prominent role of phosphate esters in cellular biology suggests a large and 
varied number of targets susceptible to phosphonate inhibition, and examination 
of the structures and targets of known phosphonates supports this assertion (39). 
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 One of the most widely utilized herbicides, glyphosate, is a synthetic 
phosphonate, whilst another, phosphinothricin tripeptide (PTT) is a natural 
product identified from Streptomyces hygroscopicus ATCC 21705 and 
Streptomyces viridochromogenes DSM 40736 (3,49). PTT functions as a 
glutamine synthetase inhibitor following uptake and subsequent intracellular 
hydrolysis to yield active phosphinothricin (33). Phosphinothricin is now also 
made synthetically (under the name glufosinate) and serves as the active 
ingredient in several non-specific herbicides including Basta®, Rely®, Finale®, 
Challenge® and Liberty®. 
Other examples of synthetically made phosphonate compounds are the 
acyclic nucleoside phosphonates Cidofovir, Adefovir, and Tenofovir (12,34,52), 
which have been approved for use in the treatment of several viral and retroviral 
infections. These phosphonate therapeutics act as inhibitors of DNA replication, 
preferentially targeting viral DNA polymerases. 
A final class of synthetic phosphonates are the bisphosphonates, 
represented by Fosamax®. Bisphosphonates are utilized in the treatment of 
osteoporosis and other bone diseases, where they function as pyrophosphate 
analogues and inhibit osteoclast mediated bone resorption by tight incorporation 
into the bone matrix. 
Fosfomycin, an epoxide-containing phosphonate produced by 
Streptomyces fradiae ATCC 21096, Streptomyces wedmorensis ATCC 21239, S. 
viridochromogenes ATCC 21240, Pseudomonas syringae PB-5123, and 
Pseudomonas viridiflava PK-5, is used under the name Monurol® in the U.S. for 
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the treatment of urinary tract infections (8,48).  This compound inhibits the early 
stages of cell wall biosynthesis and exhibits broad spectrum activity and is 
effective against several problematic infections such as methicillin resistant 
Stapylococcus aureus, and vancomycin resistant enterococci. 
Other phosphonates with potential as antibiotics have been identified. 
Related compounds fosmidomycin and FR900098 function by blocking the non-
mevalonate pathway for isoprenoid biosynthesis. These compounds inhibit deoxy 
xylulose phosphate reductoisomerase (DXR), the enzyme responsible for the first 
committed step of this pathway, and show potential as antimalarial and 
antituberculosis agents. Also of note is compound K-26, a tripeptide containing a 
phosphonate analogue of tyrosine. K-26 shows high potency as an angiotensin-
converting enzyme (ACE) inhibitor (59) and could be used in the treatment of 
hypertension. 
 
Biosynthesis of phosphonates 
 
2-AEP / Discovery of the PEP mutase  
 
 
Figure 1.4 Biochemical transformations in the biosynthesis of 2-AEP. The inset box 
depicts the preferred mechanism of the PEP mutase reaction. 
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The discovery of 2-AEP in T. pyriformis led to inquiries about the 
biosynthesis of the C-P bond. Early experiments traced radioactive labels and 
determined that phosphoenolpyruvate (PEP) was the most likely source of the 
phosphorus atom and carbon skeleton. Although these experiments provided 
valuable information, they were unsuccessful at isolating the enzyme responsible 
for C-P bond formation. It took nearly two decades to identify the 
phosphoenolpyruvate phosphomutase (PEP mutase), which was followed by 
purification and characterization (7). The PEP mutase catalyzes the 
intramolecular rearrangement of PEP to form phosphonopyruvate (PnPy). The 
presence of magnesium ions is necessary to achieve optimal activity. 
Mechanistic investigations provide support for the rearrangement to 
phosphonopyruvate via dissociation of PEP to metaphosphate and pyruvyl 
enolate, followed by rotation around the C1-C2 bond of the pyruvyl enolate and 
C-P bond formation via attack of the nucleophilic C3 of metaphosphate (Figure 
1.4, inset) (18), but these results are somewhat tentative and need further 
experimental support. 
 The equilibrium of the PEP mutase reaction lies heavily in favor of PEP, 
with the PEP/PnPy equilibrium ratio measured at ≥500:1 (7). To achieve net 
synthesis of phosphonates, the enzyme directly following the PEP mutase 
reaction catalyzes a thermodynamically favorable reaction. 2-AEP biosynthesis 
utilizes PnPy decarboxylase which catalyzes the most commonly observed 
driving reaction in phosphonate biosynthesis (56). As the name suggests, this 
protein decarboxylates PnPy to form phosphonoacetaldehyde (PnAA). Known 
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PnPy decarboxylases are thiamin pyrophosphate (TPP) dependent, require a 
divalent cation, and belong to the α-ketodecarboxylase family of enzymes (39). 
 The transamination of PnAA yields 2-AEP, and completes the biosynthetic 
pathway. Putative transaminases present within phosphonate biosynthetic 
pathways have not yet been formally characterized, but transaminases involved 
in 2-AEP utilization contain pyridoxal 5′-phosphate and utilize pyruvate as an 
ammonium acceptor (25). Interestingly, during production in a heterologous host, 
a blocked mutant of phospinothricin tripeptide biosynthesis expected to 
accumulate PnAA, excretes 2-AEP instead. The lack of an identifiable 2-AEP 
transaminase within the PTT biosynthetic gene cluster suggests that endogenous 
transaminases within the host cell may be able to fulfill this function (5).  
 
Identification of Phosphonate Biosynthetic Gene Clusters containing the 
PEP mutase gene 
 
Following the identification of the PEP mutase, early work to elucidate the 
biosynthesis of known phosphonates was limited by the absence of robust 
genetic systems for the producing organisms. Although chemical mutagenesis 
provided some insight into the genes involved in these transformations, obtaining 
complete gene clusters for many of the compounds proved problematic. The 
conservation of the PEP mutase gene in preliminary investigations of 
phosphonate biosynthesis invited a molecular approach to identify cryptic 
clusters of previously isolated phosphonates. This strategy utilized degenerate 
PCR primers designed to amplify highly conserved portions of the PEP mutase 
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gene. These primers were then used to screen genomic or environmental 
libraries and led to the identification of the biosynthetic gene clusters of 
dehydrophos, phosphinothricin tripeptide, fosfomycin, plumbemycin, FR900098 
(5,13,58) and allowed for the analysis of the biosynthesis of these compounds 
which will be discussed in the proceeding sections. 
 This screening technique has also been used to gain insight into the 
distribution and diversity of the PEP mutase gene from cultivable isolates. Initial 
results have indicated that approximately 5% of randomly isolated actinomycetes 
carry the genetic potential to synthesize a phosphonate antibiotic (39). Further 
analysis of PEP mutase diversity is underway to aid in the discovery of novel 
phosphonate antibiotics and to provide guidance in selecting PEP mutase 
positive isolates for more in depth examination. 
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FR-900098  
 
 
 
The group of antibiotics represented by FR-900098 (also including 
fosmidomycin, FR-33289, FR-32863) are inhibitors of cell wall biosynthesis. 
These compounds contain variations of N-hydroxy-propylphosphonic acid, and 
were discovered by the Fujisawa Pharmaceutical Co. in strains of Streptomyces 
lavendulae and Streptomyces rubellomurinus (30,42,43). As previously 
mentioned, molecules of this class act as inhibitors of the DXR enzyme involved 
in the non-mevalonate pathway of isoprenoid biosynthesis. 
 The recent identification of the FR-900098 biosynthetic gene cluster has 
provided insight into biosynthesis of this compound (13). The FR-900098 
biosynthetic pathway utilizes PEP mutase to generate phosphonopyruvate. 
Figure 1.5 Proposed pathway for FR-900098 biosynthesis. Dashed arrows indicate 
hypothetical reactions. 
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Interestingly, when the fosmid containing the genes necessary to confer 
heterologous production of this compound was sequenced, the gene cluster 
lacked an identifiable phosphonopyruvate decarboxylase. Based on the lack of 
this protein, an alternate mechanism was proposed in which a homolog of 
homocitrate synthase, FrbC, condenses acetyl-CoA and phosphonopyruvate in 
an exergonic reaction to yield 2-phosphonomethylmalate (Figure 1.5) and 
provide the driving force to overcome the unfavorable thermodynamics of the 
PEP mutase reaction and achieve net phosphonate synthesis. In vivo feeding 
experiments with synthetic PnPy supported this hypothetical reaction (13). 
Interestingly, the substrates of FrbC are analogous to their counterparts in the 
reaction catalyzed by the homocitrate synthase during the TCA cycle. Some 
uncertainty exists in assigning FrbE or FrbB to the following two steps in the 
pathway to produce 2-oxo-4-phosphonobutyrate, but these reactions are also 
analogous to transformations found within the TCA cycle. These transformations 
are followed by a FrbH-catalyzed cytidylation of the phosphonate group and 
subsequent decarboxylation. The resulting compound, 5′-CMP-3-
aminopropylphosphonate serves as a substrate for acetylation by FrbF followed 
by N-hydroxylation by FrbG. FrbI is capable of removing the CDP group in vitro 
but proves dispensable in vivo (20). 
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Both rhizocticins and plumbemycins contain L-2-amino-5-phosphono-3-
cis-pentenoic acid (L-APPA) attached at the C-terminus of a variety of dipeptides 
and tripeptides. Rhizocticins and plumbemycins enter the cell via the oligopeptide 
transport system (28), and following uptake these compounds are subject to 
hydrolysis by the action of intracellular peptidases. Breakdown of these 
oligopeptides results in the release of L-APPA which exerts toxic effects as a 
threonine synthase inhibitor, functioning as a molecular mimic of homoserine 
phosphate (the native substrate of threonine synthase) (31). The rhizocticins, 
Figure 1.6 Proposed pathways for the biosynthesis of rhizocticins. Three potential 
pathways are indicated by the letters a, b, and c. Taken from Borisova et al 2010. 
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consisting of rhizocticin A (Arg-APPA), rhizocticin B (Val-Arg-APPA), rhizocticin C 
(Ile-Arg-APPA), and rhizocticin D (Leu-Arg-APPA) are produced by Bacillus 
subtilus ATCC 6633 and work as antifungal agents (28). In contrast, 
plumbemycin A (Ala-Asp-APPA) and plumbemycin B (Ala-Asn-APPA) are 
produced by Streptomyces plumbeus IFO13708, and function as antibacterials 
(44). APPA has been shown to be directly responsible for toxicity of these 
antibiotics and therefore the difference in target specificities must result from 
differential uptake or hydrolysis (31). 
 The gene cluster for the production of rhizocticin has been identified, and 
biosynthetic investigations are underway (6). Early studies into the formation of 
rhizocticins have revealed some very interesting biochemistry (Figure 1.6). These 
organisms utilize both PEP mutase to generate phosphonopyruvate, and 
phosphonopyruvate decarboxylase to yield phosphonoacetaldehyde. At this point 
the carbon chain is extended by an aldol reaction with oxaloacetate to yield 2-
oxo-4-hydroxy-5-phosphonopentanoic acid. Following this reaction, 
transamination and dehydration will yield APPA, which can then be coupled to 
the appropriate peptides for rhizocticin formation.  The specifics of the 
transamination and dehydration reactions are still under investigation, but 
preliminary evidence indicates that the peptide bond forming reactions are not 
catalyzed in a non-ribosomal peptide synthetase (NRPS) dependent fashion. 
Two groups of researchers have independently verified that the enzymes 
responsible for these reactions are RhiC/RizB and RhiM/RizA, ATP-grasp 
containing enzymes which utilize ATP-dependent phosphorylation of amino acid 
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carboxylate groups as a means to activate the substrate molecules for amide 
bond formation with the requisite peptide (26,27). The specifics and exact 
substrates of these reactions are still under investigation.  
 
Fosfomycin 
  
 
Fosfomycin was the first phosphonate antibiotic discovered and is 
clinically utilized in the treatment of drug resistant bacteria. Fosfomycin contains 
a unique epoxide ring and exerts toxicity upon bacteria by inhibiting the action of 
MurA (the first committed step in bacterial cell wall biosynthesis) via covalent 
alkylation of an active site residue (22). Fosfomycin has been isolated from a 
variety of bacteria, including S. wedmorensis ATCC 21239, S. fradiae ATCC 
21096, and P. syringae PB-5123. A closely related compound, fosfadecin, a 
nucleotidylated fosfomycin molecule, is produced by P. viridflava PK-5 (23). 
Fosfadecin is presumed to release fosfomycin upon hydrolysis and function in an 
identical fashion to fosfomycin. 
 The biosynthesis of fosfomycin is straightforward, but includes some 
remarkable biochemistry. Fosfomycin biosynthesis begins with the conversion of 
Figure 1.7 Biosynthetic pathway for fosfomycin production. 
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PEP to PnPy, followed by decarboxylation to form PnAA (58). PnAA is then 
reduced by the metal-dependent dehydrogenase FomC to yield 2-HEP (50). 
Subsequent methylation by Fom3 at C2 yields 2-hydroxypropylphosphonate 
(HPP) which then undergoes Fom4-catalyzed oxidization to finish the 
biosynthesis by forming an epoxide ring  (35). 
 
K-26 
 
Compound K-26 contains N-acetylated L-isoleucine, L-tyrosine, and (R)-1-
amino-2-(4-hydroxyphenyl)ethylphosphonic acid (AHEP) (59). Bioassays for ACE 
inhibitors identified K-26 in the culture supernatant of “actinomycete K-26”, now 
designated Astrosporangium hypotensionis. Notably, compound K-26 
demonstrated comparable ACE inhibition to the clinically utilized hypotensive 
agent Captopril. Several structural relatives of K-26 are produced by 
Actinomadura strains, but research efforts have largely focused on K-26. Little is 
known about K-26 biosynthesis, as efforts to study production have been 
hampered by the slow growth rate of the native producer, as well as low 
production levels of K-26 (10 µg/L). However, feeding studies conducted with 
isotopically labeled compounds clearly demonstrated that AHEP is derived from 
tyrosine, retaining the 15N labeled amine, labeled β-deuterium atoms, as well as 
labeled aromatic deuterium atoms (41). These experiments strongly suggest that 
the phosphonate moiety in K-26 is not generated by the action of a PEP mutase, 
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but instead by some as of yet unknown mechanism. This makes K-26 unique 
amongst known phosphonic acids. 
 
Phosphinothricin 
 
 
One of the most extensively studied C-P bond-containing compounds is 
the non-proteinogenic amino acid phosphinothricin (PT). Phosphinothricin is 
unique as the only known biologically produced phosphinic acid. PT serves as 
the active component of three antibiotics: phosphinothricin tripeptide (bialaphos), 
trialaphos, and phosalacine. These phosphinothricin containing compounds are 
all peptide antibiotics, differing only in the identity and quantity of amino acids 
Figure 1.8 Proposed pathway for phosphinothricin tripeptide biosynthesis. 
 21 
linked to the carboxylate group of phosphinothricin. Following uptake of these 
compounds by non-specific oligopeptide permeases, hydrolysis releases PT 
which acts as an inhibitor of glutamine synthetase.  The majority of research 
focused on PT biosynthesis has been conducted on organisms which produce 
PTT. PTT was originally discovered in 1972 in the fermentation broth of 
Streptomyces viridochromogenes Tü494 (3). 
 The pathway for PTT biosynthesis has been stitched together over the 
years, primarily by the work of the Seto group (49). The recent cloning and 
sequencing of the entire PTT gene cluster by the Metcalf group identified several 
genes previously unassociated with PTT biosynthesis. Investigation of the 
function of these genes led to a revision of the previously proposed pathway for 
PTT biosynthesis (Figure 1.8) (5). 
Early steps in PTT production parallel the biosynthesis of fosfomycin up to 
production of the common intermediate 2-HEP. At this point, 2-HEP is converted 
to hydroxymethylphosphonate (HMP) via an unusual transformation catalyzed by 
the 2-HEP dioxygenase, HEPD. A series of in vitro assays with substrates 
containing isotopically labeled carbon, hydrogen, and oxygen atoms 
demonstrated that HEPD accepts 2-HEP and oxygen as substrates, converting 
them to HMP and formate without the need for exogenous electron donors (9). 
The mechanism of scission of the unactivated C-C bond is currently under 
investigation. 
Genetic experiments with blocked mutants have implicated PhpE and 
PhpJ as the proteins responsible for the generation of phosphonoformate (PF) 
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from HMP. Sequence homology indicates that these proteins are members of the 
alcohol and aldehyde dehydrogenase families, respectively. 
 In vitro experiments indicated that PhpF catalyzes the displacement of the 
β and γ phosphate of CTP by PF to form CMP-5′-PF and pyrophosphate (4). This 
product is predicted to be the substrate for a pair of reactions catalyzed by the 
enzymes PhpG and PhpH that mirror transformations found in glycolysis. PhpG 
contains a high level of homology to the phosphoglycerate mutase of Sulfolobus 
solfataricus, and PhpH is an enolase homolog. Therefore, in a manner 
mechanistically similar to that of the phosphoglycerate mutase from S. 
solfataricus, the activated PF could be transferred to an active site serine and 
transferred to an acceptor molecule, such as 3-phosphoglycerate.  This 
phosphonoformylated intermediate would then function as a substrate for the 
enolase homolog PhpH to yield carboxyphosphoenolpyruvate (CPEP). 
 CPEP undergoes rearrangement to form phosphinopyruvate. The CPEP 
mutase (PhpI) is responsible for the catalysis of this transformation, which is 
thought to mirror the PEP mutase reaction in many aspects, including the 
unfavorable thermodynamics (47). Organisms that produce PTT overcome the 
thermodynamics of the CPEP mutase reaction by coupling this rearrangement to 
an irreversible and highly favorable decarboxylation, similar to the reaction 
catalyzed by the PnPy decarboxylase following the PEP mutase reaction in many 
phosphonate biosynthetic pathways. Unlike the PEP mutase portion of the 
pathway, the decarboxylation that follows the CPEP mutase-catalyzed step does 
not require additional enzymes, implicating the CPEP mutase as a participant in 
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the process. Further experimentation confirmed that the CPEP mutase was 
capable of converting carboxyphospinopyruvate (CPnPy) to phosphinopyruvate, 
but raised additional questions because the rate of catalysis was substantially 
lower than that of the CPEP to phosphinopyruvate conversion rate (47).  
 Phosphinopyruvate is converted into phosphinomethylmalate following an 
acetyl-CoA dependent acetylation catalyzed by the phosphinomethylmalate 
synthase (Pms). Following this rearrangement, decarboxylation and 
transamination result in deamino-α-keto-demethylphosphinothricin (DMPT).  The 
enzymes that perform the reactions natively have not been identified, and no 
obvious candidates are present within the gene cluster. Additionally, Seto and 
coworkers demonstrated that these reactions could occur in organisms that do 
not produce PTT, suggesting that common endogenous enzymes may be 
capable of performing these reactions (51). 
 The final steps in PTT biosynthesis have been extensively studied, yet 
questions still remain. It is now known that DMPT undergoes acetylation to form 
acetyl-DMPT as a self-resistance mechanism in organisms that produce PTT, 
and prior to export from the cell this acetyl group is cleaved off to activate the PT 
“warhead” portion of the antibiotic. 
 Following acetyl-DMPT functions as the substrate for the first non-
ribosomal peptide synthetase associated with the pathway, PhsA. The 
adenylation domain of PhsA catalyzes the addition of an adenyl group to acetyl-
DMPT, but was also shown competent to adenylate of N-acetylphosphinothricin, 
albeit at a slightly lower rate. 
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P-methyltransferase (PhpK) is predicted to be responsible for the addition 
of a methyl group to the phosphorus center in PT in a methylcobalamin 
dependent fashion. The ability of PhsA to adenylate both acetyl-DMPT and 
acetylphosphinothricin has raised some questions about the timing of the peptide 
bond formation step. PhsB and PhsC are NRPS responsible for the condensation 
of adenylated acetylphosphinothricin with two alanine residues to generate 
acetyl-PTT. The final step of PTT biosynthesis is deacetylation to yield PTT. 
 
Dehydrophos, and statement of the thesis problem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 The published chemical structure(s) of dehydrophos. The top 
structure depicts the initial (incorrect) published structure, while the bottom structure 
depicts the recently revised, and demonstrably correct structure of dehydrophos. 
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Dehydrophos, originally designated A53868, was first described by Eli Lilly 
in 1984 as a broad spectrum antibiotic present in the culture supernatant of 
Streptomyces luridus (21). The compound has in vitro activity against gram 
negative and gram positive bacteria and demonstrated in vivo activity in a 
Salmonella/chicken model system (21). However, these activities are fairly 
modest, and so dehydrophos was initially notable in that it contained a direct C-P 
bond. The chemical structure of dehydrophos has been revised multiple times, 
most recently in 2007 (57). The revised structure of dehydrophos reveals a 
unique O-methylated vinylphosphonate connected to a glycine-leucine dipeptide 
via an amide bond (Figure 1.9). Based on similarity of the vinylphosphonate 
moiety to dehydroalanine, it was proposed that the compound be renamed 
dehydrophos (57). The phosphorus center present in dehydrophos drives 
antibiotic activity and research interest in the biosynthesis of this compound.  
 The study described in this thesis provides genetic and biochemical 
characterization of dehydrophos biosynthesis. Similar to many antibiotics that 
have been described to date, dehydrophos was initially identified and discovered 
with no knowledge of the genes responsible for its biosynthesis. At the time this 
project was initiated little information was available about the biosynthesis of 
phosphonate compounds. The gene cluster for dehydrophos had just been 
isolated, and preliminary efforts at heterologous production indicated the 
published structure of dehydrophos was incorrect. Many of the newly proposed 
structures included unusual and interesting functional groups. Research into the 
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biosynthesis of other phosphonate antibiotics had already indicated a 
predisposition for unusual chemical transformations, and dehydrophos looked to 
be a promising candidate to continue that trend. Additionally, as a part of a larger 
effort dedicated to discovering phosphonate antibiotics, characterization of 
dehydrophos biosynthesis and bioactivity would broaden our knowledge and 
facilitate the analysis of new phosphonate biosynthetic gene clusters. 
 The data presented herein has been organized into five main chapters. 
Chapter 2 presents evidence for the mechanism of dehydrophos bioactivity. 
Chapter 3 details the isolation, sequencing, and bioinformatic analysis of the 
genes required for dehydrophos production. Based on the data generated in 
Chapter 3, a biosynthetic framework was proposed. Chapter 4 describes efforts 
into validating the proposed pathway using genetic analysis, and Chapter 5 is 
dedicated to in vitro assays of proteins involved in dehydrophos biosynthesis. 
Finally, Chapter 6 is a brief summary of the results and includes a revised 
pathway based on the evidence generated in Chapters 4 and 5.  
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Chapter 2: The Role of Import and Proteolytic Cleavage on Dehydrophos 
Bioactivity 
 
Abstract 
 
The phosphonate antibiotic dehydrophos produced by Streptomyces 
luridus has broad spectrum activity. To differentiate between potential modes of 
action for this compound, a panel of Salmonella mutants deficient in oligopeptide 
uptake and catabolism was challenged with dehydrophos and examined for 
growth inhibition. Dehydrophos activity was determined to be dependent on 
uptake into the cell via non-specific oligopeptide permeases, followed by 
aminopeptidase catalyzed digestion. Dehydrophos bioactivity was abolished in 
Salmonella quadruple mutants lacking peptidases PepA, PepB, PepD, and 
PepN. However, reintroduction of any one of these peptidases resulted in 
restored bioactivity. In vitro incubation of dehydrophos with purified PepA in 
conjunction with 31P NMR spectroscopy confirmed the action of this peptidase 
upon dehydrophos, and allowed the fate of dehydrophos to be monitored. 
Following peptidase action the released C-terminal portion of dehydrophos, a 
phosphonate analogue of dehydroalanine, undergoes a tautomeric 
rearrangement followed by hydrolysis to yield methyl acetylphosphonate, a 
structural analogue of pyruvate, and known inhibitor of pyruvate dehydrogenase 
and pyruvate oxidase. 
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Introduction 
 
The recent structural revision and heterologous production of the antibiotic 
dehydrophos (formerly A53868) reignite questions about the mechanism of 
action of this phosphonate-containing compound. Early work performed by Eli 
Lilly identified dehydrophos from the culture supernatant of Streptomyces luridus 
based on the broad spectrum antibiotic activity this compound possesses in vitro 
(11). Further experimentation demonstrated in vivo activity of dehydrophos in 
Salmonella challenged chickens (11). Although the compound clearly possesses 
antimicrobial activity, no work was performed to ascertain the target(s) of 
dehydrophos. 
Dehydrophos consists of a glycine-leucine dipeptide linked to an 
O-methylated aminovinylphosphonate. The coupling of amino acids to a C-P 
containing moiety is a common theme in bioactive phosphonate biology. In the 
case of the rhizocticins, plumbemycins, and the phosphinothricin containing 
compounds, these amino acids function as a “trojan horse”, allowing the whole 
peptides to be brought into the cell by non-specific oligopeptide permeases, 
where peptidase action serves to release the bioactive C-P containing molecule 
(3,12). One additional example exists of a small peptide phosphonate antibiotic, 
the angiotensin-converting enzyme inhibitor K-26, consisting of Ile-Tyr coupled to 
the tyrosine analog, (R)-1-amino-2-(4-hydroxyphenyl)-ethylphosphonic acid 
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(AHEP) (17). However in this case, the role of the additional amino acids is 
unclear. 
The “trojan horse” model for dehydrophos bioactivity appears the most 
plausible explanation. The rationale lies in the expected tautomeric 
rearrangement of vinyl phosphonate following hydrolysis to yield methyl 
acetylphosphonate (MAP) (Figure 2.1). 
 MAP structurally resembles pyruvate and is a known inhibitor of both 
pyruvate oxidase and pyruvate dehydrogenase. In fact, with a Ki of 5 * 10-8, MAP 
binds to pyruvate dehydrogenase 10,000 times better than the natural substrate, 
pyruvate (18). MAP inhibits pyruvate oxidase modestly (Ki = 1 mM, pH 7.0)(18), 
which is still a ten-fold increase in binding affinity over pyruvate (5). Although 
Figure 2.1 Model for the breakdown and action of dehydrophos. As seen above, 
the action of peptidases releases 1-aminovinylphosphonate O-monomethyl ester, 
which rearranges to the preferred imine. This imine is then subject to subsequent 
attack by a water molecule to yield methyl acetylphosphonate. As can be seen by the 
boxed structures MAP closely resembles pyruvate. 
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these are the only two documented cases of MAP inhibition, the central role of 
pyruvate in cellular metabolism provides additional potential targets for MAP. 
Conversely, as a complete tripeptide, dehydrophos contains a 
dehydroalanine analogue, with a potentially reactive vinyl group. This vinyl group 
could undergo a Michael-type addition to covalently attach the antibiotic to an 
enzyme to produce the antibiotic phenotype. Studies on a number of vinyl 
sulfones have demonstrated these compounds are capable of inhibiting cysteine 
dependent proteases via covalent modification (19), and it is conceivable that the 
structurally similar vinyl phosphonates could produce a similar effect in cysteine 
proteases or other sulfhydryl containing enzymes. 
To study the role of peptidase and permease function in the action of the 
antibiotic dehydrophos we chose the model organism Salmonella typhimurium. 
This well studied organism contains three genetically distinct systems for peptide 
uptake, encoded by the opp, tpp, and dpp genes (6). These gene designations 
refer to the oligopeptide permease, tripeptide permease, and dipeptide 
permease, respectively. The oligopeptide permease functions as the primary 
uptake systems for small peptides into the cell, transporting a broad range of 
peptides up to 5 amino acids in size into the cell (7,8,9). The tripeptide permease 
possesses the most limited substrate range, preferring hydrophobic residues, 
and requires anaerobic conditions for expression (4,10). The dipeptide permease 
prefers dipeptide substrates and also acts as the receptor for peptide chemotaxis 
(1). Mutant strains which lack all three of these systems fail to exhibit uptake of a 
large assortment of peptides (6). 
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Salmonella typhimurium contains a larger number of peptidases, but 
similar to the permeases discussed above, many of their functions overlap. In 
total, Salmonella typhimurium contains eight major peptidases; A, B, D, E, N, P, 
Q, and T. Peptidases A and B possess broad substrate specificities and belong 
to the leucyl aminopeptidase family (14,16). Peptidase N also has broad 
substrate specificity, but belongs to the lysyl aminopeptidase family and appears 
subject to a more complex regulation scheme. Peptidase D is a broad range 
dipeptidase (16). The remaining peptidases possess a more restricted substrate 
range, or are only expressed under certain conditions. Of these, peptidases P 
and Q are involved in the processing of X-Pro dipeptides, whereas peptidase E 
acts upon Asp-X dipeptides (15). Finally, peptidase T is a tripeptidase expressed 
under anaerobic conditions (16). 
Here we report both the permease and peptidase dependent nature of 
dehydrophos activity in the target cell. Consistent with the ‘trojan horse’ model of 
activity we have identified the generation of methyl acetylphosphonate and a 
reduced metabolite of MAP, 1-hydroxyethylphosphonate monomethyl ester 
(1-HEP O-Me), following hydrolysis. These efforts have revealed that 
dehydrophos functions by generation of a pyruvate analogue capable of inhibiting 
multiple targets, a useful feature in minimizing the emergence of bacterial 
antibiotic resistance. 
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Materials and Methods 
 
Bacterial strains, plasmids and culture conditions. The strains and 
plasmids used in this study are listed in Appendix A. Streptomyces strains were 
propagated on ISP4 medium (Difco, Becton Dickinson Microbiology Systems, 
Sparks, Maryland) at 30 °C unless otherwise noted.  Heterologous production 
cultures were inoculated with 50 µL of spore stock (109 colony forming units) of 
the appropriate strain and incubated in 500 mL baffled flasks containing 100 mL 
of nutrient broth (Difco) agitated at 250 rpm for 48 hours prior to analysis of the 
supernatant. S. typhimurium was routinely grown in Luria-Bertani broth (LB) or on 
1.5% agar LB plates supplemented with appropriate antibiotics. Antibiotics were 
used at the following concentrations to select for plasmid propagation or 
integration events: ampicillin 100 µg/mL, chloramphenicol 10 µg/mL, apramycin 
37.5 µg/mL, kanamycin 50 µg/mL. 
 
Bioassay of dehydrophos growth inhibition. To examine the effects of 
dehydrophos on a series of Salmonella peptidase/permease mutants the 
appropriate Salmonella strain was grown to an OD600 of 0.1, and then 100 µL of 
this culture was mixed with 2 mL of molten ‘E’ media 0.5 % top agar (20) and 
distributed onto ‘E’ media 1.5% agar plates containing succinate (40 mM) and 
leucine (50 mM), where it was permitted to cool. Agar cores were then taken 
from ISP4 plates of Streptomyces luridus NRRL 15101 following 48 hour 
incubation at 30 °C. Alternatively, filter disks we re spotted with 10 µL authentic 
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standard dehydrophos (1 mg/mL). These cores and/or disks were then placed 
onto the inoculated bioassay medium ‘E’ plates. These plates were incubated at 
37 °C for 12 hours and then scored for bioactivity.  
  
Overexpression, purification, and activity assay of PepA. PepA was 
purified using a modified version of the Vogt purification of E. coli 
aminopeptidase I (21). A 500 mL culture of TN2216 was incubated for 16 hours 
at 37 °C and the cells were then harvested by centr ifugation at 5000 X g for ten 
minutes. The cell pellet was resuspended in 20 mL of ice cold buffer 1 (50 mM 
Tris-HCl pH 7.8, 200 mM KCl, 10 mM MgCl2, 100 mM EDTA, 100 mM DTT and 
5% glycerol) cells were disrupted by a single passage through a chilled French 
press cell at 20,000 psi. Solid debris was removed by centrifugation at 13,000 × g 
for 30 minutes at 4 °C. The cleared cell lysate was  then placed into a 70 °C water 
bath and continuously swirled until the temperature reached 65 °C. Precipitated 
proteins were removed by centrifugation at 13,000 X g for 15 minutes at 4 °C. 
The remainder was dialyzed (Pierce 10K MWCO) against 2 L of 0.1M phosphate 
buffer pH 7.6 for 18 hours at 4 °C with one change of buffer. Following this 
dialysis the extract was centrifuged again at 13,000 × g for 15 minutes at 4 °C to 
remove insoluble material. The supernatant was then dialyzed against buffer 2 
(20 mM Tris-HCl pH 8.4, 10 mM KCl, 1 mM Mg(OAc)2, 0.1 mM EDTA) for 18 
hours. The precipitate that formed was collected and redissolved in Buffer 3 (20 
mM KHCO3 pH 10.3, 50 mM KCl, 1 mM Mg(OAc)2 , 0.1 mM EDTA), the 
precipitate failed to completely solubilize in Buffer 3, leaving the solution turbid. 
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PepA purity was evaluated by visual inspection of an SDS-PAGE gel stained with 
Coomassie Brilliant Blue (estimated to be at least 95% pure). PepA action on 
dehydrophos was assayed at 37 °C over 18 hours by d irect addition of 
dehydrophos to dissolved PepA to a final concentration of 7 mM. The reaction 
was monitored by 31P NMR spectroscopy. 
 
31P NMR spectroscopy based identification of dehydrophos 
metabolites, and monitoring of the hydrolysis reaction. Culture supernatant 
was passed through a 0.2 micron filter, concentrated twenty fold by evaporation, 
and D2O was added to 25% as a lock solvent. 31P NMR spectra were acquired 
on a Varian Unity Inova 600 spectrophotometer equipped with a 5 mm 
AutoTuneX probe at the Varian Oxford Instrument Center for Excellence at the 
University of Illinois Urbana-Champaign. An external standard of 85% phosphoric 
acid was defined as 0 ppm. Experiments to confirm the identity of proposed 
metabolites were routinely performed by adding 1-5 mM of standard to the 
sample and then reacquiring the spectra. 
 
Results 
 
Dehydrophos action requires transport into the bacterial cell. To 
determine if dehydrophos bioactivity requires cellular uptake, we performed 
bioassays utilizing several S. typhimurium permease mutants. S. typhimurium 
strain TN1379 contains all the discussed peptide permease systems, TN2271 
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contains only the Dpp system, and strain TN1890 contains both the Dpp and Tpp 
permease systems. 
 Dehydrophos inhibits TN1379 when applied as a synthetic standard 
(Figure 2.2, a). However, dehydrophos fails to produce a zone of inhibition 
against a lawn of TN2271 (Figure 2.2, b), and shows a minimal zone of inhibition 
against TN1890 (Figure 2.2, c). These results demonstrate that uptake into the 
cell is required for dehydrophos activity and that the Opp permease functions as 
the primary driver of dehydrophos transport. 
 
Dehydrophos action requires peptidase activity. To determine whether 
the antibiotic activity of dehydrophos was a function of the full length molecule or 
some other breakdown product we examined the bioactivity of this compound in 
two Salmonella strains. TN215 lacks PepA, PepD, PepB, PepN and is a leucine 
auxotroph. An otherwise isogenic strain containing the missing peptidases was 
utilized as the positive control. Dehydrophos fails to inhibit TN215 when applied 
Figure 2.2 The oligopeptide permease is required for dehydrophos activity. 
Bioassays performed by spotting synthetic dehydrophos onto a filter disc and 
assaying activity against various Salmonella strains. Strain TN1379, containing all 
three permease systems (a); strain TN2271, lacking the oligopeptide and tripeptide 
permeases (b); and strain TN1890, lacking only the oligopeptide permease (c). 
a b c 
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as a synthetic standard or contained within an agar plug taken from a culture of 
the native producer (Figure 2.3, a). In contrast, the control strain, containing all 
native Salmonella peptidases, shows inhibition by the authentic standard of 
dehydrophos as well as the agar plug taken from the native producer 
(Figure 2.3, b). These results indicate that dehydrophos action is dependent on 
peptidase cleavage. 
 
Peptidases capable of acting upon dehydrophos. To further explore 
the peptidase dependent nature of dehydrophos bioactivity, a series of 
peptidase- deficient strains of Salmonella were examined. Derived from TN215, 
these strains have a single specific peptidase reintroduced onto the 
chromosome. Designated TN271 (PepN+), TN272 (PepA+), TN273 (PepB+), 
Figure 2.3 The antibiotic activity of dehydrophos is peptidase dependent. 
Dehydrophos fails to inhibit a S. typhimurium strain lacking Peptidases A, B, D, and N 
when applied as either an agar core from the native producer, or as pure synthetic 
compound (a). In contrast, a related S. typhimurium strain containing the full 
complement of peptidases exhibits the typically seen growth inhibition (b). 
a b 
Agar core Agar core 
Synthetic 
dehydrophos 
Synthetic 
dehydrophos 
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and TN274 (PepD+), these strains were subjected to bioassay experiments with 
synthetic dehydrophos. Interestingly, reintroduction of any of these peptidases to 
the S. typhimurium genome resulted in restoration of growth inhibition by 
dehydrophos. However, depending on the peptidase present, the severity of the 
growth inhibition varied. Strains carrying Peptidase A or Peptidase B displayed 
growth inhibition similar to wild-type (Figure 2.4, b and c) , strains carrying 
Peptidase D had slightly smaller haloes of inhibition (Figure 2.4, e), and strains 
carrying only Peptidase N had severely retarded zones of inhibition (Figure 2.4, 
d). 
Figure 2.4 Reintroduction of any single peptidase allele is sufficient to restore 
dehydrophos bioactivity. Bioassay plates examining the effects of reintroduction of 
either PepA (b), PepB (c), PepN (d), or PepD (e) to a quadruple mutant of the 
aforementioned peptidases (a).  
a 
c e 
b d
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In vitro peptidase cleavage of dehydrophos by Salmonella Peptidase 
A results in the generation of methyl acetylphosphonate. Based on the 
chemical structure of dehydrophos the predicted products of peptidase cleavage 
are glycine, leucine, and 1-aminovinylphosphonate monomethyl ester. The 
phosphonate containing moiety is expected to tautomerize to the imine and 
undergo rapid hydrolysis to yield methyl acetylphosphonate (Figure 2.1). To test 
this prediction, we incubated synthetically prepared dehydrophos with purified 
PepA from Salmonella typhimurium and monitored the products of the cleavage 
reaction with phosphorus NMR spectroscopy (Figure 2.6). Under the conditions 
tested, the reaction proceeded slowly, which allowed for the observance of  
Figure 2.5 Acetate fails to relieve antibiotic inhibition generated by 
dehydrophos. The central filter disc was spotted with synthetic dehydrophos, 
while the outer contains a solution of acetate. The plate was seeded with a 
sensitive strain of E. coli. Note the appearance of a large number of resistant 
colonies, a phenomenon not witnessed in any other dehydrophos bioassay. 
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discrete intermediates in the hydrolysis of dehydrophos. After one hour at 37 °C, 
four separate peaks can be observed. The peak at a chemical shift of 10.2 ppm 
corresponds to full length dehydrophos. The peak immediately to the right (at 10 
ppm) is presumed to be dehydrophos lacking the N-terminal glycine 
(desglycyldehydrophos). Initially, the dehydrophos peak decreases in intensity, 
while the peak corresponding to desglycyldehydrophos increases in intensity. 
Following overnight incubation no peak corresponding to desglycyldehydrophos 
is present, and the dehydrophos peak is greatly diminished. 
Figure 2.6 PepA catalyzed degradation of dehydrophos. Time 
course following the fate of dehydrophos incubated with purified S. 
typhimurium PepA. After an hour, dehydrophos (10.2 ppm) remains 
primarily intact, although a good amount of dipeptide is present (10 
ppm) (a). After three hours the dipeptide dominates the spectra and the 
peak at 1 ppm has increased in intensity (b). Following an overnight 
incubation only two peaks remain, a large peak at 1 ppm, and a 
fraction of the original dehydrophos included (c). Addition of synthetic 
MAP verified the identity of the peak at 1 ppm (d). 
a b 
c d 
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Two other peaks are present in the spectra; one located at 6.2 ppm, and 
the other at 1 ppm. The peak at 1 ppm increases in intensity over time, and 
following overnight incubation represents the most abundant phosphorus 
containing species in the reaction mixture. The peak at 6.2 ppm demonstrates a 
similar intensity during the first two time points, but is not observed after the 
overnight incubation. Addition of standard MAP to the overnight incubation 
identified the peak at 1 ppm as MAP, consistent with the proposed model of 
dehydrophos activity. 
Following the establishment of MAP as the breakdown product of 
dehydrophos we examined whether the antibiotic phenotype caused by 
dehydrophos could be relieved by supplementation with acetate, bypassing any 
potential inhibition of the pyruvate dehydrogenase. To this end, we performed a 
bioassay in the presence of dehydrophos and acetate. The zone of inhibition 
remained unaltered, but suppressor colonies were present at a much higher 
frequency than previously observed. This result is consistent with the idea that 
dehydrophos has multiple, essential cellular targets, and acetate facilitates the 
bypass of one of these targets (Figure 2.5). 
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1-HEP O-monomethyl ester is a product of dehydrophos breakdown. 
Early investigations into dehydrophos biosynthesis were confounded by the 
presence of a second phosphonate peak observed in the culture supernatant of 
the native and heterologous producer. The demonstrated peptidase dependent 
Figure 2.7 S. lividans 66 converts exogenous dehydrophos to 1-HEP O-Me. 
31P NMR spectra depicting the fate of dehydrophos fed to S. lividans 66 over time. 
Prior to inoculation dehydrophos can be observed at a chemical shift of 10.2 ppm 
(a). Following inoculation of S. lividans 66 and 48 hours of growth the peak 
corresponding to dehydrophos has decreased in intensity, and a second peak has 
appeared at 24.5 ppm (b). Addition of synthetic 1-HEP O-Me increased the 
intensity of the nascent peak and confirmed its identity as 1-HEP O-Me (c). 
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generation of MAP led to the hypothesis that cells might detoxify MAP via 
reduction to form 1-HEP O-Me. To verify that the second phosphonate containing 
compound present in the supernatant of the heterologous host, WM4467 
(Chapter 3) is the result of dehydrophos catabolism, and not an unrelated 
compound or metabolic intermediate, we fed dehydrophos to S. lividans 66 and 
monitored the culture supernatant with phosphorus NMR spectroscopy. Over 
time the phosphorus peak associated with dehydrophos diminishes in intensity 
corresponding with the appearance and growth of a second peak (Figure 2.7). 
Addition of a synthetic standard of 1-HEP O-Me increased the intensity of this 
peak, and generated no additional peaks, indicating the identity of the second 
phosphonate seen in broth from the native and heterologous producers is 1-HEP 
O-Me resultant from the breakdown of dehydrophos.  
 
Discussion 
 
Many known phosphonate antibiotics utilize the addition of a short peptide 
‘trojan horse’ to obtain access into the cellular environment. Based on the 
structure of dehydrophos it seemed a likely candidate for this mechanism of 
uptake and our data indicate that dehydrophos can be added to the group of 
molecules utilizing the ‘trojan horse’. 
 In vitro peptidase treatment of dehydrophos demonstrated production of 
methylacetyl phosphonate directly from dehydrophos. Surprisingly, the 31P NMR 
based observation of this hydrolysis reaction revealed the transient presence of a 
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phosphorus-containing compound with a chemical shift at 6.2 ppm. One possible 
identity for this compound would be 1-aminovinylphosphonate generated by 
dehydrophos cleavage prior to tautomerization and subsequent rapid hydrolysis. 
The observance of this compound would be noteworthy, because known 
examples of enamine/imine tautomerization occur rapidly and favor the imine 
form (13). It could be that the phosphonate functions as a stabilizing influence on 
the enamine tautomer, but this remains to be demonstrated. Regardless, the 
observation of this transient peak in the 31P NMR spectrum raises interesting 
questions regarding the mode of action of dehydrophos. Although methyl 
acetylphosphonate is a structural analogue of pyruvate and a known, potent 
inhibitor of pyruvate dehydrogenase the possibility exists that 
1-aminovinylphosphonate (or alternate phosphonate, corresponding to the 6.2 
ppm chemical shift) participates in the antibiotic effect. Supplementation of the 
media with acetate to compensate for pyruvate dehydrogenase inhibition fails to 
relieve growth inhibition. This finding is not altogether surprising given the 
number of essential processes that pyruvate participates in. Indeed, although 
MAP is best known as a potent pyruvate dehydrogenase inhibitor it has also 
been shown to inhibit other pyruvate utilizing enzymes (18). 
 Also of note are the disparate levels of growth inhibition demonstrated by 
the peptidase mutant strains. Although PepA, PepB, and PepD show similar 
levels of activity, PepN shows a clear deficiency in its ability to process 
dehydrophos. In the wild-type Salmonella strain this is irrelevant due to the 
presence of redundant capable peptidases, but this phenomenon is consistent 
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with peptide linkage being a potential targeting mechanism for phosphonate 
antibiotics. Rhizocticins and plumbemycins contain the same warhead molecule, 
L-APPA, but target significantly different organisms. In these cases it has been 
proposed that activity is a function of oligopeptide mediated specificity in uptake 
or processing (2,3). 
 Along with the demonstrated necessity for peptidase function, permease 
activity is also required. The necessity of these functions for the bioactivity of 
dehydrophos clearly outline a mechanism that follows the “trojan horse” model 
observed for other phosphonate antibiotics. Given the promiscuous and varied 
nature of oligopeptide uptake and cleavage, an intriguing idea would be the 
attachment of multiple small molecule antibiotics to a peptide scaffold. Applied 
appropriately, this could open the door for treatment of infections prior to 
diagnosis of the pathogen; combat the increase of bacterial resistance, and lower 
mortality and morbidity.  
Dehydrophos contains a dehydroalanine analogue, and with the 
demonstrated necessity of hydrolysis for bioactivity this moiety was 
demonstrated to rearrange to form methyl acetylphosphonate. Consistent with 
this belief, a second phosphonate-containing compound was observed in culture 
supernatants of both the native and heterologous producers (Chapter 3). 
Moreover, the relative ratio of this second phosphonate to dehydrophos 
increased over time and the effect was more pronounced when the organism 
was cultured in oligopeptide rich nutrient broth (expected to encourage 
production of peptidases) relative to the starch based ISP4 medium. However, 
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NMR experiments quickly determined that this second phosphonate peak was in 
fact not MAP but a related compound, 1-HEP O-Me. This observation led to the 
belief that 1-HEP O-Me was generated by reduction of MAP, possibly as a 
detoxification mechanism. Feeding authentic dehydrophos to the heterologous 
host confirmed dehydrophos as the source of 1-HEP O-Me, but did little to 
confirm that production of 1-HEP O-Me proceeded via a methyl 
acetylphosphonate intermediate. 
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Chapter 3: Molecular Cloning, Heterologous Expression and Bioinformatic 
Analysis of the Dehydrophos Biosynthetic Gene Cluster of Streptomyces 
luridus NRRL 15101 
 
Abstract 
 
Dehydrophos is a vinyl phosphonate tripeptide produced by Streptomyces 
luridus with demonstrated broad spectrum antibiotic activity. To identify genes 
necessary for the biosynthesis of this compound we constructed a fosmid library 
of S. luridus and screened for the presence of the phosphoenolpyruvate mutase 
gene, which is require for the biosynthesis of most phosphonates. One such 
fosmid clone contained the genes capable of conferring production of 
dehydrophos upon a heterologous host, Streptomyces lividans 66 establishing 
the groundwork for further analysis into the biosynthesis of this unique 
compound. Deletion analysis of this clone allowed identification of the minimal 
contiguous dehydrophos biosynthetic gene cluster, which contained 17 open 
reading frames (ORFs). Bioinformatic analysis of the predicted ORFs allowed for 
the development of a putative biosynthetic pathway which generates 
dehydrophos from phosphoenolpyruvate. 
 
Introduction 
 
The phosphonate compound dehydrophos possesses a set of 
characteristics that made investigating the biosynthesis of this compound highly 
desirable. For one, robust production of dehydrophos from the native producer 
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had been previously established and documented. Additionally, the compound 
possessed antibiotic activity against E. coli, simplifying the down-stream cloning 
and screening process. And perhaps most importantly, the comparison of 
synthetically prepared ‘A53868’ to the phosphonate produced by S. luridus made 
apparent the published structure of this compound was incorrect, and the actual 
structure of dehydrophos contained several unique features. To further study the 
mechanism of dehydrophos biosynthesis we decided to isolate the requisite 
genes via a molecular approach. 
The use of a gene-targeted approach has led to the successful 
identification of the biosynthetic gene clusters required for the production of the 
phosphonate antibiotics phosphinothricin tripeptide (5), fosfomycin (29), and 
FR-900098 (10) production. The conserved nature of the phosphoenolpyruvate 
(PEP) mutase reaction (24) in phosphonate biosynthesis provides the rationale 
behind this approach, as all known natural occurring phosphonic acids are 
produced in a PEP mutase dependent fashion, with the single known exception 
being the phosphonic acid K-26 (21). Comparison and alignment of gene 
sequences coding for the PEP mutase allowed for the design of degenerate PCR 
primers that have proven useful in a bifurcated approach to studying phosphonic 
acid biosynthesis: One aspect of this approach is discovery-oriented and focuses 
on the isolation of novel phosphonate antibiotics from PEP mutase-containing 
uncharacterized soil isolates. The complementary aspect revolves around the 
identification of the gene clusters required for production of known phosphonic 
acids and ensuing characterization of genes involved in phosphonic acid 
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biosynthesis. Both of these aspects lean heavily on bioinformatics to aid in the 
research process. 
Bioinformatic analysis plays a large role in guiding the discovery platform. 
The advent of next generation sequencing technologies such as 4-5-4 and 
Illumina pyrosequencing have greatly expanded the scope of this gene targeted 
screening approach and provided large amounts of data. A substantial cost 
exists to analyze an isolate past the identification stage, both in terms of time and 
material. Therefore selecting candidates to pursue must be approached in a 
systematic and informed fashion. Bioinformatics function in this role by identifying 
redundant strains and highlighting highly divergent isolates (Xiaomin Yu, 
personal communication). 
Bioinformatic analysis has also fulfilled a key function in exploring the 
biosynthesis of known reduced phosphorus compounds. Putative functions of the 
ORFs present within a gene cluster can be deduced from analysis of the primary 
amino acid sequence. From these putative functions a hypothetical biosynthetic 
pathway can be constructed. These pathways can then be validated by genetic 
and biochemical means (4,10,18,25). We used this same model to propose, test, 
and establish significant portions of the dehydrophos biosynthetic pathway. 
 
Materials and Methods  
 
Bacterial strains, plasmids and culture conditions. The strains and 
plasmids used in this study are listed in Appendix A. Streptomyces strains were 
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propagated on ISP2 medium (Difco, Becton Dickinson Microbiology Systems, 
Sparks, Maryland) at 30 °C unless otherwise noted.  Heterologous production 
cultures were inoculated with 50 µL of spore stock (109 colony forming units) of 
the appropriate strain and incubated in 500 mL baffled flasks containing 100 mL 
of nutrient broth (Difco) agitated at 250 rpm for 48 hours prior to analysis of the 
supernatant. E. coli was routinely grown in Luria-Bertani broth (LB) or on 1.5% 
agar LB plates supplemented with appropriate antibiotics. Antibiotics were used 
at the following concentrations to select for plasmid propagation or integration 
events: ampicillin 100 µg/mL, chloramphenicol 10 µg/mL, apramycin 37.5 µg/mL, 
kanamycin 50 µg/mL. Diaminopimelic acid was added to media at a 
concentration of 1 mM for growth of dapA strains. For dehydrophos bioassays 
E. coli BW13711 was grown to an OD600 of 0.1, and then 100 µL was mixed with 
2 mL of molten ‘E’ media 0.5 % top agar (27) and pipetted onto ‘E’ media 1.5% 
agar plates and allowed to solidify. These plates were incubated at 37 °C for 12 
hours. Succinate (40 mM) was provided as the carbon source during bioassays.  
 
DNA isolation, manipulation, cloning and sequencing.  Cloning was 
accomplished by routine methods (22). Restriction endonucleases and T4 DNA 
ligase were purchased from New England Biolands (Ipswich, Massachusetts) or 
Invitrogen (Carlsbad, California). KOD HotStart polymerase (Novagen, EMD 
Chemicals Inc., Gibbstown New Jersey) was used for PCR amplification in 
combination with Failsafe PCR Premix buffers (Epicentre, Madison WI). 
Oligonucleotides were obtained from Integrated DNA Technologies (Coralville, 
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Iowa). DNA fragments used in cloning experiments were isolated by gel 
purification using the Promega Wizard PCR cleanup kit (Madison, WI). Plasmid 
isolation was accomplished by Qiagen Maxiprep or Miniprep kits (Valencia, 
California). Sequencing reactions were performed at the W.M. Keck Center for 
Biotechnology at the University of Illinois Urbana-Champaign utilizing primers T7-
for/T7-rev or primers pBTC034-For/pBTC034-Rev. Sequence data were 
compiled using Sequencer (Gene Codes Co., Ann Arbor Michigan) and deduced 
ORFs were subjected to BLAST (1), InterProScan (30), and ClustalW alignments 
with proteins of determined function. 
 
Generation of a S. luridus genomic library, library screening and 
sequencing of fosmid 17E11-4. Construction of a S. luridus genomic library 
was accomplished as described previously (10) except that WM4489 was used 
as the cloning host. This library was screened by PCR for the presence of the 
PEP mutase gene as previously described (10). PCR reactions contained 1 µL of 
culture broth as template, 500 nM of primers luridusppm-for/luridusppm-rev, and 
Taq polymerase in Failsafe buffer G. To provide the functions necessary for 
downstream genetic manipulation, the PEP mutase-positive fosmid clones were 
recombined with plasmid pAE4 (10) by in vitro recombination using BP clonase 
as directed by the manufacturer (Invitrogen, Carlsbad, California). WM4489 cells 
containing fosmid/pAE4 cointegrants were selected for on LB + kanamycin 
following electroporation. Following in vitro transposon mutagenesis with the 
mini-Mu containing BglII fragment of pAE5 as described (10), sequencing of 
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fosmid 17E11-4 was performed at the W. M. Keck Center for Biotechnology with 
primers SeqAETnR/SeqAETnL. 
 
Delineation of the minimal contiguous dehydrophos biosynthetic 
cluster. Deletion constructs were generated by in vitro recombination between 
FRT or loxP sites present on the fosmid backbone and corresponding sites on 
individual mini-Mu transposon insertions within the cluster DNA as described 
(10). Following site-specific recombination catalyzed by the appropriate 
recombinase (FLP or Cre), all intervening DNA between the transposon insertion 
and the fosmid backbone was deleted. Conjugative transfer of fosmids was 
performed as described elsewhere (19) with the modifications described below. 
The donor strain (WM6026) containing the fosmid to be transferred, was mixed 
with recipient S. lividans and the entire solution was spotted onto R2 (no 
sucrose) plates (17) in 10 µL aliquots and incubated at 37 °C. After 12 hours t he 
plates were flooded with 2 mL of 1mg/mL apramycin or neomycin and returned to 
the incubator. After 48 hours, exconjugants were picked and restreaked twice 
onto selective ISP2 before PCR verification. 
 
31P NMR detection and identification of dehydrophos and 
phosphonate metabolites. Culture supernatant was passed through a 0.2 
micron filter, concentrated twenty fold by evaporation, and D2O was added to 
25% as a lock solvent. 31P NMR spectra were acquired on a Varian Unity Inova 
600 spectrophotometer equipped with a 5 mm AutoTuneX probe at the Varian 
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Oxford Instrument Center for Excellence at the University of Illinois Urbana-
Champaign. An external standard of 85% phosphoric acid was defined as 0 ppm. 
Supernatant obtained following growth on liquid ISP4 (Difco) media was utilized 
to confirm heterologous dehydrophos production. To verify heterologous 
production of dehydrophos, an authentic standard of dehydrophos was 
introduced into the NMR sample to a final concentration of 1 mM and the 
spectrum of the sample was retaken using identical parameters. 
 
Results 
 
Cloning of the dehydrophos gene cluster and heterologous 
production in Streptomyces lividans. To identify genes necessary for 
dehydrophos biosynthesis, a genomic library of Streptomyces luridus NRRL 
15101 was assembled in E. coli and individual clones were screened via PCR for 
the PEP mutase gene. Of the 2496 clones that were screened, ten were PEP 
mutase positive. To test whether these clones contained all required genes for 
dehydrophos production, they were all modified with helper plasmid pAE4 to 
allow their transfer into the chromosome of S. lividans (10). Following integration 
into the chromosome each of the ten resulting recombinant strains was examined 
for bioactivity. Only one such strain, S. lividans WM4467, carrying fosmid 
17E11-4, produced a compound that inhibited the growth of E. coli DH5α. 
Furthermore, the compound produced by this recombinant strain failed to inhibit 
an isogenic dehydrophos resistant mutant, suggesting that the strain acquired 
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the ability to synthesize dehydrophos. No growth inhibition was detected using 
supernatant from unmodified S. lividans (Figure 3.1). Further evidence that the 
compound produced by the recombinant strain was dehydrophos was provided 
by 31P NMR analysis. Supernatants from the recombinant strain exhibit a peak in 
Figure 3.1 (I) Bioassay demonstrating heterologous production of 
dehydrophos. Production of dehydrophos was assayed against sensitive (a) and 
resistant (b) strains of E. coli. Filter disks were spotted with supernatant from 
WM4467, a synthetic standard of dehydrophos, or supernatant from wild type S. 
lividans, as indicated. (II) 31P NMR spectra demonstrating heterologous production 
of dehydrophos. (a) Supernatant collected from WM4467, (b) as (a) but containing 
synthetic dehydrophos added as an internal standard. 
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the 31P NMR spectrum with a chemical shift of ~10.2 ppm, which corresponds 
closely to the chemical shift of dehydrophos from the native producer, S. luridus. 
Addition of a synthetic dehydrophos standard resulted in increased intensity of 
the 10.2 ppm peak and lacked the appearance of any new peaks, corroborating 
the identity of this phosphonate as dehydrophos (Figure 3.1). An additional 31P 
NMR peak was observed in supernatant from the heterologous producer during 
longer incubations. Located at 24.5 ppm, this peak is also present in the 
supernatant of the native producer and increases in intensity over time, possibly 
indicating a breakdown product of the tripeptide. Control experiments revealed 
that unmodified S. lividans converts dehydrophos into a compound with the same 
31P NMR spectrum, supporting this contention (Figure 3.2).  
 63 
Figure 3.2 Synthetic dehydrophos added to S. lividans cultures is degraded 
to 1-hydroxyethylphosphonate O-monomethyl ester (1-HEP O-me). A culture 
of S. lividans was incubated in the presence of 1.5 mM dehydrophos and 
monitored by 31P NMR over time. Prior to growth, all NMR visible phosphonate 
appears at 10.2 ppm in the form of dehydrophos (a), after 48 hours, the intensity of 
the 10.2 ppm peak has decreased, and a second peak has appeared at 24.5 ppm 
(b). Addition of a synthetic standard of 1-HEP O-Me to the 48 hour sample results 
in an increase in the size of the 24.5 ppm peak and confirms the identity of the 
nascent peak (c). 
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 Sequencing, delineation of boundaries, and bioinformatic analysis of 
the dehydrophos biosynthetic gene cluster. The plasmid clone that conferred  
dehydrophos production to S. lividans was sequenced and shown to carry a 
35.9 kb insert of S. luridus genomic DNA (Figure 3.3). 
In silico sequence analyses identified 27 potential genes within the insert. 
To determine the minimal contiguous cluster required for dehydrophos 
production deletion derivatives that truncated the plasmid from either the 5′ or 3′ 
end of the insert were constructed and integrated into the chromosome of S. 
lividans.  The effects of these deletions on dehydrophos production were 
monitored by 31P NMR spectroscopy and bioassay. A recombinant strain lacking 
ORFs 1-4 (WM5668) retained the ability to produce dehydrophos, whereas a 
strain in which ORFs 1-5 and a portion of dhpA were removed (WM5672) 
abolished production of dehydrophos (Figure 3.4). Likewise, a strain in which 
ORFs 22-27 were deleted (WM5693) continued to produce dehydrophos; 
whereas a strain in which a portion of dhpP was deleted in addition to ORFs 22-
27 (WM5689) was unable to produce dehydrophos (Figure 3.4).  
Figure 3.3 Genetic organization of Fosmid 17E11-4. Dark arrows indicate ORFs 
thought to be involved in dehydrophos biosynthesis. The solid lines indicate DNA 
fragments whose deletion has no effect on production of dehydrophos, whereas the 
dotted lines indicate deletions that abolish production. 
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These experiments revealed that a contiguous segment of DNA, comprised of 
ORFs orf5 to orf21, is needed to confer dehydrophos production on a 
heterologous host. Accordingly, ORFs orf6 to orf21 were designated dhpA-dhpP.  
The organization of the dhpA-dhpL genes suggests they are co-
transcribed (Figure 3.3). Many of these genes share overlapping start/stop 
codons (dhpA-dhpB, dhpC-dhpD, dhpE-dhpF-dhpG-dhpH). Three of these 
genes, dhpE (PEP mutase), dhpF (phosphonopyruvate decarboxylase), and 
dhpG (Fe-dependent alcohol dehydrogenase) have homologs present in multiple 
phosphonate biosynthetic clusters (25). Bioinformatic analysis, consisting of 
BLAST searches followed by alignment to representative proteins and 
identification of conserved active site residues allowed a proposed function to be 
assigned to each open reading frame (Table 3.1). 
Figure 3.4 31P NMR spectra from supernatant of truncated clusters. 
Dehydrophos is known to shift at 10.2 ppm. a) WM5672 b) WM5668 c) WM5689 d) 
WM5693. 
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              Table 3.1 Summary of 17E11 open reading frames 
1
 Results generated by BLAST analysis of deduced open reading frames. 
Accession numbers are listed in parentheses. 
ORF AA Protein homology1  Amino acid identity (%) 
orf1 509 Streptomyces lividans D-Ala-D-Ala carboxypeptidase (YP_002193425) 215/366 (59%) 
orf2 469 Thermomonospora curvata FAD dependent oxidoreductase (ZP_04033692) 336/465 (72%) 
orf3 624 Salinispora arenicola polysaccharide pyruvyl transferase (YP_001538394) 228/366 (62%) 
orf4 170 Bacillus sp. SG-1 steroid ∆-isomerase domain protein (ZP_01861119) 51/109 (47%) 
orf5 86 Streptomyces ghanaensis putative transglycosylase associated protein (ZP_04690162) 75/81(92%) 
dhpA 299 uncultured microorganism putative γ-butyrobetaine hydroxylase  
 (ABZ07908) 
72/254 (28%) 
dhpB 383 Vibrio splendidus glycerate kinase (YP_002394749) 115/332 (35%) 
dhpC 371 Aciduliprofundum boonei malate/L-lactate dehydrogenase  
(YP_002578914) 
130/367(35%) 
dhpD 397 Candidatus Pelagibacter ubique aspartate transaminase 
(ZP_01264754) 
112/403 (28%) 
dhpE 296 Frankia alni putative PEP phosphomutase (YP_716511) 147/275 (53%) 
dhpF 381 Amycolatopsis orientalis putative phosphonopyruvate decarboxylase 
(CAB45023) 
182/371(49%) 
dhpG 396 Amycolatopsis orientalis putative alcohol dehydrogenase (CAB45024) 152/367(41%) 
 
dhpH  
355 N′ terminal domain Amycolatopsis orientalis putative aminotransferase 
(CAB45025) 
169/355 (48%) 
 343 C′ terminal domain Yersinia pseudotuberculosis FAD linked oxidase 
domain-containing protein (YP_001721344) 
101/348 (29%) 
dhpI 218 Streptomyces clavuligerus putative S-adenosylmethionine-dependent 
methyltransferase (YP_002193190) 
89/211 (42%) 
dhpJ 230 Streptomyces albus peptide aspartate β-dioxygenase ( ZP_04702360) 113/230 (49%) 
dhpK 422 marine γ proteobacterium conserved hypothetical protein 
(YP_002651317) 
72/271 (27%) 
dhpL 422 Bradyrhizobium japonicum putative integral membrane transporter 
(NP_774016) 
160/352 (45%) 
dhpM 503 Frankia sp. CcI3 Na+/solute symporter (YP_481567) 274/465 (59%) 
dhpN 520 Frankia sp. CcI3 Na+/solute symporter (YP_481567) 307/507(61%) 
dhpO 207 Frankia sp. CcI3 σ-24 (YP_481568) 105/172 (61%) 
dhpP 339 Streptosporangium roseum lacI family transcription regulator 
(ZP_04472611) 
219/336 (65%) 
orf22 452 Actinosynnema mirum cellulase (glycosyl hydrolase family 5) 
ZP_03814915 
193/322 (60%) 
orf23 294 Streptomyces ambofaciens conserved hypothetical protein (CAI78012) 125/228 (55%) 
orf24 519 Streptomyces ambofaciens putative export protein (CAJ90162) 420/527 (80%) 
orf25 163 Streptosporangium roseum transcriptional regulator (ZP_04478568) 112/156 (72%) 
orf26 392 Streptomyces sp. Mg1 aspartate aminotransferase (YP_002180528) 305/384 (79%) 
orf27 350 Streptomyces sp. Mg1 hypothetical protein (YP_002180529) 251/306 (82%) 
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Bioinformatic analysis of individual open reading frames 
 
orf5. The involvement of orf5 in dehydrophos biosynthesis has not been 
directly established. Mutants constructed by progressively deleting DNA from the 
5’ portion of the fosmid insert clearly show the dispensability of orf4 and 
necessity of dhpA (Figure 3.4), but a mutant lacking orf5 and retaining all of dhpA 
does not exist. If required, the role of orf5 in dehydrophos biosynthesis is also 
unclear. The deduced protein is small (86 AA) and predicted to be an integral 
membrane protein. While homologous proteins have been annotated as 
transglycosylase associated proteins, these designations lack experimental 
evidence.  
 
dhpA. The first gene within the fosmid insert demonstrated necessary for 
dehydrophos biosynthesis is dhpA. A putative ribosome binding site (RBS) 
(AGGAAG) is located thirteen bases upstream of a GTG start. The protein 
product of dhpA contains homology to γ-butyrobetaine hydroxylases. These 
enzymes participate in carnitine biosynthesis by hydroxylating the C3 position of 
4-trimethylammoniobutanoate in an oxygen and 2-oxoglutarate dependent 
fashion. TauD, a close relative, and representative of the EC 1.14.11 
(2-oxoglutarate dependent dioxygenases) family of enzymes has been 
crystallized and important conserved residues have been identified. Specifically, 
a “facial triad” of residues is critical for coordinating the Fe2+ needed for activity. 
These residues are arranged in an HXDX53-57H format, although the terminal 
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histidine tolerates some variability in distance, presumptively from the overall 
arrangement of the tertiary structure. Amino acid alignment of DhpA with TauD 
reveals a potential HxD sequence, trailed by two histidine residues, both at 
lengths consistent for a facial triad (Figure 3.5). Based on the bioinformatic 
examination, DhpA was expected to be involved in a hydroxylation reaction. 
dhpB. The second predicted open reading frame present within the 
dehydrophos biosynthetic cluster was designated dhpB. This open reading frame 
shares an ATG/TGA start/stop arrangement with dhpA, and lacks an obvious 
ribosome binding site. BLAST analysis of this open reading frame indicates 
sequence similarity with the family of enzymes involved in the phosphorylation of 
glycerate. This reaction occurs in an ATP dependent fashion, and participates in 
the degradation of allantoin. The sequence homology results receive further 
TauD         MSER--LSITPLGPYIGAQISGADLTRPLSDNQFEQ----LYHAVLRHQVVFLRDQAITP 56 
DhpA         VTGGGHQTTPGQTLTDGFDAVRVAVAGPLRDHLTSAGESTADAGAARAELAALVGEHLDD 60 
             ::              *           *  .           .  *  :  : .: :   
 
TauD         -QQQRALA-----QRFGELHIHP-VYPHAEGVDE--IIVLDTHNDN------PPDNDNWH 99 
DhpA         GPGVLVLTGLPADREGGERAVLRATRLLGEPLPQNREGTLVREVRD-RGMSISQRGRTRY 119 
                  .::     :. **  :   .    :   :    .*     :      .  .   : 
 
TauD         TDVTFIETPPAGAILAAKELPSTGGDTLWTSGIAAYEALSVPFRQLLSGLRAEHDFRKSF 159 
DhpA         SDSRFGGDLHTDG--AEAPLPAPDVFTLFCVRQSVHGGALQCLHVREVERALDPEVLATL 177 
             :*  :     :.       :*: .  * :    :.: .    .:          :   :: 
 
TauD         --PEYKYRKTEEEHQRWREAVAKNPPLLHPVVRTHPVSGKQALFVNEGFTTRIVDVSEKE 217 
DhpA         RAPFRFDRRGDQEPG----QDPTTAKPVLFSQRGRPAITYLRSYIEHGHDHPGVPALTTG 233 
               *    ::               .       * :*       ::        *       
 
TauD         SEALLSFLFAHIT-KPEFQVRWRWQPNDIAIWDNRVTQHYAN-ADYLP-QRRIMHRATIL 274 
DhpA         QRAALDALDALIASSPAVLT-GKLREGELALFDNLSLLHGRTEFQDEPDHTRLLLRTWVR 292 
             . * :  * *    .. .    : : .:: ::**    *  .  :    : * : *: :  
 
TauD         GDKPFYRAG------- 283 
DhpA         RHSDERS--------- 299 
              .               
 
Figure 3.5 ClustalW alignment of DhpA and TauD. Residues known to form the 
facial triad in TauD are highlighted in red. Potential residues composing the facial triad 
in DhpA are highlighted in yellow. 
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support upon alignment to crystallized examples from this family, which reveal 
that seven of the nine identified catalytic residues are conserved (Figure 3.6). 
 
dhpC. ORF dhpC does not exhibit an overlapping stop/start codon 
arrangement with dhpB, and examination of nearby DNA sequence reveals a 
potential RBS (AGGAT) twelve bases upstream of the annotated ATG start. 
DhpB     ----------MNRGPAPAAEIVVAPNCMRGYASAAEVAAALITGVRRVRPRVRAVARPLA 50 
P57098   ------------------MKIVIAPDSFKESLTAQQVAEAIKRGFQQSIADVECLLCPVG 42 
Q9X1S1   MFDPESLKKLAIEIVKKSIEAVFPDRAVKETLPKLNLDRVILVAVGKAAWRMAKAAYEVL 60 
                            : *..  ..:   .  ::  .:  .. :    :      :  
 
DhpB     -------------DGGDGTLD--ALYAACGGVRHPVAAVDVLGRTRKAHWLALDRRTAAV 95 
P57098   -------------DGGEGTVD--AIRHSLDLEEKCLQVTGSFGQKEVMRYFQKEQ-LALF 86 
Q9X1S1   GKKIRKGVVVTKYGHSEGPIDDFEIYEAGHPVPDENTIKTTRRVLELVDQLNENDTVLFL 120 
                      . .:*.:*   :  :     .           .    :  :     . 
 
DhpB     ETAGVCGLGALRPRELRPLRATSAGAGQAVAAAVEAGATTVLVGLGGTAV--VDGGAGAL 153 
P57098   EVADLVGLGKIPLEKRNPLQIQTRGIGELIRHLISQEIKEIYIGVGGTAS--NDGGIGIA 144 
Q9X1S1   LSGGGSSLFELPLEGVSLEEIQKLTSALLKSGASIEEINTVRKHLSQVKGGRFAERVFPA 180 
           ..  .*  :  .     .  .   .           . :   :. .             
 
DhpB     AALGARFLDRDGHEVEPVPERLPDAVRVDLSAARRLLEGVTVRLLADVRTPLSGNLDS-- 211 
P57098   AGLGYQFYDEDGNALPACGQSLLNLASVSTENRYKIPEDVHIRILADVVSPLCGHQGATY 204 
Q9X1S1   KVVALVLSDVLGDRLDVIASGPAWPDSSTSEDALKVLEKYGIETSESVKRAILQETPK-- 238 
           :.  : *  *. :    .          .   :: *   :.   .*  .:  .      
 
DhpB     -FGAQKGVTAENRPAAVRALQHLTSLLGQAGDLTAADRFRTPWFGAGGGIGFGLSAVAAT 270 
P57098   TFGKQKGLDSTMFEVVDQAIQDFYEKVSPA-------TLKLKGAGAGGGIAGGLCAFAQA 257 
Q9X1S1   ---HLSNVEIHLIGNVQKVCDEAKSLAKEKGFNAEIITTSLDCEAREAGRFIASIMKEVK 295 
              ..:       . :. :.  .                   .  .*   .        
 
DhpB     TAESGTEALLDITDPGGSISTAALVITA----EGAIDPGTWQGKLPGTIARLRRDRGLPT 326 
P57098   SIVSGIDTCLDLIDFDKKVSDVDLVIVG----EGRLDRQSLAGKAPIGVAKR-TPVGVPV 312 
Q9X1S1   FKDRPLKKPAALIFGGETVVHVKGNGIGGRNQELALSAAIALEGIEGVILCSAGTDGTDG 355 
               .    :   . .:  .     .    *  :.           :       *    
 
DhpB     AMVAARAEADAATADPLVTVHLAADPPLDAPLVGPALHEG---LARAAAAACRTWAVAAA 383 
P57098   VAICG-SLVEDLPSLPFENIQAAFSILEKSEPLEDSLKNASLYLEHTASNIGHLLNMPKI 371 
Q9X1S1   PTDAAGGIVDGSTAKTLKAMGEDPYQYLKNNDSYNALKKSGALLITGPTGTNVNDLIIGL 415 
            .. . .:  .: .:  :        .      :*::.   *   .:       :    
 
DhpB     -- 417 
P57098   -- 
Q9X1S1   IV 
            
 
Figure 3.6 Multiple glycerate kinase active site residues are conserved in DhpB. 
ClustalW alignment of DhpB with two characterized glycerate kinases (designated by their 
Uniprot accession numbers). Active site residues in the crystallized glycerate kinase 
P57098 are highlighted in red, and the corresponding residues in DhpB have been 
highlighted in yellow. 
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Sequence analysis indicates that DhpC contains homology to malate and lactate 
dehydrogenases, which catalyze the reversible oxidation of the resident hydroxyl 
group to a keto group to form oxaloacetate and pyruvate, respectively. This 
reaction occurs in an NAD+ dependent fashion and under standard conditions 
favors the formation of lactate 24,343:1. Alignment of the amino acid sequence to 
a representative malate dehydrogenase which has been crystallized reveals that 
four of six active site residues are conserved in DhpC (Figure 3.7). The 
conservation of ‘D53’ and ‘R102’ are particularly informative. The retention of 
‘D53’ suggests that DhpC prefers NAD+ over NAD(P)+ as a cofactor. ‘R102’ is 
functionally conserved as a glutamine, predicting the protein has specificity for 
DhpC    MYASDGTDRASVVGRKPLTDFVIEALTSVGAGEADAALTADVLVAADLAGVDSHGVARLR 60 
A7ZSD0  -------MKVAVLGAAGGIGQALALLLKT------QLPSGSELSLYDIAPVTPGVAVDLS 47 
                :.:*:*     . .:  * ..         :.. *   *:* * .  .. *  
 
DhpC    RYVEGLRNGTINGRARPRVEREHGGVSVVDAQNGLGQPALCFAVDLAVERAREHGVAAVA 120 
A7ZSD0  HIPTAVK---IKGFSGEDATPALEGADVVLISAGVAR-------KPGMDRSDLFNVNAGI 97 
        :   .::   *:* :   .     *..**  . *:.:       . .::*:  ..* *   
 
DhpC    VRRSNHIGIAGWYTERAARSGTFAMVTTNATPQVAPTGAAEPMFGTDPVSYAVPTAGEPL 180 
A7ZSD0  VKN---------LVQQVAKTCPKACIGIITNPVNTTVAIAAEVLKKAGVYDKN------K 142 
        *:.          .::.*:: . * :   :.*  :... *  :: .  *            
 
DhpC    CYDAATSIVPRGKLERLDREGKPMLPGWAVGPDGATSTDIPRVVAGLKAREGYALLPVGG 240 
A7ZSD0  LFGVTTLDIIRSNTFVAELKGK---------QPGEVEVPVIGGHSGVTILPLLSQVPGVS 193 
         :..:*  : *.:    : :**           * ... :    :*:.     : :*  . 
 
DhpC    LGEEYGGHKGSGIGLLAELLCGPLTGASWSKHTYGPEGADLGQFVLCLDLAALGDAGRIT 300 
A7ZSD0  FTEQEVADLTKRIQNAGTEVVEAKAGGGSATLSMGQAAARFG---LSLVRALQGEQG--V 248 
        : *:  ..  . *   .  :  . :*.. :. : *  .* :*   *.*  *  *: *  . 
 
DhpC    RDVDAMAAEIRAARRADEDVPVRLPGERRHRCAEERSARGIPLLPPVVRDLGKIAELTGI 360 
A7ZSD0  VECAYVEGDGQYARFFSQPLLLGKNGVEERKSIGTLSAFEQNALEGMLDTLKKDIALG-- 306 
         :   : .: : **  .: : :   * ..::.    **     *  ::  * *   *    
 
DhpC    KPLGARDGQDA 371 
A7ZSD0  EEFVNK----- 312 
        : :  :      
 
Figure 3.7 Conservation of active site residues in DhpC suggest involvement 
in a NAD+ coupled redox reaction. ClustalW alignment of DhpC with a crystallized 
malate dehydrogenase (Uniprot accession number shown). Active site residues 
from A7ZSD0 are highlighted in red, with the corresponding residues in DhpC 
highlighted in yellow, “D53” and “R102” are shown in bold yellow text. 
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pyruvate, rather than oxaloacetate (14). The presence of glutamine at the R102 
position is thus consistent with a smaller 3-carbon substrate, rather than the 
slightly larger substrate of malate dehydrogenase. The conclusion made from 
these analyses predicted DhpC to be involved in the oxidation/reduction of a 
hydroxyl group contained on a relatively small molecule, most likely utilizing 
NAD(H) as a cofactor. 
 
dhpD. The start codon of dhpD (GTG) overlaps with the stop codon of dhpC 
(TGA), and visual inspection of the upstream region fails to identify a strong ribosome 
binding site. BLAST analysis of the predicted dhpD ORF reveals homology to the 
aspartate aminotransferase (EC 2.6.1.1) superfamily of enzymes. These enzymes 
utilize the cofactor pyridoxal phosphate (PLP) to react with an alpha-amino acid to 
generate a Schiff base, which can subsequently undergo one of four types of 
transformations: transamination, decarboxylation, racemization, or a variety of side-
chain reactions that are dependent on the enzyme involved. ClustalW alignment to a 
crystallized member of this family revealed complete conservation of the active site 
residues (Y70, W140, Y225, K258, R292, R386) involved in binding and positioning of 
the PLP group necessary for catalysis (Figure 3.8). Although the breadth of PLP-
catalyzed reactions must be considered, the most likely role for dhpD is catalysis of a 
transamination reaction.  
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dhpE. This ORF does not share an overlapping start/stop codon with the 
preceding ORF (dhpD) and dhpE lacks an easily identifiable RBS. Perhaps 
compensating for these attributes, the distance between the two ORFs is minimal 
(10 bases). ORF dhpE contains a high level of identity to the PEP mutase of 
Frankia alni (53% identical). As discussed in Chapter 1, the PEP mutase enzyme 
catalyzes the intramolecular rearrangement of phosphoenolpyruvate to 
phosphonopyruvate. Alignment of dhpE to the crystallized PEP mutase of Mytilus 
DhpD   -----------VTGSARGSSPAPSLAVR------EDTGPPVIDLSSGQILEPLPEAARAA 43 
Q9L0L5 MSAAIPPTERRVSARVGAISESATLAVDAKAKALKAAGRPVIGFGAGEPDFPTPDYIVEA 60 
                  *:. . . * :.:***       : :* ***.:.:*:   * *:    * 
 
DhpD   IRRATESPEASGYAPGPGRADLRTAVADHYARRTGAATDPDHVTVTAGARHGLFAAVAAA 103 
Q9L0L5 AVEACKNPKFHRYTPAGGLPELKAAIAAKTLRDSGYEVDPSQILVTNGGKQAIYEAFAAI 120 
         .* :.*:   *:*. * .:*::*:* :  * :*  .**.:: ** *.::.:: *.**  
 
DhpD   A-AGREVLVPAPHWSHYPTVIRQAGAVPVTVAGDPLHGLLVDPARLDAAWTPRTGAVLVN 162 
Q9L0L5 LDPGDEVIVPAPYWTTYPESIRLAGGVPVEVVADETTGYRVTVEQLEAARTEKTKVVLFV 180 
         .* **:****:*: **  ** **.*** *..*   *  *   :*:** * :* .**.  
 
DhpD   SPVNPSGACYDEGRLRELRAWAAARNVRLIVDDIY--WAYGSHIDTRLLPGP-----HEV 215 
Q9L0L5 SPSNPTGAVYGEAETEAIGRWAVEHGLWVLTDEIYEHLVYGDAVSVSLPALLPELRDKCI 240 
       ** **:** *.*.. . :  **. :.: ::.*:**   .**. :.. * .       : : 
 
DhpD   VVGGASKVYALAGLRIGWVWAEPALGAAVREIVEHTTGPVSGPAQAAAAAVLAYENGTGG 275 
Q9L0L5 VVNGVAKTYAMTGWRVGWVIGPKDVVKAATNLQSHATSNVANVSQAAALAAVSGN----- 295 
       **.*.:*.**::* *:*** .   :  *. :: .*:*. *:. :**** *.:: :      
 
DhpD   TGAAVAGAGVARRADRLARQRAEAVQAMAAVPYLRPVPPAGGIYLCLDASEALGLRLLG- 334 
Q9L0L5 ------LDAVAKMREAFDRRRQTIVRMLNEIDGVLCPEPEGAFYAYPSVKALLGKEIRGK 349 
               .**:  : : *:*   *: :  :  :    * *.:*   ...  ** .: *  
 
DhpD   -AGDDQELCRALRSGAGVGLRAGSTFGMPGFLRLCVAESHEVLLTAAHRLTTCLTAAARE 393 
Q9L0L5 RPQDSVELAALILEEAEVAVVPGEAFGTPGYLRLSYALGDEDLVEGVSRIQKLLAEARD- 408 
        . *. **.  : . * *.: .*.:** **:***. * ..* *: .. *: . *: *    
 
DhpD   VTHH 397 
Q9L0L5 ---- 
                
 
Figure 3.8 Residues necessary for PLP-binding are completely conserved 
in DhpD. A ClustalW alignment with residues from a characterized enzyme 
(Uniprot accession number shown) highlighted in red, while the corresponding 
residues in DhpD are highlighted in yellow. 
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edulus revealed complete conservation of the PEP mutase active site residues 
(Figure 3.9). Based on the strong homology of dhpE to known PEP mutases, the 
conservation of active site residues, and the ability of a cosmid containing dhpE 
to confer heterologous production of a phosphonate-containing molecule upon an 
organism empirically known not to produce phosphonate compounds we have a 
strong confidence that dhpE encodes a functional PEP mutase. 
 
dhpF. Immediately following dhpE and sharing an overlapping stop/start 
codon arrangement (TGA/GTG) is ORF dhpF. This ORF lacks an easily 
identifiable RBS, and demonstrates significant BLAST identity (49% identical) to 
the phosphonopyruvate (PnPy) decarboxylase of Amycolatopsis orientalis. The 
phosphonopyruvate decarboxylase is commonly coupled to the PEP mutase to 
provide the thermodynamic driving force to overcome the unfavorable equilibrium 
DhpE   MTIASYGPSTLPGSRAATLRDAFANGRLVRVAGAHDGLSARLAEEAGFDSVWASGLEISA 60 
P56839 --------MSTKVKKTTQLKQMLNSKDLEFIMEAHNGLSARIVQEAGFKGIWGSGLSVSA 52 
                :   .::: *:: : .  *  :  **:*****:.:****..:*.***.:** 
 
DhpE   AHGLPDVSLLGMAEYLSAAVAMQRSVSVPVVADCDTGFGGVLNAAYTMMRYEEAGVAGVC 120 
P56839 QLGVRDSNEASWTQVVEVLEFMSDASDVPILLDADTGYGNFNNARRLVRKLEDRGVAGAC 112 
         *: * .  . :: :..   *. : .**:: *.***:*.. **   : : *: ****.* 
 
DhpE   IEDKIFPKRNSFVN-SGQKLLDVDEFGRKLEAAKRAQVSSDTVLIARTEAFICGLGLQEA 179 
P56839 LEDKLFPKTNSLHDGRAQPLADIEEFALKIKACKDSQTDPDFCIVARVEAFIAGWGLDEA 172 
       :***:*** **: :  .* * *::**. *::*.* :*...*  ::**.****.* **:** 
 
DhpE   LTRCHHYVDAGADAVLVHSKAVDSGEVVSFMKEWNHRAPVVVVPTTYADFSAAEAQEAGI 239 
P56839 LKRAEAYRNAGADAILMHSKKADPSDIEAFMKAWNNQGPVVIVPTKYYKTPTDHFRDMGV 232 
       *.*.. * :*****:*:*** .*..:: :*** **::.***:***.* . .: . :: *: 
 
DhpE   SMVIYANQGMRAAITAIRSTWATVLAEGSTAPVEPRIASVKDIFAISGMDQWLDLDR--- 296 
P56839 SMVIWANHNLRASVSAIQQTTKQIYDDQSLVNVEDKIVSVKEIFRLQRDDELVQAEDKYL 292 
       ****:**:.:**:::**:.*   :  : * . ** :*.***:** :.  *: :: :     
 
DhpE   --- 
P56839 PKN 295 
 
Figure 3.9 Known PEP mutase active site residues show complete conservation 
in DhpE. Active site residues identified from the PEP mutase of M. edulus are 
highlighted in red, while those residues in DhpE are highlighted in yellow. 
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of the PEP mutase permitting net biosynthesis of phosphonates. Consistent with 
the work of Shao et al, dhpF immediately follows the PEP mutase as the second 
component of a three gene motif (PEP mutase, PnPY decarboxylase, PnAA 
reductase) present in multiple phosphonate biosynthetic gene clusters, with the 
genes commonly arranged in a linear fashion. The putative decarboyxlation 
catalyzed by DhpF occurs in a thiamin pyrophosphate (TPP) dependent manner, 
and alignment of dhpF to the well characterized Bacteroides fragilis PnPy 
decarboxylase confirmed the complete conservation of active site residues 
known to interact with TPP/Mg++ (Figure 3.10), as well as a very high degree of 
conservation of the ‘TPP box’ (31) . Using a similar rationale applied to the PEP 
DhpF   MSDRITAEEFVAALRAHGVQRVTGVPCGHLAGPWALFDG---AGDLTPAASEGAALALAA 57 
Q9F764 ---MVSVEKIYDTFLHHGVDFFTGVPDSLLKNICAYITDHAPRGKHIIAANEGSAVGIAC 57 
           ::.*::  ::  ***: .**** . * .  * : .    *.   **.**:*:.:*. 
 
DhpF   GWELAG-RTSVVLCQNSGFGNLVNPLTSLLLP--YRVPVLVVMTMRGWPDPAEDEPQHAA  
Q9F764 GYYMASGNVPLVYMQNSGLGNTVNPLLSLADEKVYSLPLLLLVGWRGEPG-TKDEPQHKK  
       *: :*. ...:*  ****:** **** **     * :*:*:::  ** *. ::*****   
 
DhpF   MGTSTVALLETLDVPHAVLWPG---KLEEALGQAADARAAGRPFFLLVPRGAIGKAAGAY  
Q9F764 QGEVTLDLLKAMKIPFIILDTDEDEALAQIHDAVVSAKSRSIPHAIVIRKDTFGKYK--L  
        *  *: **:::.:*. :* ..    * :  . ...*:: . *. ::: :.::**      
 
DhpF   PAGAPADDRLTRPRAVAALMAELTD-ELMVTTTGYLSRQAHHERD-----RPDTFYMQGS  
Q9F764 RQEALNDYPLSREEALMQVVDHLGDNDIVVSTTGKLSRELFEYRESKGQGHARDFLTVGS  
          *  *  *:* .*:  :: .* * :::*:*** ***: .. *:     :.  *   ** 
 
DhpF   MGHASAVGLGLATARPERRTVVLDGDGAFLMHLGSGSTIGSSGARNLTHVVVDNGCYEST  
Q9F764 MGHSSSIALGIALEKPDRRVYCLDGDGAFIMHMGAVSNIGDLSPKNYRHVLFNNGAHESV  
       ***:*::.**:*  :*:**.  *******:**:*: *.**. ..:*  **:.:**.:**. 
 
DhpF   GCQPTTSGGLDWASLGTGLGYRTVLTCDSTGDLTGSLRAALTAEGPVLLALTVVPTPGEV  
Q9F764 GGQPTLGFRLDIASIAKGCGYAHVLTASDKEGLSCALEKLSGLSGPVLLEIKVRIDSRDD  
       * *** .  ** **:..* **  ***.... .*: :*.     .***** :.*   . :  
 
DhpF   HPRATASLGPELIAGRFREAAAAAAGGGAPEPERLP 381 
Q9F764 LGRPTTTP----VENKEHFMAFLKDTHS-------- 378 
         *.*::     : .: :  *      .         
 
Figure 3.10 DhpF retains all residues known to be involved in TPP and Mg++ 
binding. Alignment of DhpF to the well studied PnPy decarboxylase of B. fragilis 
reveals complete retention of important residues (highlighted in red, with the 
corresponding DhpF residues in yellow), and a very high degree of identity in the 
‘TPP box’ (highlighted in teal). 
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mutase analysis, we have a high degree of confidence that dhpF encodes a 
functional PnPy decarboxylase. 
 
dhpG. The predicted start codon (ATG) for dhpG overlaps with the stop 
codon (TGA) for the previous ORF (dhpF). An identifiable RBS is not present 
upstream of dhpG. BLAST analysis of the predicted dhpG ORF identifies 
homology to group III iron-dependent alcohol dehydrogenases. These enzymes 
are involved in the reversible reduction of keto or aldehyde groups to the 
corresponding alchohol in an Fe++ dependent fashion. Preceding work on dhpG 
DhpG   MSRPLARGSGPRRDTVLLTGRGSFGRVPGLSEGR---RVLVVASSRALLRAPVAAWLP--  
FomC   --------MSPRR-PVVRYGRGAIASLPQLVEGLGATRVLVVHGAHSFEASGASRMMESF  
                .*** .*:  ***::. :* * **    ***** .::::  : .:  :    
 
DhpG   ---PDAVTFTAFHPNPTVAQGVEAARLRRASGADLVVGIGGGSALDVAKAARVLPGDAGA  
FomC   GRRTLVHRWHDFSPNPAVDDVARGLDAVRELRPDAVVGVGGGSAMDMAKLLCVLDGVPRA  
          . .  :  * ***:* : ...    *   .* ***:*****:*:**   ** * . * 
 
DhpG   ADEVIAGRRPVPEG-VPELLLVPTTAGTGSEVTQFATLYRGHRKVSLDTPAARADVAVVD  
FomC   DLEDRVRTGPAADTRRMKLVLAPTTSGSGSEATQFAVVYVGDAKYSVAGAGLLPDAAVLD  
         *  .   *..:    :*:*.***:*:***.****.:* *. * *:  ..  .*.**:* 
 
DhpG   PELTETCPADLTWTCAFDTLAHAVESLWSVRSTAESREHAVAALRSSLPVLRCAGDLPSP  
FomC   PALTESGTPHQRATSGVDAIAQGIESLWAVGGDDESRGLARRGLRLLLAGIEDFVAGRTP  
       * ***: ...   *...*::*:.:****:* .  ***  *  .**  *. :.      :* 
 
DhpG   AERDALSRAATLAGQAIDLTRTTAAHALSYPLTAHLGIPHGLACALNLAWLAPLVEAAGP  
FomC   ASPAPWRWAATSSG-------------------------------------APSTAPRRP  
       *.  .   *** :*                                     ** . .  * 
 
DhpG   ERVTDPRGHAAVREAVGTLRELFGADEQGTDLAGALRALLARRASFPYAGAPDAPYDLLV  
FomC   ARTPSRTG----------------------------------------------------  
        *...  *                                                     
 
DhpG   AEGLSSDRMSGMPVRLERHEARAGLETVLGAGTERKRGTTCATTG 396 
FomC      --------------------------------------------- 
 
Figure 3.11 Sequence analysis of DhpG reveals key characteristics of the 
enzyme. Following alignment to FomC, a relative and known PnAA reductase 
conserved residues reveal cofactor preference (highlighted in red, NADH), 
cofactor binding (highlighted in yellow) and iron coordination (highlighted in 
green).  
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identified residues predictive of the cofactor involved (NADH), the amino acids 
involved in iron coordination, and experimentally verified the function and 
requirements of this enzyme (25). DhpG is an iron-dependent 
phosphonoacetaldehyde (PnAA) reductase involved in the production of 2-
hydroxyethylphosphonate (HEP). DhpG constitutes the final member of the 
previously mentioned triad of genes composing a common motif in phosphonate 
biosynthesis. 
 
dhpH. The next ORF, dhpH, has two potential start codons. The first 
possible start codon is located 16 bases upstream of the stop codon for the 
previous ORF (dhpG), and this start codon possesses a predicted RBS 
(AGCGAAG) upstream. The second possible start codon corresponds with a 
start/stop (GTG/TGA) codon overlap from the preceding gene (dhpG) but lacks 
an obvious RBS. Vectors which utilized the first possible start codon resulted in 
soluble expression, and sequence alignments including the five additional amino 
acids from the upstream start codon showed these residues were conserved in 
close homologues. As such, the first potential start codon was annotated as the 
true start codon. It should be noted however, that without sequencing the N′ 
terminus of DhpH to verify this designation that it retains substantial uncertainty. 
 The putative ORF encoding DhpH is quite large, covering 2094 base 
pairs with the currently annotated start site. Preliminary sequence analysis of this 
open reading frame indicated that the protein product of dhpH had two distinct 
domains. In an effort to more accurately analyze these disparate domains the 
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nucleotide sequence of dhpH was arbitrarily divided into two sections 
corresponding to these domains.  
The first 1065 bases encode the N′ terminal domain of DhpH. This portion 
of the protein contains homology to Class V aminotransferase proteins. Although 
similar in function to the Class I aminotransferase that DhpD contains homology 
to, Class V aminotransferases possess an alternate binding site for the pyridoxal 
phosphate cofactor. The most common aminotransferase present in 
phosphonate biosynthetic gene clusters, 2-aminoethylphosphonate 
aminotransferase is listed as a ‘child’ of the class V aminotransferases by 
InterPro. Amino acid sequence alignment with the closely related phosphoserine 
DhpHI   MRNYR--VTGPVEVPDGTLAAMTTRM------------ISHRSDGFRDLFGGIAPRLGAL  
P23721  MAQIFNFSSGPAMLPAEVLKQAQQELRDWNGLGTSVMEVSHRGKEFIQVAEEAEKDFRDL  
        * :     :**. :*  .*     .:            :***.. * ::       :  * 
 
DhpHI   FGTAGTVLPLTCSG--TGGLEAVAASLLRPGDRVLSVQLGYFGERFAEIAEHHG--AVVD  
P23721  LNVPSNYKVLFCHGGGRGQFAAVPLNILGDKTTADYVDAGYWAASAIKEAKKYCTPNVFD  
        :.....   * * *   * : **. .:*     .  *: **:.    : *:::    *.* 
 
DhpHI   VLAAPWGQVVDTALITERLAAGYDAVLLTHNETSTGVVAPLRAWAQAIRAVSDCLILVDV  
P23721  AKVTVDGLRAVKPMREWQLSDNAAYMHYCPNETIDGIAI-----DETPDFGKDVVVAADF  
        . .:  *  . ..:   :*: .   :    ***  *:.       ::    .* :: .*. 
 
DhpHI   VSSLAAVEIGFDELGLDAAVGVTQKALACPPGLSLVAVSERALARAAEPGEGSYYLSLAR  
P23721  SSTILSRPIDVSRYGVIYAG--AQKNIG-PAGLTIVIVREDLLGKANIACP-----SILD  
         *:: :  *.... *:  *   :** :. *.**::* * *  *.:*  .       *:   
 
DhpHI   AAEHARAGTTTYTPALSVLYALDTALAAIEKEGVEAVWERHARTARRCRDALRARGLVVV  
P23721  YSILNDNGSMFNTPPTFAWYLSGLVFKWLKANGGVAEMDKINQQKAELLYGVIDNSDFYR  
         :     *:   **.  . *  . .:  :: :*  *  ::  :   .   .:  .. .   
 
DhpHI   PDEAHSSPTVTAVRLPAGGAVRVREALAAEHDTWVSSGRGPWKDEVLRIGHMGPVEPAGV  
P23721  NDVAKANRSRMNVPFQLADSALDKLFLEESFAAGLHALKGHRVVGGMRASIYNAMPLEGV  
         * *::. :   * :  ..:.  :  *  .. : : : :*      :* .  ..:   ** 
 
DhpHI   DACAAAIAACLDG-- 355 
P23721  KALTDFMVEFERRHG 362 
                .* :  :.     
 
Figure 3.12 The N′ domain of DhpH contains 10 of the 11 known active site 
residues contained in Class V aminotransferases. Alignment to a 
characterized Class V aminotransferase (UniProt accession number shown) with 
active site residues from the characterized example highlighted in red and 
complementary residues in DhpH highlighted in yellow. 
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aminotransferase of E. coli revealed near perfect conservation of residues 
involved in PLP-binding (Figure 3.12). 
The C′ terminal domain of DhpH remains enigmatic. This portion of dhpH 
is slightly smaller than the N′ terminal domain at 1029 bases. Amino acid 
sequence comparison reveals very little, as the top hit contains modest identity to 
an uncharacterized protein from Yersinia pseudotuberculosis. Motif analysis 
provides some information, predicting that DhpH C′ contains a domain similar to 
those found in FemAB linked proteins in addition to an acyl-CoA N-
acyltransferase domain. The FemXAB proteins are associated with cell wall 
biosynthesis, catalyzing the stepwise addition of the pentaglycine side chain to 
the ε amino group of the lysine side chain (3,12,23). The pentaglycine peptide is 
then crosslinked to the penultimate D-Ala of the growing peptidoglycan chain 
providing a measure of stability to the bacterial cell wall. The mechanism of 
peptide addition diverges from common methods of peptide bond formation, 
utilizing neither the function of the ribosome nor the action of non-ribosomal 
peptide synthetases (NRPS). Instead, FemXAB proteins utilize activated 
aminoacyl-tRNA’s as substrates with the cognate amino acid (12). By functioning 
in a similar manner, DhpH could catalyze the addition of the glycine or leucine 
residues to the dehydrophos molecule. The suggested bifunctionality DhpH 
possesses indicate this enzyme could be involved in both a PLP-dependent 
transformation and the formation of one or more of the peptide bonds present in 
the dehydrophos molecule. 
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dhpI. The next predicted ORF in the dehydrophos biosynthetic cluster 
lacks a start/stop codon arrangement with dhpH, with the start codon located 40 
bases downstream from the stop codon of dhpH. Perhaps to compensate for this 
distance, dhpI has a putative RBS located 14 bases upstream (GAGGAAG). 
Sequence analysis of the protein product shows that this ORF has homology to 
S-adenosylmethionine (SAM) dependent methyltransferases. This group of 
enzymes is involved in the transfer of methyl groups. The DhpI protein is the 
prime candidate for installation of the O-methylation present on the phosphonate 
moiety of dehydrophos.  
 
dhpJ. Located 55 bases downstream from the DhpI stop codon lies the 
predicated start codon for the next ORF in the dehydrophos biosynthetic gene 
cluster, dhpJ. This ORF also has an identifiable putative RBS located 14 bases 
upstream of the start codon (AAGGAG). Sequence analysis of the protein 
product of this predicted ORF demonstrates homology to peptide β-aspartate 
dioxygenases. β-aspartate dioxygenases catalyze a transformation similar to the 
one predicted to be performed by DhpA, an Fe++, O2, and 2-oxoglutarate 
dependent carbon center hydroxylation. Despite identical functions, the structure 
of these two enzymes differs drastically. Unlike DhpA and most related peptide β-
aspartate dioxygenases, DhpJ has no identifiable facial triad to coordinate the 
reduced iron necessary for activity and has sequence elements that more closely 
resemble members of the cupin family (2,9). There is precedent in the literature 
for proteins bearing cupin related folds to catalyze Fe++ dependent non-heme 
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oxygenations (26) and it appears likely that DhpJ may be functioning in a similar 
fashion to accomplish hydroxylation of a carbon center during the biosynthesis of 
the dehydrophos molecule.  
 
dhpK. The final ORF expected to be involved in biochemical 
transformations during dehydrophos biosynthesis is dhpK. The start codon for 
this open reading frame is 73 bases downstream from the stop codon of dhpJ. 
Beginning eleven bases upstream is a potential RBS (GGAGGA). Sequence 
analysis of dhpK is particularly noninformative, yielding hypothetical proteins for 
the majority of the top matches. Similar to the C′ terminal portion of DhpH 
however, motif examination reveals similarity to the FemAB superfamily and the 
presence of an Acyl-CoA N-acytransferase domain suggesting that DhpK could 
also be involved in the formation of one or more of the peptide bonds necessary 
for the biosynthesis of dehydrophos. 
 
dhpL. The next ORF in the operon is dhpL, the start codon of which is 
located 55 bases downstream of the DhpK stop codon. Although somewhat 
distant, a putative RBS appears to be located 19 bases upstream of the dhpL 
start codon (AGGGAG). Sequence analysis of this ORF reveals homology to 
members of the major facilitator superfamily (MFS). MFS proteins are a large, 
diverse collection of secondary transporters involved in the movement of 
molecules across the cell membrane. In bacteria, these proteins are typically 
involved in the import of nutrients or in drug export as a mechanism of antibiotic 
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resistance. Most MFS proteins contains twelve transmembrane helices and 
sequence analysis of DhpL using the membrane topology prediction program 
TopPred (8) identified twelve transmembrane helices present in DhpL (Figure 
3.13), consistent with the expected number. Based on these results, DhpL is 
predicted to be involved with export of dehydrophos from the cell, possibly as a 
mechanism of self-resistance. 
 
dhpM. Marking a departure from the previous predicted ORFs in the gene 
cluster, dhpM is oriented in the opposite direction of the previous ORFs 
discussed (and the remainder to be discussed). A potential RBS is located 13 
bases upstream (AGAGGCA). Sequence analysis of this ORF reveals 
demonstrable homology to members of the sodium/solute symporter family. 
Figure 3.13 DhpL is predicted to contain twelve transmembrane helices. 
Depicted is the graphical output of the program TopPred following analysis of the 
amino acid sequence of DhpL. Dark grey ovals represent the predicted helices and 
are numbered sequentially. 
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These enzymes are transmembrane proteins that utilize the sodium motive force 
to transport compounds across the membrane against a concentration gradient. 
TopPred analysis of dhpM reveals 13 transmembrane helices, consistent with 
typical members of the sodium/solute symporter family (Figure 3.14). Also of 
note, DhpM contains a remarkable level of identity to DhpN (68%, 318/471 
residues) suggesting these two related ORFs may function in concert as a dimer. 
Based on the bioinformatic analysis the role these two ORFs play in the 
biosynthesis is unclear, although it appears unlikely that they are directly involved 
in the biochemical transformation necessary to produce dehydrophos. 
 
dhpN. No RBS is identifiable for dhpN, and it does not appear to be 
transcriptionally coupled to any of the other ORFs within the cluster. BLAST 
analysis reveals that the protein product contains homology to members of the 
Figure 3.14 DhpM is predicted to contain thirteen transmembrane helices. 
Depicted is the graphical output of the program TopPred following analysis of the 
amino acid sequence of DhpM. Dark grey ovals represent the predicted helices and 
are numbered sequentially, the white oval indicates predictive uncertainty about that 
particular helix. 
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sodium/solute symporter family, and similar to DhpM it contains the characteristic 
13 transmembrane helices. As mentioned above, this protein has a high level of 
identity with DhpM suggesting that they may function as a dimer involved in the 
uptake of some unknown compound inactivation and evolutionary divergence. 
 
dhpO. The next ORF in the dehydrophos gene cluster, dhpO shares a 
stop/start codon arrangement with dhpN. Upstream 16 bases from the start 
codon of dhpO is a putative RBS (GAGGAA). BLAST homology analysis 
indicates that DhpO has similarity to σ-24 transcriptional factors involved in the 
initiation of transcription by enabling the binding of the RNA polymerase to 
specific gene promoters. Most likely DhpO is involved in the regulation of all or 
some portion of the dehydrophos biosynthetic pathway in response to a currently 
unknown signal. 
 
dhpP. The final ORF within the minimal contiguous cluster of DNA 
capable of conferring production of dehydrophos to a heterologous host is dhpP. 
This ORF lacks a stop/start codon arrangement and an identifiable RBS, and is 
located quite downstream from the preceding ORF in the gene cluster (518 
bases). The DhpP protein is homolous to the LacI family of transcriptional 
repressors, containing both a helix-turn-helix DNA-binding motif and a 
periplasmic binding protein domain. Based on these results DhpP is also 
involved in the regulation of dehydrophos biosynthesis in an as yet unknown 
capacity. 
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Discussion 
Dehydrophos is an unusual natural product with several features that are 
unique among known natural products. The initial heterologous expression of 
dehydrophos allowed for identification of the biosynthetic gene cluster and led to 
a proposed biosynthetic pathway (Figure 3.15).  
 
This pathway begins with conversion of PEP to phosphonopyruvate 
(PnPy) (Step I), subsequent decarboxylation (Step II) to generate 
phosphonoacetaldehyde (PnAA), and reduction of PnAA to yield 2-
hydroxyethylphosphonate (HEP) (Step III). A hydroxy group is then introduced at 
C1 of HEP (Step IV). Following this the C1 hydroxy group is oxidized (Step V), 
Figure 3.15 Proposed pathway for dehydrophos biosynthesis. The presence 
of the ‘R’ group in the pathway, beginning with the product of Step IV (DHEP) 
reflects the uncertainty of the point in the pathway at which the proposed 
methyltransferase, DhpI, functions.  
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and transaminated (Step VI). At this point a number of transformations are 
possible - generation of the vinyl group, addition of the glycine and leucine 
residues and O-methylation are all necessary to round out completion of the 
dehydrophos molecule.  
 The first two steps proposed in the pathway mirror those of all other 
known phosphonate biosynthetic pathways. The PEP mutase reaction is 
thermodynamically unfavorable (6) and often coupled to PnPy decarboxylase to 
yield net synthesis of phosphonates. Based on significant amino acid identity to 
biochemically characterized examples, DhpE and DhpF catalyze the PEP 
mutase and PnPy decarboxylase reactions, respectively (Steps I and II). Both of 
these enzymes also possess complete conservation of residues known to be 
important for catalytic activity (15,31).  
The next proposed reaction is a metal-dependent dehydrogenase 
catalyzed reduction of PnAA to HEP (Step III). This reaction is common to 
several unrelated phosphonate biosynthetic pathways. We previously 
overexpressed and purified DhpG. The enzyme was shown to be a Group III Fe-
dependent PnAA dehydrogenase which consumes NAD(P)H during the reduction 
reaction (25).  
 Given the final structure of dehydrophos, biochemical logic suggests that a 
free primary amine be available at C1 for peptide bond formation. The 
hypothetical pathway achieves this placement by hydroxylation of HEP at C1 
(Step IV), followed by oxidation and transamination reactions (Steps V, VI). 
 86 
1,2-DHEP is a phosphonic acid analog of glyceric acid. Thus, it was 
interesting to note that DhpC has significant similarity to malate and lactate 
dehydrogenases, which catalyze oxidation of similar substrates. Further, 
comparison of DhpC to known malate dehydrogenases revealed conservation of 
all important active site residues in DhpC (14). Based on these observations we 
expected DhpC to catalyze oxidation of 1,2-DHEP to 1-oxo, 2-
hydroxyethylphosphonate (OHEP).  
 Step VI is predicted to be a transamination of OHEP. DhpD contains 
sequence homology to aspartate aminotransferases and residues known to be 
involved in PLP binding (11) are conserved. Pending further investigation, we 
have tentatively assigned DhpD to step VI. 
 The compound resulting from these reactions, 1-amino-2-
hydroxyethylphosphonate (AHEP) is proposed to be four steps away from 
dehydrophos: addition of leucine and glycine residues, dehydration to form the 
vinyl group, and O-methylation. Although dehydrophos contains two peptide 
bonds, the minimal cluster lacks identifiable non-ribosomal peptide synthetases. 
It seems unlikely that dehydrophos is ribosomally synthesized, because of its 
small size and the need for the specialized genetic code required to identify, 
charge, and load a phosphonate precursor. The protein products of dhpH and 
dhpK contain putative Acyl-CoA N-acyltransferase domains. Similar domains are 
found in FemXAB family proteins responsible for peptide bond formation during 
cross-linking of bacterial cell wall peptidoglycan (3). FemXAB proteins utilize 
activated aminoacyl-tRNAs to generate peptide bonds. Additional examples of 
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aminoacyl-tRNA based peptide bond formation in small molecule biosynthesis 
(13) make the potential use of an analagous mechanism by DhpH and DhpK 
intriguing.  
The mechanism of vinyl group formation also remains uncertain. It seems 
likely that this step occurs either simultaneously with, or after, peptide bond 
formation because dehydration of the primary amine would form an eneamine, 
which would tautomerize to the imine and undergo hydrolysis. An attractive 
solution to this problem is present in the ORF encoding DhpH. The ORF encodes 
a large protein (698 AA) that consists of two distinct domains. The N′ terminal 
domain possesses homology to serine-glyoxylate aminotransferases and 
contains conserved residues known to bind pyridoxal phosphate (PLP). The C′ 
terminal domain displays homology to proteins with oxidase activity, but further 
analysis by InterProScan reveals the aforementioned N-acyl CoA acyltransferase 
functionality presumably responsible for peptide bond formation. PLP containing 
enzymes are capable of catalyzing β-eliminations (11) and therefore, DhpH could 
eliminate the phosphate from intermediate AP-EP, generating 
1-aminovinylphosphonate. If so, this intermediate would have to be protected 
from hydrolysis to allow peptide bond formation by the second domain. 
Alternatively, the vinyl group could be formed after peptide bond formation, 
driven by hydrolysis of the phosphate ester on the 1-amino-
2-phosphorylethylphosphonate moiety. 
 Dehydrophos contains a unique O-methylation of the phosphonate group. 
A likely candidate to perform this reaction is DhpI, which contains homology to 
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SAM-dependent methyltransferase enzymes. Where methylation fits into the 
proposed biosynthetic pathway proves troublesome to assign a priori. The 
difficulty arises from the fact that the methylation occurs on the phosphonate 
moiety, unlike the remainder of the proposed reactions, which occur on the main 
carbon chain, and often have clearly necessary substrates (e.g. a hydroxyl group 
for an oxidation to a ketone). As such, any of the proposed reaction 
intermediates could function as the substrate for DhpI. Additional enzymatic 
studies may clarify the preferred substrate of DhpI.  
 BLAST homology analysis of the protein product of dhpL reveals similarity 
to membrane transport proteins, suggesting that DhpL is involved in self-
resistance and/or export of the finished compound. Similarly DhpM and DhpN 
show homology to Na+/solute symporters and both are predicted to contain the 
13 transmembrane domains characteristic of these proteins (16). DhpM and 
DhpN show remarkable similarity to each other (68% identity, 318/471 residues) 
suggesting that they may function as a dimer. An alternative explanation for the 
high level of identity lies in a duplication event of dhpN or dhpM, resulting in an 
extra copy of the gene, which was then subject to mutatational inactivation and 
evolutionary divergence. 
Finally, DhpP is homologous to sigma-24 transcriptional factors, while 
DhpO is a member of the LacI repressor family of transcriptional regulators. Both 
of these may be involved in regulation of the cluster, although the specific roles 
they play in the heterologous host are unknown. Orf5 falls within the segment of 
DNA necessary to confer production to S. lividans. This ORF contains a small 
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peptide with weak identity to signal peptides and transglycosylases. It is 
uncertain what role, if any, this ORF plays in the biosynthesis of dehydrophos.  
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Chapter 4: Genetic Analysis of Dehydrophos Biosynthesis1 
 
Abstract 
 
Establishment of a hypothetical biosynthetic pathway for the antibiotic 
dehydrophos led to a set of testable predictions. Although, the bioinformatic 
analysis strongly supported the proposed role of several genes, other assigned 
transformations were highly speculative, requiring experimental evidence to 
corroborate the assigned functions. To validate the proposed enzymatic 
reactions within the putative biosynthetic pathway a two-fold strategy was 
implemented. First, the function of each individual gene was examined by 
mutational analysis. These experiments identified genes within the minimal 
contiguous cluster essential for dehydrophos production and the results verified 
or falsified the proposed role for the protein product of the gene. The data 
generated by the mutational analysis also provide strong evidence for the early 
steps in the putative pathway, and provide preliminary data for investigating the 
final reactions involved in the biosynthesis of the antibiotic dehydrophos. These 
results were then supplemented by the data generated by the biochemical 
approach to analyzing the biosynthesis, the results of which will be discussed in 
Chapter 5. 
 
1
 See published manuscript (Circello BT, Eliot AC, Lee JH, van der Donk WA, Metcalf WW. 2010. 
Molecular Cloning and Heterologous Expression of the Dehydrophos Biosynthetic Gene Cluster. 
Chem Biol. 17(4):402-11.) BT Circello performed all of the experiments described herein, save 
the construction and screening of the S. luridus genomic library, performed by AC Eliot, and the 
chemical synthesis, performed by JH Lee. 
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Introduction 
 
The identification of the dehydrophos biosynthetic gene cluster via 
heterologous production established a foundation to further explore the 
biosynthesis of this unique compound. The native and heterologous producers 
both belong to the genus Streptomyces, which have been the focus of extensive 
research due to their primacy among natural product producing microorganisms. 
As such, a body of knowledge exists about the genetic manipulation of these 
organisms, as well as the organization of secondary metabolite gene clusters 
and the manner in which they are regulated. 
 The utility of Streptomyces as a heterologous expression system for 
genes and gene clusters of interest has increased drastically in recent years. The 
development of the REDirect system (and related analogues) by Chater et al, 
has provided a convenient method to rapidly introduce specific mutations into a 
variety of Streptomyces hosts for genetic analysis. At the same time a variety of 
phage biotechniques have provided a way to efficiently integrate large amounts 
of DNA into specific sites on the host chromosome (2,8). 
 These technologies, along with the demonstrated robust heterologous 
production of dehydrophos in S. lividans provide an engine to gather a large 
amount of genetic information about the biosynthesis of dehydrophos. Although 
the high level of identity and total conservation of known catalytic residues in 
both the PEP mutase (dhpE) and PnPy decarboxylase (dhpF) provide a great 
level of confidence in the preliminary steps necessary to generate the C-P bond 
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the remainder of the pathway remained largely hypothetical before the 
experiments described in this Chapter. 
 For example, the dehydrophos cluster contains a gene (dhpG) with a high 
degree of identity to genes involved in the biosynthesis of phosphinothricin 
tripeptide (phpG) and fosfomycin (fomC). Prior work performed on these 
enzymes established their role as iron (II) dependent phosphonoacetaldehyde 
reductases. The genetic experiments described below confirmed that DhpG 
performs a similar function. 
 Similarly, the hypothetical pathway predicts an early hydroxylation at the 
C1 position. Analysis of the ORFs present within the minimal contiguous cluster 
provided two key candidates, both containing homology to 2-oxoglutarate 
dependent dioxygenases. Establishing the ability of one or both of these 
enzymes to perform the predicted reaction would partially validate one of the key 
tenets used to construct the early pathway (the necessity of a free primary amine 
to form one of the amide bonds seen in the final product). 
 We describe here the genetic analysis of each ORF in the dehydrophos 
biosynthetic gene cluster, and discuss how these results support the proposed 
biosynthetic pathway. 
 
Materials and Methods 
 
Bacterial strains, plasmids and culture conditions. The strains and 
plasmids used in this study are listed in Appendix A. Streptomyces strains were 
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propagated on ISP2 medium (Difco, Becton Dickinson Microbiology Systems, 
Sparks, MY) at 30 °C. Heterologous production cultu res were inoculated with 50 
µL of spore stock (109 colony forming units) of the appropriate strain and 
incubated in 500 mL baffled flasks containing 100 mL of nutrient broth (Difco) 
agitated at 250 rpm for 48 hours. E. coli was routinely grown in Luria-Bertani 
broth (LB) or on 1.5% agar LB plates supplemented appropriately. Antibiotics 
were used at the following concentrations to select for plasmid propagation or 
integration events: ampicillin 100 µg/mL, chloramphenicol 10 µg/mL, apramycin 
37.5 µg/mL, kanamycin 50 µg/mL. Diaminopimelic acid was added to media at a 
concentration of 1 mM for growth of dapA mutants. For dehydrophos bioassays 
E. coli BW13711 was grown to an OD600 of 0.1, and then 100 µL was mixed with 
2 mL of molten ‘E’ media 0.5 % top agar (15) and pipetted onto ‘E’ media 1.5% 
agar plates and allowed to solidify. Succinate (40 mM) was provided as the 
carbon source during bioassays and these plates were incubated at 37 °C for 12 
hours 
 
DNA isolation, manipulation, cloning and sequencing.  Cloning was 
accomplished by routine methods (12). Restriction endonucleases and T4 DNA 
ligase were purchased from New England Biolabs (Ipswich, MA) or Invitrogen 
(Carlsbad, CA). KOD HotStart polymerase (Novagen, EMD Chemicals Inc., 
Gibbstown, NJ) was used for PCR amplification in combination with Failsafe PCR 
Premix buffers (Epicentre, Madison, WI). Oligonucleotides were obtained from 
Integrated DNA Technologies (Coralville, IA). DNA fragments used in cloning 
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experiments were isolated by gel purification using the Promega Wizard PCR 
cleanup kit (Madison, WI). Plasmid isolation was accomplished using Qiagen 
Maxiprep or Miniprep kits (Valencia, CA). Sequencing reactions were performed 
at the W.M. Keck Center for Biotechnology at the University of Illinois Urbana-
Champaign utilizing primers T7-for/T7-rev or primers pBTC034-For/pBTC034-
Rev. Sequence data were compiled using Sequencher (Gene Codes Co., Ann 
Arbor, MI). 
 
Generation of additional mutant clusters. Three types of individual 
gene mutants were generated for analysis of dehydrophos biosynthesis: 
transposon inactivated mutants, gene replacements, and gene deletions. Gene 
replacements and gene deletions were constructed in WM7264 by utilizing the λ 
Red mediated recombination method of Datsenko and Wanner (6). Briefly, 
regions of homology upstream and downstream of the target are included on 
PCR primers designed to amplify a chosen resistance cassette. The target gene 
is then replaced by the kanamycin resistance gene of pAE5 following 
recombination between the PCR product and fosmid 17E11-4. Gene 
replacements of dhpA, dhpD, dhpM, dhpN, and dhpO were made in this fashion 
and retain the kanamycin resistance cassette. This cassette has a synthetic, 
outward-directed promoter designed to express downstream genes to minimize 
polar effects. The primers used in gene replacement construction also introduce 
an AvrII site not present on fosmid 17E11-4, which allows for excision of the 
antibiotic cassette following digestion and self-ligation of the fosmid. Digestion 
 98 
with AvrII and self-ligation results in deletion of the target gene and the 
resistance cassette, leaving only a 6 base pair AvrII scar. Gene deletions of 
dhpB, dhpC, dhpE, dhpF, dhpG, dhpH, and dhpI were constructed using the 
aforementioned procedure. The remainder of the genes analyzed (dhpJ, dhpK, 
dhpL) are insertional mutants obtained following the saturation transposon 
mutagenesis with pAE5 generated for sequencing of the cluster (7). After PCR 
verification, the mutant clusters were electroporated into WM6026 and conjugally 
transferred to S. lividans as described above. 
 
1P NMR detection and identification of dehydrophos and 
phosphonate metabolites. Culture supernatant was passed through a 0.2 
micron filter, concentrated twenty fold by evaporation, and D2O was added to 
25% as a lock solvent. 31P NMR spectra were acquired on a Varian Unity Inova 
600 spectrometer equipped with a 5 mm AutoTuneX probe at the Varian Oxford 
Instrument Center for Excellence at the University of Illinois Urbana-Champaign. 
An external standard of 85% phosphoric acid was defined as 0 ppm. To 
demonstrate that intermediates in the dehydrophos pathway contained a 
phosphate ester, 100 µL (1 u/µL) of calf intestinal alkaline phosphatase (CIAP) 
(Promega, Madison, Wisconsin) was added directly to the NMR tube, mixed by 
inversion, and allowed to incubate at 37 °C for one  hour before reacquiring the 
NMR spectra under identical conditions. Chemical shifts in 31P NMR are highly 
pH dependent and so experiments to confirm the identity of pathway 
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intermediates were routinely performed by adding 1-5 mM of standard to the 
sample and then reacquiring the spectra.  
 
Bioassay of dehydrophos production. Streptomyces lividans WM4467 
and the collection of isogenic dhp mutants were grown on ISP4 plates (Difco) at 
30 °C for 48 hours. Agar cores were then taken from  these plates and placed 
onto bioassay medium containing either E. coli DH5α or WM4553 (a 
spontaneous dehydrophos resistant mutant of DH5α). Alternatively, filter disks 
spotted with 10 µL authentic standard or concentrated culture supernatant were 
used in place of the agar cores. These plates were incubated at 37 ° for 16 hours 
and examined for growth inhibition of the indicator strain. 
 
Construction of complementation vectors. Complementation 
experiments were performed using ΦBT1 integrating vectors developed by Smith 
et al. (8). However, these vectors did not include a streptomycete promoter for 
expression purposes. This function was added by PCR amplification and 
subsequent cloning of the strong, constitutive streptomycete promoter pERM* 
from pANT841 into the pRT802 vector (1). This resulted in the creation of 
pBTC034, which was used as the vector for cloning and conjugative transfer of 
genes being tested for complementation (Scheme 4.1). 
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Results 
 
Mutant analysis of dhpA-dhpP. Our original approach to genetic 
examination of dehydrophos biosynthesis involved utilization of the transposon 
insertion library generated for the sequencing of the fosmid containing the gene 
cluster. These transposons were specifically designed for this use, containing as 
few as possible base pairs between the stop codon of the antibiotic resistance 
cassette used as a selectable marker and the 3′ boundary of the transposon to 
pBTC034 
5473 bp 
ΦBT1 integrase 
aac(3)IV 
ori pUC18 
oriT RK2 
pERM -10 Signal 1 
pERM* -10 Signal 2 
pERM* -35 Signal 1 
pERM* -35 Signal 2 
ΦBT1 attP 
MCS 
Scheme 4.1 Plasmid map of pBTC034, used for complementation of mutant 
clusters. Relevant features include the ΦBT1 attP and integrase for site specific 
integration into the S. lividans chromosome, as well as the constitutive pERM* 
promoter oriented toward a multiple cloning site for expression of the desired gene(s).  
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minimize polar effects. However, preliminary experiments revealed that insertion 
of the transposon into genes located upstream of the PEP mutase (DhpE) 
abrogated accumulation of any phosphonate intermediates (Figure 4.1). These 
results suggest that genes dhpA-dhpF operate as a single transcriptional unit, 
and that most, if not all of the transposon insertions generate deleterious polar 
effects on the transcription of downstream genes. Complementation of a  
Figure 4.1 Transposon insertions generate polar effects on the transcription of 
downstream genes. Mutants generated by transposon insertions (a). Those that 
accumulate phosphonic acids as detected by 31P NMR spectroscopy are colored 
red, those that fail to accumulate a phosphonate intermediate are shown in grey. All 
genes located upstream of dhpE, the PEP mutase, catalyzing the first step in the 
production of phosphonate fail to accumulate these intermediates. Identical analysis, 
save these mutants were generated by deletion or replacement (b). It was expected 
that mutants of dhpF (PnPy decarboxylase) would fail to accumulate phosphonate 
intermediates, as the protein product of this gene is required in concert with the PEP 
mutase to generate net synthesis of phosphonates. 
dhpP - LacI
phosphonate metabolite detected
phosphonate metabolite absent
dhpF
dhpG
dhpE
dhpD
dhpC
dhpB
dhpH dhpI
dhpJ
dhpK
dhpL
dhpM - Permease
dhpA
Phosphonate metabolites produced by transposon insertion mutants
dhpN - Permease
dnaO - sigma factor
dhpF
dhpG
dhpE
dhpD
dhpC
dhpB
dhpH dhpI
dhpJ
dhpK
dhpL
dhpM - Permease
dhpA
Phosphonate metabolites produced by deletion mutants
a 
b 
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transposon-disrupted dhpB mutant with a second dhpB allele inserted into a 
distal site on the chromosome did not restore phosphonate production, 
confirming the polarity of these transposon insertions (Figure 4.2). 
Unfortunately, the polar nature of the transposon insertions precluded their 
use in obtaining meaningful data about most of the genes located within the 
minimal contiguous cluster. Therefore, to define the role of individual dhp genes 
in dehydrophos biosynthesis we constructed a series of fosmids containing 
deletions or replacements of each gene in the biosynthetic cluster using λ red 
based recombination (6). To prevent polar effects, these cassettes were 
designed to preserve the original gene spacing in the operon, with the exception 
b 
a Figure 4.2 Transposon insertion 
into dhpB proves polar. 31P NMR 
spectra from crude culture 
supernatant of a S. lividans strain 
containing a mutant fosmid cluster 
with a transposon interruption of 
dhpB (a). 31P NMR spectra of the 
same strain with a wild-type copy of 
dhpB inserted at a distal site of the 
chromosome under control of a 
constitutive promoter (b). 
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of a 6 bp AvrII scar. The resultant plasmids were then transferred into the 
heterologous host S. lividans and dehydrophos production was queried by 
bioassay and 31P NMR analysis. Following are the data obtained for each of 
these recombinant strains. 
 
dhpA. This mutant was generated by replacement of the dhpA ORF with 
an antibiotic resistance cassette. Removal of this gene from the biosynthetic 
gene cluster abolishes bioactivity, and results in a 31P NMR spectrum lacking 
dehydrophos-associated peak (approximately 10 ppm) in the phosphonate 
region. However, this mutant retains the ability to produce phosphonate- 
containing compounds, evidenced by peaks present at 25.5, 23.5, 19.2, and 17.2 
ppm (Figure 4.3). Previous work performed on dhpG mutants identified a 
phosphonate intermediate at 17.2 as 2-aminoethylphosphonate, generated in 
mutants unable to convert phosphonoacetaldehyde to 
2-hydroxyethylphosphonate (HEP) (14).  
Spiking experiments performed with synthetic standards confirmed the 
identity of the major phosphonate peak at 19 ppm in dhpA mutants as HEP. In a 
separate spiking experiment, the peak at 25.5 ppm was identified as 2-
hydroxyethylphosphonate O-monomethyl ester (HEP O-Me). 
Based on the upfield shift caused by addition of a single methyl group to 
the phosphonate moiety of HEP (+6.5ppm), it seems reasonable to suggest that 
the peak located at 23.5 ppm is the corresponding methylated version of AEP, 
although this was not directly tested due to the lack of an authentic standard. 
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Biochemical assays validated the role of DhpA as a 2-oxoglutarate dependent 
dioxygenase responsible for the hydroxylation of the C1 position of HEP in 
dehydrophos biosynthesis and corroborated strongly with the genetic data (see 
Chapter 5). 
 
Figure 4.3 31P NMR spectrum of dhpA mutant supernatant. Peaks in the 
phosphonate region presumably belong to metabolites produced by the mutant 
dehydrophos gene cluster. The boxed compounds depict the accumulated 
intermediates, and their proposed method of generation. AEP = 
2-aminoethylphosphonate, HEP = 2-hydroxyethylphosphonate, PnAA = 
phosphonoacetaldehyde, AEP O-Me = 2-aminoethylphosphonate O-
monomethyl ester, HEP O-Me = 2-hydroxyethylphosphonate O-monomethyl 
ester. 
Phosphonates 
HEP 
AEP 
AEP O-Me  
HEP O-Me 
Phosphate esters 
O
P
OH
OH
O
OH
P
OH
OH
O
DhpG DhpA
PnAA HEP
NH2
P
OH
OH
O
OH
P
OH
O
O
NH2
P
OH
O
O
HEP O-Me
AEP O-Me
AEP
DhpI
DhpI
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dhpB. This mutant was generated by deletion of the entire dhpB gene as 
described above. This deletion abolishes antibiotic activity, and results in an 
altered phosphorus NMR spectrum lacking peaks corresponding to the 
dehydrophos molecule. Similar to the dhpA mutant this strain also retains the 
ability to generate phosphonate-containing molecules, witnessed by a single 
peak in the phosphonate region at 15.2 ppm (Figure 4.4). Spiking experiments 
OH
P
OH
OH
O
DhpA
HEP
OH
P
OH
OH
O
HO DhpB
DHEP
15.2 ppm
Figure 4.4 Elimination of dhpB results in accumulation of 1,2-DHEP (DHEP). 
Shown in the top panel is the 31P NMR spectra from the crude culture supernatant of 
a recombinant strain of S. lividans containing all dehydrophos biosynthetic genes, 
save dhpB. The peak present at 15.2 ppm represents a compound containing a 
phosphorus atom with a shift in the region characteristic for phosphonate 
compounds (a). Addition of an authentic standard of DHEP results in an increased 
intensity for this peak and fails to generate additional peaks confirming the identity of 
this intermediate (b). 
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performed with a chemically synthesized standard identified this compound as 
1,2-dihydroxyethylphosphonate (DHEP). Complementation of this mutant by 
reintroduction of the dhpB gene at an alternate site on the chromosome under 
the control of a constitutive promoter restored the ability to inhibit the growth of E. 
coli and resulted in an NMR spectrum with peaks corresponding to dehydrophos 
and the breakdown product of dehydrophos, 1-HEP O-Me. This complementation 
experiment eliminated the possibility that the deletion of dhpB abolished 
downstream transcription (Figure 4.5). 
 
dhpC. A dhpC mutant was generated by the replacement of the dhpC 
gene with an antibiotic resistance marker. Supernatant from the mutant strain 
dehydrophos 
1-HEP O-Me 
Figure 4.5 A dhpB gene deletion fails to exhibit polarity. A wild type copy of 
dhpB inserted into the ΦBT1 attB site of S.lividans restores the ability of a dhpB 
deleted strain to produce dehydrophos, as demonstrated by 31P NMR spectra of 
culture supernatant of this strain containing dehydrophos and corresponding 
metabolite 1-HEP O-Me. 
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fails to inhibit the growth of sensitive organisms. Additionally, examination of the 
concentrated culture supernatant by 31P NMR spectroscopy reveals an altered 
spectrum in which peaks corresponding to dehydrophos are absent, but several 
new peaks are seen in the phosphonate region possessing chemical shifts of 
19.2, 17.2, 16.0, 15.2, and 15.0 ppm (Figure 4.6). Based on previously performed 
spiking experiments the peak at 19.2 ppm corresponds to HEP, the peak at 17.2 
ppm corresponds to AEP, and the peak at 15.2 ppm corresponds to DHEP. The 
peak at 16 ppm was also observed in highly concentrated controls of nutrient 
broth when the samples are examined for an extended time period by 31P NMR, 
and therefore is most likely an artifact of the conditions used in this experiment 
O
P
OH
OH
O
OH
P
OH
OH
O
DhpG DhpA
PnAA HEP
NH2
P
OH
OH
O
AEP
OH
P
OH
OH
O
HO
DHEP HP-EP
O
P
OH
OH
O
HO
P OHHO
O
DhpB DhpC
HEP  DHEP  
AEP  
Figure 4.6 Phosphonate intermediates accumulate in the 
supernatant of a dhpC mutant. 31P NMR spectra reveals the 
presence of several phosphonate compounds, including HEP (19.2), 
AEP (17.2), and DHEP (15.2). 
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(Joel Cioni, personal communication). The remaining intermediate possessed a 
chemical shift very similar to that of DHEP, the sole phosphonate intermediate 
witnessed in dhpB mutants. Based on the predicted function of proteins with a 
high level of identity to dhpB (glycerate kinases) one possible identity for the 
peak at 15.0 ppm would be a phosphorylated analogue of DHEP. To test this 
assertion, the concentrated supernatant was treated with calf intestinal alkaline 
phosphatase (CIAP) and reexamined by 31P NMR spectroscopy. The peak at 15 
ppm disappeared following the CIAP treatment and the peak corresponding to 
DHEP increased in area, consistent with the belief that the 15 ppm peak was a 
phosphorylated analogue of DHEP, (Figure 4.7). 
 
 Before CIAP After CIAP 
19.2 ppm (HEP) 1 1 
15.2 ppm (DHEP)  0.15 0.25 
15.0 ppm 0.15 0.02 
 
Figure 4.7 Supernatant from dhpC mutants contains 1-hydroxy-2-
phosphorylethylphosphonate (HP-EP). 31P NMR analysis of supernatant from 
a dhpC mutant strain prior to (a) and following treatment (b) with CIAP. The table 
displays the relative areas under the specified peaks determined by integration 
both before and after CIAP treatment. 
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dhpD. Genetic analysis of the role dhpD plays in the biosynthesis of 
dehydrophos provides conflicting evidence for the necessity of this gene. Spent 
supernatant taken from cultures of the dhpD mutant were not bioactive. However 
31P NMR examination of concentrated spent supernatant reveals that although 
dehydrophos is absent, two peaks commonly seen in organisms known to 
produce dehydrophos are present at 24.5 ppm and 13.2 ppm. Based on spiking 
experiments that will be discussed in greater detail in Chapter 5, the identity of 
these two peaks are 1-hydroxyethylphosphonate monomethyl ester and 
1-aminoethylphosphonate, respectively. The remaining peaks (19.2, 17.2, 16 
ppm) could be identified as previously discussed (Figure 4.8). 
1-HEP O-Me 
HEP  
AEP  
1-AEP  
Figure 4.8 31P NMR from dhpD mutant strains. The supernatant contains several 
phosphonate intermediates including HEP (19.2 ppm), AEP (17.2 ppm), and 
unexpectedly the dehydrophos metabolites 1-AEP (13.2 ppm) and 1-HEP O-Me 
(24.5 ppm). 
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dhpE. This gene encodes the predicted PEP mutase, one of two enzymes 
required for the net synthesis of the C-P bond. As such, mutants lacking this 
gene were not expected to retain bioactivity or produce any phosphonate-
containing compounds. A deletion of dhpE confirmed these predictions. A copy of 
dhpE inserted into a distal site on the chromosome complemented this mutation, 
Figure 4.9 Deletion of dhpE abolishes all phosphonate production. 
Supernatant from a dhpE mutant examined by 31P NMR spectroscopy fails to 
accumulate phosphonate-containing compounds (top). Complementation 
with dhpE restores the production of 1-HEP O-Me(bottom). 
1-HEP O-Me 
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restoring both bioactivity and the ability to produce a known breakdown product 
of dehydrophos (1-HEP O-Me, seen at 24.5 ppm, Figure 4.9). Thus polar effects 
were not responsible for this phenotype.  
 
dhpF. Based on the bioinformatic analysis described in Chapter 2, dhpF is 
predicted to encode a phosphonopyruvate (PnPy) decarboxylase. Due to the 
thermodynamics of the PEP mutase reaction, the PnPy decarboxylase should be 
required to generate net synthesis of any phosphonate. Consistent with this 
prediction, supernatant from a mutant lacking this gene fails to inhibit the growth 
of the indicator organism and spent supernatant from this mutant does not 
possess any phosphonate-containing compounds visible in 31P NMR spectra 
(Figure 4.10). 
Figure 4.10 The phosphonopyruvate decarboxylase (dhpF) proves 
absolutely required for dehydrophos production. Supernatant from a dhpF 
mutant strain does not contain dehydrophos or any phosphonate intermediate, 
as evidenced by 31P NMR spectroscopy. 
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dhpG. Mutant clusters that do not possess the dhpG gene lack bioactivtiy. 
Querying spent supernatant from cultures of this mutant by phosphorus NMR 
analysis revealed the presence of one compound with a chemical shift in the 
phosphonate region at 17.2 ppm (Figure 4.11). Based on previous work, the 
identity of this peak was established to be AEP. 
Figure 4.11 Accumulation of AEP by mutants of dhpG. The 31P NMR spectra of 
spent supernatant from a dhpG mutant strain (bottom) and that same sample 
following addition of an AEP synthetic standard (top). 
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dhpH. dhpH mutants are unable to produce dehydrophos, as shown by 
loss of bioactivity and an altered 31P NMR spectra. The NMR spectrum contains 
DHEP  
AHEP  
DHEP  
AHEP  
Figure 4.12 dhpH mutants accumulate 1-amino-2-
hydoxyethyphosphonate (AHEP). Spent supernatant from a strain 
lacking dhpH was queried by 31P NMR spectroscopy and shown to 
accumulate a variety of phosphonate intermediates (top). Addition of a 
synthetic standard of AHEP directly to the previously examined NMR 
sample verified the identity of the peak at 9.4 ppm (bottom). 
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seven peaks in the phosphonate range, several of which are unique to this 
particular mutant. Two major phosphonate peaks possess chemical shifts of 15.2 
ppm (DHEP) and 9.4 ppm (unknown compound), with minor peaks 
corresponding to HEP (19.2 ppm), AEP (17.2 ppm), growth media component 
(16.0 ppm) and HP-EP (14.9 ppm), and an unidentified compound at 9.0 ppm. 
Figure 4.13 The culture supernatant from dhpH mutant strains 
contains a phosphorylated intermediate. Relevant portion of a 
31P NMR spectra taken from spent supernatant of a strain lacking 
the dhpH gene before (top) and after (bottom) treatment with CIAP.  
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Based on the putative pathway for dehydrophos biosynthesis, dhpH mutants 
would be expected to accumulate 1-amino-2-phosphorylethylphosphonate. This 
compound was not available for spiking experiments and so we tested this 
hypothesis in an indirect fashion via a combination of spiking experiments with 1-
amino-2-hydroxyethylphosphonate (AHEP) and CIAP hydrolysis experiments. 
Following the addition of a synthetic standard of AHEP, the intensity of the 9.4 
ppm peak increased greatly, and no additional peaks in the phosphonate range 
were generated, confirming the identity of the compound with a chemical shift of 
9.4 ppm as AHEP (Figure 4.12, bottom). Complementing this experiment, and 
supporting the idea that AP-EP serves as the substrate for DhpH, CIAP 
treatment of concentrated culture supernatant from dhpH mutants results in the 
1-HEP O-Me 
Figure 4.14 The deletion of dhpH is not polar. Complementation with dhpH 
restores the ability of the mutant strain to produce the dehydrophos breakdown 
product 1-HEP O-Me. 
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disappearance of the peak at 9.0 ppm and increase in the intensity of the peak at 
9.4 ppm, confirming these peaks belong to AP-EP and AHEP, respectively 
(Figure 4.13). 
 
dhpI. This predicted SAM-dependent methyltransferase proves essential 
for the production of dehydrophos as mutant clusters lacking the corresponding 
1-AEP  
AEP  HEP  
1-HEP O-Me 
Figure 4.15 Supernatant from a dhpI mutant strain accumulates 1-AEP. 
The 31P NMR spectra from the spent culture supernatant of a dhpI mutant 
(top). Complementation with dhpI restores the ability of the mutant strain to 
produce the dehydrophos breakdown product 1-HEP O-Me (bottom).  
 117 
gene failed to produce the phosphonate peak corresponding to dehydrophos and 
extract taken from mutant strains is not bioactive against the indicator strain. 
Supernatant from the mutant strain contains several phosphonate-containing 
compounds (Figure 4.15), including previously discussed compounds with 
chemical shifts of 17.2 ppm (AEP), 19 ppm (HEP), and 13.2 ppm (1-AEP).  
 
dhpJ. Disruption of dhpJ by insertion of a transposon into the coding 
region, abolished bioactivity and resulted in an altered phosphorus NMR spectra 
containing no dehydrophos signal but two peaks in the phosphonate region. To 
Figure 4.16 The phosphorus NMR spectrum from a transposon inactivated 
mutant of dhpJ.  
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test whether the transposon insertion caused a polar effect on downstream 
transcription a second mutant cluster containing a deletion of dhpJ was also 
constructed. This mutant also lacked bioactivity and resulted in an altered 
phosphorus NMR spectrum. However, the NMR spectrum of the deletion mutant 
contained no peaks in the phosphonate region of the spectrum, whereas the 
insertion mutant had two strong peaks in the phosphonate region, at 13.2 ppm 
and 20.2 ppm (Figure 4.16). Complementation experiments were not performed 
for either mutant, leaving open the possibility that the phenotype witnessed 
results from polar effects on the transcription of dhpK or dhpL.  
 
dhpK. The mutant cluster used for the genetic analysis of dhpK was 
generated by transposon insertion. Similar to dhpJ, this insertion may potentially 
cause polar effects, although it should be noted that the only gene present 
downstream of dhpK in this operon has been shown to be dispensable for 
dehydrophos production. Analysis of culture supernatant obtained from these 
mutants reveals a 31P spectrum similar to the heterologous producer, but the 
supernatant fails to exhibit bioactivity. These mutants appear to accumulate a 
sole phosphonate metabolite, which possesses a chemical shift of 24.5 ppm 
(Figure 4.17). Spiking with a synthetic standard revealed that the identity of this 
compound was 1-hydroxyethylphosphonate O-monomethyl ester. This 
compound occurs as a breakdown product of dehydrophos, and potentially as a 
breakdown product of desglycyldehydrophos. A more detailed examination of this 
topic is covered in Chapter 2.  
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dhpL. Genetic analysis of dhpL revealed that this gene is not required for 
dehydrophos biosynthesis. Disruption of the dhpL ORF by transposon insertion 
neither abolished bioactivity nor altered the phosphorus NMR spectrum from the 
profile of the wild-type. 
1-HEP O-Me 
Figure 4.17 Accumulation of 1-HEP O-Me in dhpK mutants. The 
phosphorus NMR spectrum of supernatant from a dhpK mutant reveals 
the presence of a known dehydrophos metabolite. 
1-HEP O-Me 
Figure 4.18 Mutants of dhpL accumulate 1-HEP O-Me. 
The 31P NMR spectra of supernatant from a dhpL mutant 
reveal the presence of a known dehydrophos metabolite. 
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dhpM. To determine the function dhpM serves during the production of 
dehydrophos a mutant cluster in which dhpM had been replaced by an antibiotic 
resistance cassette was constructed. The results of these experiments indicate 
an essential role for dhpM in the production of dehydrophos. Spent culture 
supernatant was not bioactive and failed to accumulate a detectable level of 
Figure 4.19 Culture supernatant and cell extract obtained 
from dhpM mutants does not contain phosphonate 
compounds. The 31P NMR spectra of spent supernatant (top) 
and crude cell extract following lysis in a french pressure cell 
(bottom). 
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dehydrophos or other phosphonate-containing compounds. The bioinformatic 
analyses performed in Chapter 3 indicate that DhpM is most likely a membrane 
protein, possessing a high level of identity with proteins involved in export and 
antibiotic resistance. Consistent with this possible function, one explanation for 
the absence of bioactivity and phosphonate peaks is an inability of dhpM mutants 
to excrete dehydrophos from the interior of the cell. To test this idea, cells were 
collected from spent culture supernatant and subjected to lysis in a pressure cell. 
The crude extract was then examined by 31P NMR spectroscopy, which also 
failed to reveal the presence of any phosphonates (Figure 4.19). 
 
dhpN. Genetic analysis of dhpN revealed that this gene was not 
necessary for dehydrophos biosynthesis. Replacement of the dhpN ORF by a 
kanamycin resistance cassette failed to abolish bioactivity. Interestingly, removal 
Figure 4.20 dhpN mutants fail to excrete phosphonate-containing 
compounds. The 31P NMR spectrum taken from supernatant of a 
dhpN mutant. Interestingly, this mutant is capable of killing an indicator 
strain in a dehydrophos-dependent fashion.  
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of this gene does result in a phenotype. The 31P NMR spectrum of supernatant 
obtained from an organism containing the mutant cluster does not exhibit any 
peaks in the phosphonate range (Figure 4.20).  
 
dhpP. This ORF marks the 3′ boundary of the minimal dehydrophos 
biosynthetic gene cluster and proves essential for production. Mutant clusters 
lacking dhpP do not produce dehydrophos, as demonstrated by bioassay 
(Andrew Eliot; Personal Communication) and 31P NMR experiments. These 
mutants accumulate a sole phosphonate intermediate, 
1-hydroxyethylphosphonate O-monomethyl ester (Figure 4.21). 
 
 
 
 
 
1-HEP O-Me 
Figure 4.21 dhpP mutants accumulate 1-HEP O-Me. The 31P NMR spectrum 
of supernatant from a dhpP mutant reveals the presence of a known 
dehydrophos metabolite. 
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Discussion 
 
The genetic experiments described above were useful in the validation of 
the proposed biosynthetic pathway. Mutations in dhpA, dhpB, dhpC, dhpD, dhpE, 
dhpF, dhpG, dhpH, dhpI, dhpJ, dhpK, dhpM and dhpP abolished antibiotic 
production and led to the disappearance of the dehydrophos peak from the 31P 
NMR spectra. Most of these strains also accumulate new phosphonate 
compounds with peaks in the 10-25 ppm range, suggesting that dehydrophos 
biosynthetic intermediates are accumulating in these blocked mutants. Mutations 
affecting dhpL and dhpN have no discernible effect on bioactivity. In sum, these 
results indicate that all genes examined, with the exceptions of dhpL and dhpN 
are required for dehydrophos biosynthesis. 
Genetic complementation experiments were carried out on select mutants 
to examine the possibility that their phenotypes were mediated by transcriptional 
Figure 4.22 Bioassay of Streptomyces lividans 17E11-4 mutant cultures.  
Agar cores from the various mutants were tested for growth inhibition of E. coli 
DH5α.  Each number represents a single mutant. 1-dhpA::KnR, 2-∆dhpB, 3-
∆dhpC , 4 - dhpD::KnR, 5 – ∆dhpE, 6 – ∆dhpF , 7 – ∆dhpG, 8 -∆dhpH, 9 – ∆dhpI, 
10  - ∆dhpJ, 11-dhpK::KnR, 12 – ∆dhpP, 13 – dhpL::KnR, 14 - complementation of 
∆dhpB, 15 – complementation of ∆dhpH, 16 – complementation of ∆dhpI, 17- 
dhpM::KnR 18 – dhpN::KnR. 
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polarity. To do this, a functional copy of the deleted gene was introduced at a 
distant site in the S. lividans chromosome under the control of the constitutive 
pERM* promoter. Restoration of dehydrophos biosynthesis after 
complementation of the dhpB, dhpE dhpH, and dhpI mutations demonstrates that 
these particular mutations were not affecting expression of downstream genes. 
Other mutations were not tested for polar effects due to their position in the gene 
cluster (i.e. they are not upstream of any other dhp genes), or because the 
mutation did not effect bioactivity. Mutant gene clusters of dhpC and dhpJ were 
not tested for complementation and therefore the formal possibility of polar 
effects being responsible for their observed phenotypes exists. We view this as 
unlikely in the case of dhpC because the products of the downstream genes 
(dhpE, dhpF, and dhpG) are needed to produce the intermediates observed to 
accumulate in the dhpC mutant (see below). 
One helpful feature of secondary metabolism is the tendency of organisms 
containing a blockage of a linear biosynthetic pathway to excrete pathway 
intermediates that can then accumulate in these mutants. The use of 31P NMR 
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Figure 4.23 Step III of dehydrophos biosynthesis, a DhpG 
catalyzed reduction of phosphonoacetaldehyde (PnAA) to 2-
hydroxyethylphosphonate (HEP). 
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spectroscopy and the characteristic chemical shift of phosphonate-containing 
compounds have enabled us to detect and identify many of these accumulated 
intermediates. This approach is not without drawbacks as on occasion the 
intermediates that accumulate are not ‘true’ metabolites, but a breakdown, shunt, 
or modified relative. This phenomenon can be seen upon disruption of Step III of 
the dehydrophos pathway, a predicted reduction of PnAA to HEP catalyzed by 
DhpG. Mutants lacking DhpG would be expected to accumulate PnAA. 
Interestingly, this is not the case, as mutants of DhpG accumulate AEP, a 
transamination product of PnAA. Due to the predicted highly reactive nature of 
the aldehyde group of PnAA, this compound may not be stable for long periods 
of time and may even be toxic to the cell. Transamination may provide the cell 
with a means to store excess amounts of PnAA. The reaction is freely reversible, 
evidenced in the PTT pathway by feeding AEP to mutants lacking a PEP mutase, 
which then restored their ability to produce PTT (3,4). Additionally, the PTT 
pathway contains a DhpG homologue, PhpC, and disruption of PhpC results in 
an identical accumulation of AEP. Biochemical assays verified the proposed 
function for DhpG, complementing the genetic data (see Chapter 5). 
 Following the reduction of PnAA to HEP, Step IV of the pathway was 
predicted to be a C1 hydroxylation catalyzed by DhpA (another candidate to 
catalyze this reaction was DhpJ, also a 2-oxoglutarate dependent dioxygenase). 
Blocked mutants of dhpA would be expected to accumulate HEP, and extensive 
use of synthetic HEP during investigations of phosphinothricin biosynthesis 
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revealed this compound to be quite stable, neither breaking down over time in 
solution, nor undergoing spurious reactions in crude cell supernatant (J. Blodgett, 
 personal communication). Indeed the major metabolite accumulated by dhpA 
mutants is HEP. AEP also builds up in these mutants, likely resulting from the 
increasing concentration of products creating unfavorable thermodynamic 
conditions. The presence of two smaller peaks downfield of HEP and AEP was 
somewhat surprising however. Addition of synthetic standard identified the peak 
at 25.5 ppm as HEP O-monomethyl ester, and by analogy we propose the 
second peak to be AEP O-monomethyl ester. These products are of note, 
because they shed light on the timing of the methylation reaction catalyzed by 
DhpI (see Chapter 5). In vitro biochemical analysis complemented the genetic 
results obtained for dhpA mutants and confirmed the function of DhpA as a 
2-oxoglutarate dependent dioxygenase (see Chapter 5). 
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Figure 4.24 Step IV of dehydrophos biosynthesis, a DhpA 
catalyzed hydroxylation of 2-hydroxyethylphosphonate (HEP) to 1,2-
dihydroxyethylphosphonate (DHEP). 
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The phosphorylation of DHEP to form 1-hydroxy-2-
phosphorylethylphosponate (HP-EP) was not initially predicted (Step V, Figure 
4.25). The enzyme performing this reaction, DhpB, shares a high level of identity 
with a large family of glycerate kinases , including conservation of seven out of 
nine important active site residues (5). Consistent with the proposed function, 
mutant clusters lacking dhpB accumulate DHEP in the spent culture supernatant, 
Unlike the HEP and AEP derivatives present in dhpA mutant supernatant, a 
corresponding methylated analogue of DHEP fails to accumulate in dhpB 
mutants. Also of note - the product of 1,2-DHEP phosphorylation, 1-hydroxy-2-
phosphorylethylphosphonate (HP-EP), is a phosphonate analog of 3-
phosphoglycerate. 
The function that phosphorylation of 1,2-DHEP serves is uncertain, but 
several scenarios exist which require phosphorylation. For example, during 
lantibiotic biosynthesis, phosphorylation precedes the dehydration reaction 
involved in the formation of dehydroalanine and dehydrobutyrine residues (16). A 
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Figure 4.25 Step V of dehydrophos biosynthesis, a DhpB catalyzed 
phosphorylation of 1,2-dihydroxyethylphosphonate (DHEP) to 1-
hydroxy-2-phosphorylethylphosphonate (HP-EP). 
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similar reaction could generate the vinyl group in dehydrophos. However, the 
dehydrophos gene cluster lacks ORFs with recognizable homology to the 
enzymes that perform these dehydrations in lantibiotic biosynthesis. Alternatively, 
the phosphorylation event could provide protection from an otherwise toxic 
intermediate, in a manner similar to acetylation of demethylphosphinothricin (3).  
 Following the phosphorylation reaction to generate HP-EP, we believed an 
oxidation at C1 takes place (Figure 4.24). The resulting keto group can then 
undergo a transamination reaction to yield the free primary amine necessary for 
peptide bond formation. DhpC is likely to perform this initial oxidation based on 
the high level of identity shared with known malate and lactate dehydrogenases. 
There exists some uncertainty regarding what intermediates to expect in the 
culture supernatant of dhpC mutants. Academically, a blockage at dhpC should 
result in accumulation of HP-EP, but the stability of the phosphate ester bond in 
the supernatant of an actively growing culture for several days was unknown. 
Additionally, obtaining a synthetic standard of HP-EP to confirm HP-EP as the 
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Figure 4.26 Step VI of dehydrophos biosynthesis, a DhpC-
catalyzed oxidation of HP-EP to 1-oxo-2-phosphorylethylphosphonate. 
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sole intermediate present in dhpC culture broth proved to be difficult. Fortunately, 
the dhpC mutant accumulated both DHEP and HP-EP, as shown by experiments 
with calf intestinal alkaline phosphatase and addition of the standard of DHEP. 
The phosphatase treatment proved a potent tool, eliminating most of the 
phosphate esters in solution, but leaving the C-P bond of phosphonic acids 
untouched. 
The subsequent transamination (Step VII), believed to be catalyzed by 
DhpD, has proven difficult to study by genetic means for several reasons. The 
first of these involves the thermodynamics of the prior reaction. An oxidation of 
the C1 hydroxyl by DhpC is an unfavorable process, with the ∆G°′ of a related 
reaction (the oxidation of lactate to pyruvate) measuring 25 kcal mol-1, which 
translates to an equilibrium favoring the substrate nearly 25,000-fold under 
standard conditions. This complicates analysis of blocked mutants following this 
reaction, as observing the product of the reaction seems unlikely. A more 
probable outcome would be the observation of an intermediate profile identical to 
that of dhpC blocked mutants. But, even this outcome does not present itself in 
dhpD blocked mutants, which appear capable of bypassing the blockage in an 
inefficient manner. This mutant accumulates several known intermediates in the 
dehydrophos pathway, including 1-HEP O-monomethyl ester and 1-AEP, 
compounds present in supernatant from the heterologous host containing the 
entire minimal cluster. However, no evidence of bioactivity or dehydrophos 
production was detectable. One possibility is that the metabolic flux through the 
bypass occurs at a lower rate than that of peptidase-catalyzed dehydrophos 
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breakdown, rendering only the catabolic products visible. Non-specific 
transamination of phosphonates has been previously observed in the case of 
PnAA so it is unsurprising that a transaminase-dependent step may be able to be 
bypassed. Regardless of the necessity of DhpD, the predicted product of this 
transamination, 1-amino-2-phosphorylethylphosphonate accumulates in 
supernant from mutant clusters which lack the dhpH gene, indicating that the 
proposed transamination does in fact take place (although not necessarily by the 
action of DhpD) and that DhpH catalyzes the following reaction. 
The reactions putatively catalyzed by DhpB, DhpC, and DhpD lend 
remarkable structural similarity between the intermediates and transformations 
found in steps V, VI, VII of the proposed dehydrophos pathway and those found 
in serine biosynthesis. Interestingly, several other phosphonate biosynthetic 
pathways contain reactions ‘borrowed’ from central metabolic pathways (4,7,9). 
This suggests the intriguing possibility that dehydrophos biosynthesis evolved 
from enzymes of the related serine biosynthetic pathway. 
Following transamination, the experimental evidence fails to clearly 
delineate the pathway. By this point in the biosynthesis most of the ORFs within 
the minimal contiguous gene cluster already been assigned an established 
function. The final reactions must be performed by some combination of the 
protein products of dhpH, dhpI, dhpJ, and dhpK. DhpH and DhpK are the two 
ORFs predicted to be involved in peptide bond formation, based on bioinformatic 
analysis identifying domains with similarity to the FemXAB family of proteins. 
Work performed by collaborators identified DhpI as the enzyme catalyzing the 
 131 
ultimate reaction, the O-methylation of desmethyldehydrophos. And finally, the 
predicted 2-oxoglutarate dependent dioxygenase DhpJ performs an unknown, 
yet apparently essential role.  
Chemical logic also played a role in elaborating the terminal portion of the 
pathway. We knew that the formation of the vinyl group must occur following the 
formation of at least one, if not both peptide bonds. This follows because 
generation of the vinyl group from 1-amino-2-phosphorylethylphosphonate would 
result in a dehydroalanine analogue subject to enamine-imine tautomerization. 
The resulting highly favored imine would then be subject to attack and 
subsequent hydrolysis by water, generating methyl acetylphosphonate. Based on 
results discussed in depth in Chapter 5, methyl acetylphosphonate undergoes 
reduction to yield 1-HEP O-monomethyl ester, readily observed at 24.5 ppm in 
the 31P NMR spectrum. 
The accumulation of 1-HEP O-Me served as a complicating factor in the 
analysis of dehydrophos biosynthesis. The problem arises because 1-HEP O-Me 
can be generated not only by breakdown of the complete dehydrophos molecule, 
but also by the breakdown of desglycyldehydrophos. Therefore uncertainty arises 
when 1-HEP O-Me is observed in mutants – does this indicate a non-essential 
gene, or does this indicate the ultimate gene, or some regulator thereof, in the 
biosynthetic pathway? In these instances, we utilized a bioassay of antibiotic 
activity as the determining factor in classifying the essentiality of the gene 
Because successful installation of the vinyl group can only occur following 
peptide bond generation, formation of 1-HEP O-monomethyl ester can serve as a 
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proxy for dehydrophos or desglycyldehydrophos in culture supernatant, based on 
results previously discussed in Chapter 2. 
Based on the constraints discussed above, we believed the logical next 
step in the pathway was the installation of the first peptide bond. Of the two 
candidate enzymes for this reaction (DhpH and DhpK), the data point to the 
catalysis of this reaction by DhpH. Supernatant from mutant clusters lacking 
DhpH contains 1-amino-2-phosphorylethylphosphonate, a predicted substrate for 
the formation of the first peptide bond, and additionally, the absence of DhpK 
results in a phenotype containing high levels of 1-HEP O-monomethyl ester, a 
known breakdown product of dehydrophos and desglycyldehydrophos (Chapter 
2). These results suggest that vinyl group installation and at least one amide 
bond are present prior to the reaction catalyzed by DhpK, supporting the idea 
that DhpH catalyzes the initial peptide bond formation. A curious phenomenon 
implied by this data is that the dehydrophos peptide “grows” from C to N 
terminus, consistent with the notion that FemXAB-related enzymes perform this 
reaction, as the extension of the interpeptide side chain in the cell wall proceeds 
in a similar fashion (13). 
The product of the predicted DhpH reaction, Gly-AP-EP could then serve 
as the substrate for dehydration or a second transpeptidation. In theory, the next 
step in the pathway could be deduced by identifying Gly-AP-EP from spent 
culture supernatant or alternatively the peptidase breakdown product AP-EP. 
However, neither of these phosphonate intermediates accumulate in the 
supernatant from mutant clusters of the remaining possible ORFs. 
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One explanation for the discrepancy would be installation of the vinyl 
group concurrent with the generation of the first peptide bond. DhpH contains two 
domains, the aforementioned FemXAB region in addition to a PLP binding 
domain located near the N terminus. PLP-dependent enzymes are capable of 
catalyzing a variety of reactions, including transaminations and β-eliminations of 
functional groups in molecules containing a free primary amine. The proposed 
reaction would proceed via the aminovinylphosphonate intermediate, but would 
circumvent the previously discussed problems associated with tautomerization 
and hydrolysis by channeling this intermediate through the enzyme in a solvent 
protected fashion to the second domain where peptide bond formation could 
occur. 
Finally, DhpI-catalyzed methylation of the phosphonate moiety of 
desmethyldehydrophos completes the biosynthesis of the dehydrophos 
molecule. In tandem with the genetic studies of dhpI, collaborators examined the 
substrate specificity of DhpI, solved the X-ray crystal structure, and performed 
structure/function analysis of the enzyme. Collectively these results indicate that 
of the substrates tested, the ideal candidate for methylation closely resembles 
desmethyldehydrophos (Lee et al., In press). 
While these results fit the proposed pathway for biosynthesis of 
dehydrophos, they leave unaddressed the role of dhpJ and the accumulation of 
1-aminoethylphosphonate and corresponding methyl ester that are observed in 
several mutants. The function of dhpJ is perplexing. Containing homology to 
peptide dioxygenases, DhpJ was initially believed to catalyze the hydroxylation of 
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HEP to DHEP. However this was later shown to be a DhpA-dependent reaction. 
Nevertheless, transposon insertions into dhpJ fail to produce both bioactivity and 
dehydrophos. Importantly, mutants of the gene immediately downstream (the 
final gene in the primary operon) possess a different intermediate profile, 
suggesting either the lack of polarity for the dhpJ transposon insertion or that the 
action of DhpJ precedes that of DhpK. The intermediates observable in dhpJ 
mutants (1-AEP O-monomethyl ester and 1-AEP) are currently absent from the 
proposed biosynthetic pathway. 
The dhpJ results can be rationalized in several ways. Hydrolysis of 
desglycyldehydrophos and dehydrophos results in production of methyl 
acetylphosphonate (MAP), a potent pyruvate dehydrogenase inhibitor. This 
compound may be detoxified either by reduction to 1-HEP O-Me or 
transamination to 1-AEP O-Me. As previously noted, non-specific 
transaminations have been observed in phosphonate biosynthesis and this may 
be the dominant means of MAP detoxification in vivo. However, 1-AEP is also 
capable of inhibiting cell wall biosynthesis and therefore accumulating large 
amounts may be detrimental to the cell. One possible role for DhpJ would be to 
scavenge 1-AEP generated from the breakdown of dehydrophos. This 
scavenging ability would serve to recycle this toxic ‘dead-end’ metabolite back 
into the biosynthetic pathway as 1-amino-2-hydroxyethylphosphonate, which 
could serve as the substrate for DhpB or DhpH. The large peak produced by 
1-HEP O-Me, on the other hand, would represent a true metabolic dead end, 
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resulting from the reduction of MAP with the producing organisms having no 
means to recapture it.  
A second possible role for DhpJ in the production of dehydrophos might 
occur via participation in an alternative biosynthetic pathway. In this pathway, 
DhpH would catalyze not only the PLP-dependent β-elimination and the primary 
peptide bond formation, but also would reduce the vinyl group to a methyl group. 
Subsequently, DhpJ would serve to reattach the hydroxyl group at C2. The 
remaining steps would mirror the original proposed pathway, with DhpK 
catalyzing the addition of glycine and DhpI installing the methyl group. 
Elimination of water across C1-C2 would then serve to generate the vinyl group, 
however the mechanism for this reaction remains unexplained by this alternate 
pathway. 
The alternate pathway, while less feasible, provides a secondary 
explanation for the function of DhpJ and the accumulation of 1-AEP, in this case 
predicting its nature as a true metabolic intermediate in the biosynthesis of 
dehydrophos. 
The remainder of the ORFs examined do not appear to be directly 
involved in biosynthetic transformations required for dehydrophos production. 
The bioinformatic analysis of these genes indicated involvement in regulation, 
export, or self-resistance. More specifically, DhpM, DhpN, and DhpL all contain 
homology to transport related proteins. The protein product of dhpM shares a 
high level of amino acid identity with DhpN leading to the idea that DhpM and 
DhpN serve as a heterodimer necessary for the export of nascent dehydrophos 
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molecules. The remaining integral membrane protein predicted to be encoded by 
the gene cluster, DhpL, would then function to mediate resistance via efflux. This 
organization presents itself in other antibiotic production systems. For example, 
the operon for nisin biosynthesis contains 2 sets of ABC transporters: NisT and 
NisFEG. Investigations into the role of these two groups clearly show that NisT 
functions to translocate nisin out of the cell, whereas cells require NisFEG (along 
with NisI) to mediate immunity (10,11). Unlike the nisin system, DhpL, DhpM, and 
DhpN do not function by an ATP-dependent mechanism, but a similar 
arrangement can be envisioned. 
Genetic analysis of these mutants fails to definitively address the 
proposed functions of these transmembrane proteins. The predicted outcomes 
for clusters containing mutants of these genes range from no effect to 
intracellular accumulation. This is not what is witnessed. For example, although 
DhpL and DhpN mutants retain the ability to produce dehydrophos, recombinant 
strains lacking DhpM fail to produce dehydrophos. One explanation for the 
inability of DhpM mutants to produce dehydrophos could lie in a failure to excrete 
the compound from the cells. However, NMR data from the supernatant of lysed 
cells containing the mutant cluster appears to invalidate this idea. A second 
explanation can be found in the high level of identity that DhpM and DhpN share. 
A duplication event followed by mutational inactivation of DhpN could also 
account for the dispensable nature of DhpN and requirement for DhpM. 
The final two open reading frames located within the minimal cluster for 
dehydrophos biosynthesis, dhpO and dhpP, appear to be involved in regulatory 
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processes. At this point, the bioinformatic data comprise most of what is known 
about these genes.  
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Chapter 5: Biochemical Characterization of Dehydrophos Biosynthesis 
 
Abstract 
 
Bioinformatic and genetic studies of the dehydrophos biosynthetic gene 
cluster established an empirical basis for many of the transformations proposed 
in the hypothetical pathway. To complement existing data and further support our 
genetic model we also took a biochemical approach to analyzing individual steps 
within the pathway. Characterization of selected proteins was accomplished by 
over-expression, purification, and attempted in vitro reconstitution of enzymatic 
activity. Seven of the eight proteins in the pathway were recombinantly 
expressed in soluble form from Escherichia coli. However we were only able to 
demonstrate in vitro activity for three of the proteins assayed. The results 
demonstrate generation of the common phosphonate intermediate 
2-hydroxyethylphosphonate (HEP) via reduction of phosphonoacetaldehyde and 
subsequent conversion of HEP into 1,2-dihydroxyethylphosphonate (DHEP) as 
well as establishing the novel O-methylation of the phosphonate group of 
dehydrophos as the terminal step in dehydrophos biosynthesis. Altogether these 
data supplement the genetic data and further flesh out the manner in which 
Streptomyces luridus produces dehydrophos. 
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Introduction 
 
 The genetic investigation of the dehydrophos biosynthetic gene cluster 
resulted in empirical evidence supporting the first seven proposed reactions. The 
accumulation of identifiable intermediates from blocked mutants proved a useful 
complement to bioinformatic investigations in verifying many of the 
transformations, but in some cases intermediates that accumulated failed to 
provide useful information or contradicted with the proposed reaction (see 
Chapter 4 results, dhpG and dhpI for specific examples). To better understand 
what was transpiring in vivo, we decided to subject certain enzymes to in vitro 
experimentation. 
 One of the major aims of the research in this chapter is to investigate the 
step at which the O-methyl group present on the dehydrophos molecule is 
added. Because this modification takes places on the phosphonate group and 
not the carbon backbone it is not directly required for downstream 
transformations and could conceivably occur at any step during biosynthesis. 
 To gain insight into the methylation step we examined the functions of 
DhpI and DhpA. These proteins were chosen on the basis of bioinformatic and 
genetic results. In the case of DhpA, a mutant cluster lacking dhpA accumulated 
a methylated derivative of 2-hydroxyethylphosphonate (HEP) (and most likely 2-
aminoethylphosphonate (AEP) as well), indicating that the methylation could 
potentially occur before the action of DhpA. If proven correct, then DhpA should 
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be capable of catalyzing the hydroxylation of HEP O-Me in addition to HEP. DhpI 
was selected for analysis as bioinformatic analysis had identified this gene as a 
homologue of known methyltransferases. Additionally, genetics had failed to 
decisively identify the step this reaction took place, as mutants only accumulated 
small amounts of AEP in addition to the cryptic intermediate 
1-aminoethylphosphonate (1-AEP). Identifying the compound that DhpI could 
methylate with the lowest Km would provide one line of evidence to where this 
enzyme fits into the biosynthetic pathway. 
 The final enzyme characterized is DhpG. This protein contains similarity to 
iron (II) dependent dehydrogenases (Chapter 3) and based on the precedent set 
during investigations of fosfomycin and phosphinothricin tripeptide biosynthesis 
(4) we believed this enzyme capable of reducing phosphonoacetaldehyde 
(PnAA) to HEP. As such, we expected mutants lacking a functional DhpG to 
accumulate PnAA. This was not the case, as supernatant from dhpG mutants 
contained AEP, resulting from the putative transamination of PnAA (as discussed 
in Chapter 4). Although several rationalizations exist for the accumulation of AEP 
in dhpG mutants, direct evidence for the catalysis of PnAA to HEP by DhpG 
would serve to confirm the role of DhpG in dehydrophos biosynthesis. 
 In addition to the characterizations described above, we attempted three 
other biochemical analyses on enzymes within the dehydrophos pathway. These 
efforts included in vitro monitoring of DhpC activity, attempted identification of the 
substrate of DhpJ, and probing the activity of DhpH with substrate analogs. 
These experiments and resulting conclusions will be briefly described. 
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Materials and Methods 
 
31P NMR analysis of enzymatic assays and identification of reaction 
products. 31P NMR spectra were acquired on a Varian Unity Inova 600 
spectrophotometer equipped with a 5 mm AutoTuneX probe at the Varian Oxford 
Instrument Center for Excellence at the University of Illinois Urbana-Champaign. 
An external standard of 85% phosphoric acid was defined as 0 ppm. Because 
31P NMR chemical shifts are highly pH dependent, experiments to confirm the 
identity of enzymatic products were routinely performed by adding 1-5 mM of 
standard to the reaction and then reacquiring the spectra.  
 
Overexpression and purification of His6-DhpA, His6-DhpC, His6-DhpH 
and His6-DhpJ. The appropriate E. coli strains were grown in Luria-Bertani broth 
supplemented with the appropriate antibiotics at 37 °C to an OD 600 of 0.6, then 
cooled to 22 °C for ten minutes prior to the additi on of 250 µM isopropyl β-D-1-
thiogalactopyranoside (IPTG).  
The cultures were incubated for an additional 18 h at 22 °C before 
harvesting by centrifugation at 5000 X g for ten minutes. The cell pellets were 
resuspended in 15 mL of ice cold Buffer 1 (50 mM HEPES pH 7.5, 250 mM NaCl, 
25 mM imidazole, and 0.5% glycerol) and cells were disrupted by a single 
passage through a chilled French press cell at 20,000 psi.  
Solid debris was removed by centrifugation at 13,000 × g for 30 minutes at 
4 °C., and clarified supernatants passed over a col umn containing 5 mL of Ni-
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NTA affinity resin (Qiagen, Valencia, California) equilibrated with Buffer 1. 
Unbound proteins were washed from the column with 50 mL wash Buffer 2 
(Buffer 1 with 50 mM imidazole). Hexahistidine tagged proteins were eluted from 
the column with 5 mL Buffer 3 (Buffer 1 with 250 mM imidazole). 
The eluant was desalted by passage over a PD-10 column (GE 
Healthcare), following the manufacturer’s instructions and eluted with Buffer 4 
(Buffer 1 lacking imidazole). Purity of the isolated proteins was evaluated by 
visual inspection of an SDS-PAGE gel stained with Coomassie Brilliant Blue 
(estimated to be at least 95% pure).  
 
Overexpression, purification, and enzymatic assay of DhpG. 
Overnight cultures of E. coli BL21 (DE3) cells transformed with the construct 
pET15-DhpG were diluted 1:100 into M medium (9.3 g/L K2HPO4, 2 g/L KH2PO4, 
6.7 g/L glucose, 1.3 g/L (NH4)2SO4, 1.3 g/L MgSO4, 2.7 g/L Tris, 5.3 mL glycerol, 
13.3 g/L yeast extract, 20 g/L LB).  
Cultures were grown at 37 °C to an OD 600 of ∼1.0 prior to the addition of 
300 µM IPTG. The culture was incubated for an additional 14 h at 20 °C before 
harvesting by centrifugation at 6000 X g for ten minutes at 4°C.  Purification and 
determination of DhpG activity then proceeded as described in Shao et al, 2008  
 
Overexpression, purification, and enzymatic assay of DhpI. Overnight 
cultures of E. coli BL21 (DE3) cells harboring the DhpI encoding plasmid as well 
as the pLysSRARE2 helper plasmid (EMD Chemicals, Damstadt, Germany), 
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were grown in Luria-Bertani (LB) medium supplemented with the appropriate 
antibiotics (100 µg/mL ampicillin and 20 µg/mL chloramphenicol) at 37 °C until 
the OD600 reached 0.5 - 0.7 prior to the addition of 0.5 mM IPTG to induce 
expression. The culture was then incubated an additional 15 h at 18 °C. The 
protein was purified by nickel-nitrilotriacetic acid (Ni-NTA) affinity 
chromatography and assayed as described in Lee et al, 2010. 
 
Assay of DhpA activity. His6-DhpA activity was assayed at 30°C for 30 
min in 50 mM HEPES buffer pH 7.5, 250 mM NaCl, 0.5% glycerol. Each 1 mL 
reaction also included: 5 mM HEP or HEP O-phosphomonomethyl ester, 
approximately 100 µg purified protein, 5 mM 2-oxoglutarate, and 10 µM ferrous 
ammonium sulfate. The reactions were stopped by incubation at 100 °C for 5 
minutes, and 100 µL of 0.5M EDTA was added to chelate excess Fe(II) prior to 
31P NMR analysis. 
 
Assay of DhpC activity. The activity of His6-DhpC was assayed at 30°C 
for 5 min in 50 mM HEPES buffer pH 7.5, 250 mM NaCl, 0.5% glycerol. Each 1 
mL reaction also included: 1 mM DHEP, approximately 100 µg purified protein, 
and 100 µM NAD+/NAD(P)+. The reactions were monitored for an increase in 
absorbance at 340 nm by UV/Vis spectroscopy. In each case, the reactions were 
started by the addition of substrate to a cuvette containing all of the other 
necessary reagents. 
 
 145 
Assay of DhpJ activity. His6-DhpJ was assayed in crude cell extract at 
30°C for 60 min in 50 mM HEPES buffer pH 7.5, 250 m M NaCl, 0.5% glycerol. 
Each 1 mL reaction also included: 5 mM 1-AEP or 1-AEP O-phosphomonomethyl 
ester, 500 µL crude culture supernatant, 5 mM 2-oxoglutarate, and 10 µM ferrous 
ammonium sulfate. The reactions were stopped by incubation at 100 °C for 5 
minutes, and 100 µL of 0.5M EDTA was added to chelate excess Fe(II) prior to 
31P NMR analysis. 
 
Assay of DhpH activity. The activity of His6-DhpH was assayed at 30°C 
for 5 minutes in 50 mM HEPES buffer pH 7.5, 250 mM NaCl, 0.5% glycerol. Each 
1 mL reaction also included: 10 mM phosphoserine, 50 µM pyridoxal phosphate 
(PLP), 2 units L-lactate dehydrogenase (Roche Diagnostics, Indianapolis, IN) 
approximately 100 µg purified protein, 300 µM NADH, and when necessary as a 
control, 100 µM pyruvate. 
The reactions were monitored for an increase in absorbance at 340 nm by 
UV/Vis spectroscopy on a Cary 4000 UV/Vis spectrophotometer. In each case, 
the reactions were started by the addition of substrate (phosphoserine/pyruvate) 
to a cuvette containing all of the other necessary reagents that were allowed to 
equilibrilate for two minutes at room temperature. The reagent used to start the 
reaction was added directly to a cuvette located within the spectrophotometer 
and immediately mixed by pippetting. 
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Results 
 
Purification and In vitro activity of DhpA.  DhpA contains homology to 
known 2-oxoglutarate-dependent dioxygenases (Chapter 3), and accumulation of 
HEP in the supernatant of a ∆dhpA mutant (Chapter 4) led to the prediction that 
DhpA converted HEP to DHEP. To test this hypothesis, the protein was 
overproduced in E. coli as a 6X-His-tagged protein, purified, and assayed for 2-
oxoglutarate-dependent dioxygenase activity with synthetic HEP. The reaction  
124 kDa 
Figure 5.1 Overexpression and purification of recombinant His6-DhpA from E. 
coli as seen by SDS-PAGE. Lane 1, molecular weight marker; Lane 2, cell extract 
following lysis of induced cells; Lane 3, column flow-through during cell extract loading; 
Lane 4, column fraction following 50 mM imidazole rinse; Lane 5, blank; Lane 6, 
protein eluted with 250 mM imidazole following desalting. The expected weight of 
His6-DhpA is 33.14 kDa.  
1 2 3 4 5 6 
80 kDa 
34.8 kDa 
49.1 kDa 
28.9 kDa 
209 kDa 
20.6 kDa 
7.1 kDa 
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was monitored via 31P NMR spectroscopy. After 30 minutes, the presence of a 
second phosphonate peak was observed in the 31P NMR spectrum (Figure 5.2). 
Addition of authentic DHEP into the sample confirmed that DhpA converted HEP 
into DHEP. This reaction occurred in a 2-oxoglutarate dependent fashion, but did 
not proceed to completion in the reaction time. Interestingly, additional 
experiments indicated DhpA could also convert HEP O-phosphomonomethyl 
ester into DHEP O-phosphomonomethyl ester in a 2-oxoglutarate dependent 
fashion (Figure 5.3).  
Figure 5.2 31P NMR spectroscopy demonstrates that DhpA converts HEP to DHEP. 
HEP was incubated with purified DhpA and 2-oxoglutarate (c), incubated without enzyme 
(a), or incubated without 2-oxoglutarate (b). The reaction shown in (c) was then spiked 
with DHEP to verify the product (d). 
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Purification and In Vitro Activity of DhpG (These results were part of a 
collaborative effort with the laboratory of Huimin Zhao. The assays were 
performed by Zengyi Shao, and I was responsible for the construction of 
overexpression vectors and suitable conditions for soluble expression.) To 
determine if DhpG functioned as a phosphonoacetaldehyde reductase the 
recombinant protein was heterologously expressed in E. coli, purified, and 
assayed for the ability to generate HEP when incubated with PnAA and 
NADH/NAD(P)H. These experiments determined that DhpG catalyzes the 
proposed reaction and established NAD(P)H as the necessary cofactor (Shao et 
al., 2008). 
 
Purification and In Vitro Activity of DhpI (These results were part of a 
collaborative effort with the laboratory of Wilfred van der Donk. The assays were 
performed by Jin-Hee Lee, and I was responsible for the construction of 
overexpression vectors and suitable conditions for soluble expression.) To verify 
Figure 5.3 DhpA catalyzes the hydroxylation of O-methylated HEP. 
Phosphorus NMR spectra of DhpA following incubation with HEP O-Me (a). An 
authentic standard of DHEP O-Me was added to the reaction shown in (a) to 
verify the product of the reaction. 
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the proposed methyltransferase function of DhpI and identify the in vivo substrate 
of this enzyme, this protein was overexpressed, purified, and subjected to in vitro 
investigation with a number of proposed substrates. These experiments 
demonstrated the ideal substrate for this enzyme corresponded to a full length 
desmethyldehydrophos molecule, a result corroborated by a substrate binding 
pocket capable of accommodating a tripeptide in the recently solved x-ray crystal 
structure (Lee et al., In press). 
 
Purification and In Vitro Activity of DhpC. Based on bioinformatic 
evidence, we proposed a DhpC-catalyzed oxidation of the C1 hydroxy group of 
DHEP. To test this assertion, we incubated purified DhpC with DHEP and + NAD 
Figure 5.4 Overexpression and purification of His6-DhpC evidenced by 
SDS-PAGE. Lane 1, cell extract prior to IPTG induction; Lane 2 cell extract 
following IPTG induction; Lane 3 insoluble cell debris; Lane 4 soluble cell extract; 
Lane 5, molecular weight marker; Lane 6, column flowthrough of cell extract; Lane 
7, column fraction following 50 mM imidazole rinse; Lane 8, protein eluted with 
250 mM imidazole following desalting. The expected molecular weight of 
His6-DhpC is 39.47 kDa. 
1 2 3 4 6 5 7 8 
47 kDa 
37 kDa 
28 kDa 
120 kDa 
19 kDa 
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/ NAD(P)+. The progress of the reaction was followed by monitoring the 
formation of NADH/NAD(P)H on a Cary 5000 UV/Vis spectrophotometer. Under 
the conditions utilized, no significant activity could be observed (Figure 5.5). 
 Purification and In Vitro activity of DhpH. To test the hypothesis that 
DhpH performs a concerted two-step transformation, we attempted to observe 
the first half reaction, a β-elimination from AP-EP in a reaction dependent on the 
PLP-containing domain of DhpH. Due to the lack of available AP-EP we 
attempted to use an analog of the proposed substrate, phosphoserine.  By 
analogy to AP-EP, the product formed by elimination from phosphoserine is 
expected to undergo enamine-imine tautomerization, followed by rapid hydrolysis 
to yield pyruvate, formation of which was assayed by coupling to lactate 
dehydrogenase and monitoring the increase in NADH via UV/Vis spectroscopy. 
The precipitation of DhpH upon addition to the reaction mixture precluded 
measurement. 
+NAD+ +NADP+ 
+DHEP 
+DHEP 
Figure 5.5 Activity assay of DhpC. DhpC activity was assayed by adding NAD+ or 
NAD(P)+ and DHEP to purified DhpC. The reaction was monitored by UV/Vis 
spectroscopy for an increase in absorbance at 340 nm following the addition of DHEP. 
No activity was observed. 
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Activity assay of DhpJ. One proposed function of DhpJ involved 
hydroxylation at the C-2 position of 1-AEP, a potential dead-end toxic metabolite 
resulting from intracellular hydrolysis of dehydrophos. To validate this proposed 
function, crude cell extract of a strain overexpressing DhpJ was incubated with 
commercially available 1-AEP and the reaction was monitored with 31P NMR 
spectroscopy. Following 90 minute incubation with DhpJ, no significant 
conversion was observed (Figure 5.7, b). 
Figure 5.6 Overexpression and purification of recombinant His6-DhpH from E. 
coli as evidenced by SDS-PAGE. Lane 1, cell extract following IPTG induction; 
Lane 2, molecular weight marker; Lane 3, column flow-through of cell extract; Lane 
4, column fraction following elution with 250 mM imidazole. The expected 
molecular weight of His6-DhpH is 75.86 kDa. 
1 2 3 4 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
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Discussion 
 
The biosynthesis of the antibiotic dehydrophos contains four ‘notable’ 
biochemical transformations; 1) the generation of a direct C-P bond, 2) the 
dehydration to generate the vinyl group, 3) the apparent non-ribosomal, non-
NRPS based mechanism of peptide bond formation, and 4) the installation of an 
O-methyl group onto the phosphonate moiety. Unfortunately, only one of these 
reactions (generation of the C-P bond) received sufficient support from the 
Figure 5.7 Overexpression of His6-DhpJ (a), as evidenced by SDS-PAGE. Lane 
1, cell extract following IPTG induction; Lane 2, molecular weight marker; Lane 3, 
insoluble cell debris; Lane 4, soluble cell extract. The expected size of His6-DhpJ 
is 27.25 kDa. 31P NMR analysis of DhpJ activity utilizing 1-AEP O-Me as a 
substrate (b, top). Addition of authentic 1-AEP, identifies the secondary peak in 
the top spectrum as a spurious hydrolysis product (b, bottom), and no enzymatic 
activity is observed.  
b 
1 2 3 4 
97 kDa 
66 kDa 
45 kDa 
31 kDa 
21 kDa 
14 kDa 
a 
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genetic and bioinformatic data. The results from the biochemical investigations 
discussed in this chapter address some of these gaps. In particular, the 
installation of the methyl group by DhpI is described by these biochemical 
experiments. 
 The methylation of phosphate groups occurs in a limited number of 
documented instances involving phospholipids or mRNA processing (2,3,5). The 
dearth of these reactions in phosphorus biochemistry increases the significance 
of the DhpI catalyzed methyltransferase reaction. Not only does DhpI catalyze 
the addition of the methyl group to the phosphonate moiety of dehydrophos, but 
the enzyme demonstrates promiscuous behavior as shown by the methylation of 
a number of known phosphonate antibiotics, including fosfomycin and 
fosmidomycin (Lee et al., In press).  
 The broad substrate specificity makes DhpI a promising candidate for 
engineering applications, but also generates a great deal of uncertainty about 
where this protein fits into the biosynthetic scheme for dehydrophos. Several of 
the mutants examined accumulate monomethylated intermediates, and DhpA 
quite clearly transforms HEP O-Me to DHEP O-Me, raising the distinct possibility 
that DhpI acts much earlier in the pathway. The methyltransferase assays echo 
this in vivo result, but also clearly demonstrate a pronounced substrate 
preference for a tripeptide phosphonate substrate, with a Km many times lower 
than those of the intermediates that are seen to be methylated in particular 
mutants. This suggests that the observed methylated intermediates are artifacts 
of the unnaturally high intermediate concentrations found in these blocked 
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mutants. While the ability of DhpA to utilize methylated substrate provides some 
uncertainty, it should be noted that none of the mutants generated are observed 
to accumulate methylated DHEP in vivo. One possible explanation for the 
promiscuous activity of DhpA could be evolutionary descent from an enzyme 
which acted upon a carboxylate, supported by the presence of a carboxylate on 
the known substrate of the homologous gamma-butyrobetaine hydroxylases 
(Chapter 3). It may even be possible that methylation of the phosphonate group 
generates a preferred substrate. However, the end-point experiments performed 
do not allow elaboration of this point. 
 The ability of DhpG to reduce phosphonoacetaldehyde to HEP confirmed 
the role of this enzyme in dehydrophos biosynthesis, and came as no surprise 
based on sequence comparisons with related enzymes in the PTT and 
fosfomycin biosynthetic pathways (4). While the accumulation of 2-AEP in dhpG 
mutants proves interesting, a similar phenomenon occurs in phosphinothricin 
tripeptide biosynthesis (1). The presence of 2-AEP may have implications during 
structural analysis of any new phosphonate antibiotics containing amino or keto 
groups in the final molecular structure, as they may be the product of, or subject 
to the activity of non-specific aminotransferases. 
 As discussed in the previous chapter DhpJ could exist to hydroxylate the 
C-2 of 1-AEP, potentially recycling a toxic metabolite back into the pathway. The 
testing of this activity in crude supernatant resulted in no significant activity. It 
remains unclear if the His6 tag or absence of an unknown cofactor minimized 
enzymatic activity. A faint peak does appear after incubation near 9.0 ppm. The 
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product of the predicted reaction, 1-amino-2-hydroxyethylphosphonate does 
contain a chemical shift in this region (Chapter 4), but the signal to noise of this 
peak is poor enough to prevent concrete conclusions from being made. However, 
the presence of a peak does generate interest in further experiments with purified 
enzyme. 
 The DhpC assays were conducted prior to identification of 
1-hydroxy-2-phosphorylethylphosponate as an intermediate in the pathway, and 
thus we utilized DHEP as the (incorrect) substrate. In addition, these assays 
were conducted against the thermodynamic favorability of this particular reaction 
(Chapter 4), and therefore the absence of activity proves unsurprising. 
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 The predicted reaction(s) catalyzed by DhpH make this enzyme the most 
‘complicated’ step in the pathway. We attempted to assess the viability of the first 
putative transformation catalyzed by this protein by incubation with the substrate 
analog phosphoserine (Figure 5.8). Although we were able to purify DhpH, this 
protein exhibited poor solubility and precipitated from solution almost immediately 
upon removal from ice. This phenomenon also occurred during attempted 
crystallization of the protein (Zhi Li, Personal Communication). Thus the 
biochemical function of DhpH remains unknown. 
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Chapter 6: Summary and Concluding Remarks 
 
Investigation into the biosynthesis of dehydrophos is one facet of a larger 
program to uncover novel antibiotics, based on the premise that the phosphonate 
moiety is a potentially potent inhibitor of enzymatic reactions involving substrates 
containing phosphate esters or carboxylate groups, ubiquitous participants in 
cellular biochemistry. The study of dehydrophos was predicated upon the belief 
that understanding the biosynthesis of one specific phosphonate compound 
could directly benefit our understanding into the transformations available and 
common to all phosphonate-containing compounds, as well as reveal potentially 
novel biochemical transformations in its own right.  
Our research efforts proved rewarding, as the early sequencing and 
heterologous expression of dehydrophos demonstrated the published structure of 
dehydrophos to be incorrect and revealed a molecule containing a phosphonate 
dehydroalanine analogue in addition to an unusual O-methylation of the 
phosphonate moiety. Additionally, the sequencing of the cluster suggested a 
unique, non-ribosomal, non-NRPS method of peptide bond formation. We were 
able to propose a hypothetical pathway (Chapter 3) based on the corrected 
structure of dehydrophos and bioinformatic analysis of the ORFs present within 
the minimal biosynthetic gene cluster. 
To further characterize dehydrophos biosynthesis, we utilized genetic 
techniques to generate deletions of the genes proposed necessary for production 
of dehydrophos and introduced mutant clusters onto the chromosome of the 
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heterologous producer, Streptomyces lividans. We then developed a system to 
test these mutations for negative effects on downstream transcription by 
modifying a vector capable of integrating at a remote site on the chromosome 
with a strong, constitutive promoter and appropriate cloning sites (Chapter 4). 
Supplementing the genetic analysis of dehydrophos biosynthesis, we 
over-expressed and purified selected proteins from the biosynthetic gene cluster 
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Figure 6.1 Revised pathway for dehydrophos biosynthesis (a) and the portion of 
the serine biosynthetic pathway that bear structural similarity to step V, VI, and 
VII of the proposed pathway. Broken arrows indicate hypothetical reactions. PEP = 
phosphoenolpyruvate, PnPy = phosphonopyruvate, PnAA = phosphonoacetaldehyde 
HP-EP = 1-hydroxy-2-phosphorylethylphosphonate, 
 OP-EP = 1-oxo-2-phosphorylethylphosphonate, 
AP-EP = 1-amino-2-phosphorylethylphosphonate.  
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for in vitro analysis (Chapter 5). Although unable to reconstitute several of the 
reactions predicted to occur, biochemical analysis was able to provide evidence 
for the point in the pathway at which the O-methylation of the phosphonate group 
is introduced. 
The results generated in Chapters 4 and 5 have led to revision of the 
proposed hypothetical biosynthetic pathway to reflect the empirical evidence 
(Figure 6.1). Dehydrophos biosynthesis begins with the conversion of 
phosphoenolpyruvate to phosphonopyruvate and subsequent decarboxylation to 
yield phosphonoacetaldehyde, catalyzed by DhpE and DhpF, respectively (Steps 
1 and II). These reactions are supported by bioinformatic analysis and the 
inability of dhpE and dhpF mutants to produce any phosphonate-containing 
compounds. Phosphonoacetaldehyde then undergoes reduction to produce 
2-hydroxyethylphosphonate (HEP), in a DhpG-catalyzed transformation (Step III). 
This reaction was validated in vitro using purified DhpG. Following reduction, 
DhpA catalyzed the hydroxylation of the C1 position of HEP to yield 
1,2-dihydroxyethylphosphonate (DHEP) (Step IV). Both genetic and biochemical 
evidence support this assertion, as dhpA mutants accumulate the substrate of 
the proposed reaction, and purified DhpA was shown capable of converting HEP 
to DHEP. DHEP then undergoes phosphorylation, oxidation of C1, and 
subsequent transamination (Steps V, VI, and VII) as evidenced by analysis of the 
intermediates that accumulate in the relevant blocked mutants. As noted in 
Chapter 4, the structures and reactions present in this sequence recall portions 
of serine biosynthesis (Figure 6.1, b). To complete the biosynthesis of 
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dehydrophos, glycine and leucine residues must be linked to the phosphonate 
moiety, the vinyl group must be installed, and the O-methylation performed. 
Based on genetic analysis, DhpH catalyzes the reaction following transamination 
and is proposed to generate the first peptide linkage and install the vinyl group. 
DhpK is then proposed to add the glycine residue to the molecule and lastly, 
DhpI installs the methyl group onto the phosphonate group, as shown by 
biochemical experiments with potential substrates. 
While the proposed hypothetical pathway is nearly complete, the steps 
that remain undescribed contain potentially unique biochemistry, mostly due to 
lack of easily obtainable substrates for the proposed reactions. In particular 
future study of the proposed tRNA-dependent mechanism of peptide bond 
formation is warranted. 
 162 
Appendix A: Strains, Plasmids, and Primers 
 
 
 
Strain/Plasmid Notable features Source 
Escherichia 
coli 
  
DH10B Φ80dlacZ∆M15/araD139 ∆(ara-leu)7697 ∆lacX74 galU galK rpsL 
deoR endA1 nupG recA1 mcrA ∆(mrr hsdRMS mcrBC) 
(Grant et al., 
1990) 
DH5α Φ80dlacZ∆M15 ∆(lacZYA-argF)U169 recA1 hsdR17 deoR thi-1 
supE44 gyrA96 relA1 
(Grant et al., 
1990) 
WM4489 DH10B derivative with rhamnose inducible trfA33 (Eliot et al., 
2008) 
WM7264 WM4489/pKD46 This study 
WM6026 lacIq, rrnB3, ∆lacZ4787, hsdR514,∆araBAD567, ∆rhaBAD568, rph-1, 
attλ::pAE12(∆oriR6K-cat::Frt5),∆endA::Frt,uidA(∆MluI)::pir,attHK::pJK
1006∆(oriR6K-cat::Frt5;trfA::Frt) 
(Blodgett et 
al., 2007) 
Rosetta 2 BL21(DE3)/pRARE2/pLysS Novagen 
WM4553 Spontaneous dehydrophosR mutant of DH5α This study 
WM7284 Rosetta 2/pBTC017 This study 
Salmonella 
typhimurium  
 
 
TN215 leu-485, pepA1, pepB1, pepD1, pepN1 Charles 
Miller 
TN272 leu-485, pepA1, pepB1, pepD1 Charles 
Miller 
TN272 leu-485, pepB1, pepD1, pepN1 Charles 
Miller 
TN273 leu-485, pepA1, pepD1, pepN1 Charles 
Miller 
TN274 leu-485, pepA1, pepB1, pepN1 Charles 
Miller 
TN1379 leuBCD485 Charles 
Miller 
TN1890 leuBCD485, oppA208 Charles 
Miller 
TN2271 oppBC250, leu::Tn10, tppB9::Tn5 Charles 
Miller 
Streptomyces 
luridus 
Native dehydrophos producer NRRL 
Streptomyces 
lividans 66 
‘Wild-type’ ARS culture 
collection 
WM4467 S. lividans with fosmid 17E11-4 integrated into ΦC31 attB site This study 
WM7265 S. lividans with fosmid 17E11-4∆dhpA::kan integrated into ΦC31 attB 
site 
This study 
WM7266 S. lividans with fosmid 17E11-4∆dhpB integrated into ΦC31 attB site This study 
WM7267 S. lividans with fosmid 17E11-4∆dhpB integrated into ΦC31 attB site 
and pBTC035 integrated into ΦBT1 attB site 
This study 
WM7268 S. lividans with fosmid 17E11-4∆dhpC integrated into ΦC31 attB site This study 
WM7269 S. lividans with fosmid 17E11-4∆dhpD::kan integrated into ΦC31 attB 
site 
This study 
WM7270 S. lividans with fosmid 17E11-4∆dhpE integrated into ΦC31 attB site This study 
WM7271 S. lividans with fosmid 17E11-4∆dhpE integrated into ΦC31 attB site 
and pBTC035 integrated into ΦBT1 attB site 
This study 
WM7272 S. lividans with fosmid 17E11-4∆dhpF integrated into ΦC31 attB site This study 
WM7273 S. lividans with fosmid 17E11-4∆dhpG integrated into ΦC31 attB site This study 
WM7274 S. lividans with fosmid 17E11-4∆dhpH integrated into ΦC31 attB site This study 
WM7275 S. lividans with fosmid 17E11-4∆dhpH integrated into ΦC31 attB site 
and pBTC036 integrated into ΦBT1 attB site 
This study 
Table A1 Strains and plasmids used in the course of this work 
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WM7276 S. lividans with fosmid 17E11-4∆dhpI integrated into ΦC31 attB site This study 
WM7277 S. lividans with fosmid 17E11-4∆dhpI integrated into ΦC31 attB site 
and pBTC037 integrated into ΦBT1 attB site 
This study 
WM7278 S. lividans with fosmid 17E11-4 dhpJ::kan integrated into ΦC31 attB 
site 
This study 
WM7279 S. lividans with fosmid 17E11-4 dhpK::kan integrated into ΦC31 attB 
site 
This study 
WM7280 S. lividans with fosmid 17E11-4 dhpL::kan integrated into ΦC31 attB 
site 
This study 
WM7281 S. lividans with fosmid 17E11-4∆dhpM::kan integrated into ΦC31 attB 
site 
This study 
WM7282 S. lividans with fosmid 17E11-4∆dhpN::kan integrated into ΦC31 attB 
site 
This study 
WM7283 S. lividans with fosmid 17E11-4∆dhpO::kan integrated into ΦC31 attB 
site  
This study 
WM5668 S. lividans with fosmid 17E11-4  Tn008∆frt integrated into ΦC31 attB 
site 
This study 
WM5672 S. lividans with fosmid 17E11-4  Tn046∆frt integrated into ΦC31 attB 
site 
This study 
WM5689 S. lividans with fosmid 17E11-4 TnC∆loxP integrated into ΦC31 attB 
site 
This study 
WM5693 S. lividans with fosmid 17E11-4 Tn180∆loxP integrated into ΦC31 attB 
site 
This study 
Plasmids   
pJK050 Dual-cos fosmid, oriV, λattB, RP4 oriV, loxP, FRT, CmR (Eliot et al., 
2008) 
Fosmid 17E11 pJK050 carrying cloned S. luridus genomic DNA insert with the 
dehydrophos biosynthetic cluster 
This study 
Fosmid 
17E11-4 
Fosmid 17E11/ pAE4 cointegrant  This study 
pBTC017 NdeI/BamHI cut PCR product from template 17E11 using primers 
dhpA-For and dhpA-Rev cloned into NdeI/BamHI cut pET-15b 
This study 
pBTC018 NdeI/BglII cut PCR product from template 17E11 using primers dhpC-
For and dhpC-Rev cloned into NdeI/BamHI cut pET-15b 
This study 
pBTC019 NdeI/BglII cut PCR product from template 17E11 using primers dhpJ-
For and dhpH-Rev cloned into NdeI/BamHI cut pET-15b 
This study 
pBTC025 NdeI/BglII cut PCR product from template 17E11 using primers dhpH-
For and dhpH-Rev cloned into NdeI/BamHI cut pET-15b 
 
pBTC034 SpeI/XbaI cut PCR product from pANT841 using primers pERM-For 
and pERM-Rev cloned into SpeI cut pRT802. 
This study 
pBTC038 Fosmid 17E11-4 with dhpA replaced by pAE5 KanR marker This study 
pBTC039 Fosmid 17E11-4 with dhpB replaced by pAE5 KanR marker This study 
pBTC040 Fosmid 17E11-4 with dhpB deleted  This study 
pBTC041 Fosmid 17E11-4 with dhpC replaced by pAE5 KanR marker This study 
pBTC042 Fosmid 17E11-4 with dhpC deleted This study 
pBTC043 Fosmid 17E11-4 with dhpD replaced by pAE5 KanR marker This study 
pBTC044 Fosmid 17E11-4 with dhpE replaced by pAE5 KanR marker This study 
pBTC045 Fosmid 17E11-4 with dhpE deleted. This study 
pBTC046 Fosmid 17E11-4 with dhpF replaced by pAE5 KanR marker This study 
pBTC047 Fosmid 17E11-4 with dhpF deleted. This study 
pBTC048 Fosmid 17E11-4 with dhpG replaced by pAE5 KanR marker. This study 
pBTC049 Fosmid 17E11-4 with dhpG deleted. This study 
pBTC050 Fosmid 17E11-4 with dhpH replaced by pAE5 KanR marker This study 
pBTC051 Fosmid 17E11-4 with dhpH deleted. This study 
pBTC052 Fosmid 17E11-4 with dhpI replaced by pAE5 KanR marker This study 
pBTC053 Fosmid 17E11-4 with dhpI deleted. This study 
Table A1 Strains and plasmids used in the course of this work (continued) 
 164 
  
 
  
 
pBTC054 Fosmid 17E11-4 with dhpJ interrupted by pAE5 KanR  This study 
pBTC055 Fosmid 17E11-4 with dhpK interrupted by pAE5 KanR This study 
pBTC056 Fosmid 17E11-4 with dhpL interrupted by pAE5 KanR This study 
pBTC057 Fosmid 17E11-4 with dhpM replaced by pAE5 KanR marker This study 
pBTC058 Fosmid 17E11-4 with dhpN replaced by pAE5 KanR marker This study 
pBTC059 Fosmid 17E11-4 with dhpN replaced by pAE5 KanR marker This study 
pBTC060 SpeI cut PCR product from 17E11 using primers dhpB-For and dhpB-
Rev cloned into SpeI cut pBTC034 
This study 
pBTC061 SpeI cut PCR product from 17E11 using primers dhpH-For and dhpH-
Rev cloned into SpeI cut pBTC034 
This study 
pBTC062 SpeI cut PCR product from 17E11 using primers dhpI-For and dhpI-
Rev cloned into SpeI cut pBTC034 
This study 
pAE4 oriT, AprR, λattP, ΦC31 int, ΦC31attP (Eliot et al) 
pAE5 Mini-Mu transposon, KanR (Eliot et al., 
2008) 
pET15b T7 based expression vector, N-terminal His6, AmpR Novagen 
pKD46 redBCD (Datsenko 
and Wanner, 
2000) 
pRT802 E. coli/Streptomyces shuttle vector, ΦBT1 int, ΦBT1attP, oriT, KnR (Gregory et 
al., 2003) 
pANT841 pERM* containing vector Michael 
Thomas 
 
* The mutant gene clusters designated pBTC038-pBTC059 were constructed utilizing primers detailed in 
Table A2. 
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dhpA redswap-F gggccgtccggcccgcggcatccgcgcaggaagcaggggcctaggtcgaggttgacatcttttgc 
dhpA redswap-R ccaccacgatctccgcggcgggtgccgggccccggttcacctaggtcagaagaactcgtcaagaagg 
dhpB redswap-F cgcacctgggtgcggcgccactccgacgagcggtcatgacctaggtcgaggttgacatcttttgc 
dhpB redswap-R tgggcagggatccccgccgctcttcgtggtgctcggccgcctaggtcagaagaactcgtcaagaag g 
dhpC redswap-F tggagccctatgtacgccagtgacggcaccgaccgcgcacctaggtcgaggttgacatcttttgc 
dhpC redswap-R agccggtcacgcgtcctgcccgtcccgtgcgccgagcggcctaggtcagaagaactcgtcaagaagg 
dhpD redswap-F atcaagccgctcggcgcacgggacgggcaggacgcgtgacctaggtcgaggttgacatcttttgc 
dhpD redswap-R gtggatggtccatacgaagcaatggtcattggtatcccccctaggtcagaagaactcgtcaagaagg 
dhpE redswap-F ctgcggcgcgcgaggtcacccatcactgaggggataccacctaggtcgaggttgacatcttttgc 
dhpE redswap-R cgccgcgacgaactcctccgcggtgatccggtcgctcatcctaggtcagaagaactcgtcaagaagg 
dhpF redswap-F atctccggcatggaccagtggctggacctcgaccgatgacctaggtcgaggttgacatcttttgc 
dhpF redswap-R cggagccgcgcgccaggggccggctcatggcagcctctccctaggtcagaagaactcgtcaagaagg 
dhpG redswap-F gccggcggcggtgcccccgagccggagaggctgccatgacctaggtcgaggttgacatcttttgc 
dhpG redswap-R tcaccctgtagttgcgcatgtcgtgcctcgctttcgctccctaggtcagaagaactcgtcaagaagg 
dhpH redswap-F gagcgaaagcgaggcacgacatgcgcaactacagggtgacctaggtcgaggttgacatcttttgc 
dhpH redswap-R cctcttcctcgattgctgggaatacggtggtgcgggtcatgacctaggtcagaagaactcgtcaagaagg 
dhpI redswap-F caccaccgtattcccagcaatcgaggaagaggaccccctaggtcgaggttgacatcttttgc 
dhpI redswap-R gggcggacggaccgggcagcggggcgggccgggcctaggtcagaagaactcgtcaagaagg 
dhpJ redswap-F ggcttcctgtacgccacgtgccgccccggaccgcggtgacctaggtcgaggttgacatcttttgc 
dhpJ redswap-R ccggcgccccgggcgcggcgaccgctccggccaccatcacctaggtcagaagaactcgtcaagaagg 
dhpM redswap-F tgaggaacagcgagatgacgaggttgagcagcagggcgacctaggtcgaggttgacatcttttgc 
dhpM redswap-R gtcaggcaagggacccccacaccaccagaggcagcgacgcctaggtcagaagaactcgtcaagaagg 
dhpN redswap-F ctctcggtcgtcggcgcgacgtccttatgggcggtgtcgcctaggtcgaggttgacatcttttgc 
dhpN redswap-R cccggcggccgggcgttgcggcagggcggtggttgcggccctaggtcagaagaactcgtcaagaagg 
pERM-For ggatcctctagaggtaccagcccgacccgagc 
pERM-Rev gcggccgcactagtcctcctggggttgcgttgggtgggga 
dhpB-For ggcgcgccactagtatgaaccggggcccggcacccgcc 
dhpB-Rev ggcgcgccactagttggtgctcggccgtcaggcggcgg 
dhpH-For ggcgcgccactagtatgcgcaactacagggtgacg 
dhpH-Rev ggcgcgccactagttcagagcgaagggccgagc 
dhpI-For ggcgcgccactagtatgaccacttcgcacggtctgatcg 
dhpI-Rev ggcgcgccactagttcaccgcggtccggggcggc 
dhpA-For ggatccgaaggaaagcttcatatgacaggcggcgggcacc 
dhpA-Rev ggcgcgccagatctgaattctcatgaccgctcgtcggagtgg 
dhpC-For ggatccgaaggaaagcttcatatgtacgccagtgacggc 
dhpC-Rev ggcgcgccagatctgaattctcacgcgtcctgcccgtcc 
dhpH-For ggatccgaaggaaagcttcatatgcgcaactac 
dhpH-Rev ggcgcgccagatctgaattctcagagcgaagg 
dhpJ-For ggatccgaaggaaagcttcatatgaacggttccctcagc 
dhpJ-Rev ggcgcgccagatctgaattctcagatgtcgccgcccgattcc 
seqAETnL tcgccttcttgacgagttct 
seqAETnR taggaacttcgggatccgtt 
T7-for taatacgactcactataggg 
T7-rev gctagttattgctcagcgg 
pBTC034-for tggtaggatccccacccaacg 
pBTC034-rev ccttgaaattagttaggc 
 
Table A2 PCR primers used in the course of this work  
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